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Chapter 1
Despite expanding primary prevention efforts, the majority of individuals in Western societies 
will develop cardiovascular disease (CVD) during their lifetime.2 CVD is an age-related disease and 
comes in many forms, ranging from exertional angina and intermittent claudication to disabling 
stroke, myocardial infarction or sudden cardiac death. Since a substantial proportion of first 
CVD events has fatal or incapacitating consequences primary prevention is of key importance. 
Primary prevention encompasses all efforts to anticipate the development of atherosclerosis 
and forestall its progression to clinical manifestations. A focus on prevention does not imply that 
all CVD can be eliminated but instead embraces Fries’s model of ‘compression of morbidity’.3 In 
this model disease-free life span is extended through the prevention of complications and the 
symptom burden is compressed into a limited period preceding death.4 Thus, primary prevention 
is ideally suited to address chronic conditions, such as CVD, that take decades to develop and 
then manifest as life-threatening and ultimately fatal events. Well-established modifiable risk 
factors, which contribute to build up of atherosclerosis, include smoking, diabetes, obesity, high 
blood pressure and serum low-density lipoprotein (LDL) cholesterol. As such, prevention of CVD 
can be executed according to two parallel strategies. First, through population measures to 
disincentivize smoking and to adhere to a healthy lifestyle by means of diet and exercise. And 
second, by treating individuals to attain optimal glucose, blood pressure, and cholesterol levels 
using pharmacological agents.
Clinical practice guidelines for primary prevention of CVD at individual level are centered on 
a traditional high-risk approach. Based on an individual’s age and risk factor profile, CVD risk 
calculators provide clinicians with an estimate of the individual’s probability for developing 
CVD in the following 10 years.5-7 The role of cardiovascular risk assessment in clinical practice 
is twofold. First, it serves as a starting point for risk communication between physicians and 
patients. Secondly, it is used as the primary mode to select candidates at high risk of CVD 
for lipid-lowering treatment (see Appendix Figures 1.1, 1.2, and 1.3 for current guideline 
recommendations).8-10
Outline of this thesis
Part I – Methodological considerations in cardiovascular epidemiologic research
Traditionally, most data on occurrence and risk factors for cardiovascular diseases have been 
derived from prospective population-based cohort studies. These studies are designed to 
follow large groups of healthy individuals over a longer period of time. Potential risk factors and 
subclinical measures of cardiovascular disease are measured using standardized methods, at 
times when the participants have not yet experienced any cardiovascular events. Already over 
50 years ago, the pioneers from the Framingham Heart Study leveraged this design to provide 
insight into the growing burden of cardiovascular disease in the general population and enabled 
the identification of causal factors, such as cholesterol and blood pressure.11 The Framingham 
Heart Study, established in 1948, is a cohort study comprised of healthy volunteers from the 
general population of the town of Framingham, MA, U.S. The study design of enrolling healthy, 
rather than diseased, individuals in order to study risk factors, potential high-risk indicators, and 
frequency of occurrence of disease, was adopted by many other researchers and made the field 
of epidemiology come to full fruition by the end of the 20th century.
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General introduction
Most of the work in this thesis is based on data from the Rotterdam Study, a Dutch prospective 
population-based cohort study with similar design and objectives as the Framingham Heart 
Study (Figure 1.1). In Chapter 2 of this thesis the methods for the follow-up of incident cardiac 
events is detailed, since any comparison to data from other studies (such as in Chapters 4 and 
15) requires clear definitions of disease outcomes.
The Framingham Heart Study aimed to be “not atypical” of the general American suburban 
population.12 Shortly after the initiation of this seminal study, however, the investigators 
noted that the participants who volunteered were more healthy than those who declined 
to participate and hence raised the question to what extend findings were generalizable to 
the general population.12 This phenomenon was referred to as the ‘healthy volunteer effect’. 
In Chapter 3 of this thesis the impact of the healthy volunteer effect on cardiovascular risk 
estimates in the Rotterdam Study is presented.
Over the last 6 decades population science has evolved from small case-control studies to 
prospective population-based cohort studies, and more recently to “mega cohorts” where data 
from multiple cohort studies are pooled.13, 14 Different study designs have different strengths 
and weaknesses, which are clearly brought to light when results on similar research questions 
– answered using these different study designs – are directly compared. In Chapter 4 reasons 
for widely varying estimates on lifetime risk of CVD and risk of death from cardiovascular 
causes obtained in the Rotterdam Study and the British QResearch administrative database are 
discussed.
Part II – Methodological considerations in quantifying improvements in risk stratification
The first ever risk estimation tools in the field of CVD originate from the original publications of 
the Framingham Heart Study 11 and comprised of graphs and cross-tabulations of systolic blood 
pressure and total cholesterol levels with subsequent 6-year risk of coronary heart disease 
(CHD). Ever since, risk stratification tools have become more and more sophisticated, nowadays 
being released with online calculators (e.g. https://www.framinghamheartstudy.org/risk-
functions/index.php) and companion applications for mobile devices (e.g. https://itunes.apple.
com/us/app/ascvd-risk-estimator/id808875968). Nowadays, the majority of risk stratification 
tools in clinical practice rely on traditional CVD risk factors, including age, sex, blood pressure, 
cholesterol levels, smoking, and diabetes mellitus. These CVD risk prediction models provide 
reasonable precision for a group, but uncertainty about any individual patient’s true risk as 
estimated by these models remains.15 Therefore, in order to improve CVD risk estimations, 
a plethora of newer risk factors and high-risk indicators have been proposed (including in 
Chapters 13 through 15 of this thesis).
A key challenge of this field of research is how to quantify the improvements in risk estimation 
obtained by adding a new marker. Well-known model parameters of discrimination (i.e. the 
ability to distinguish individuals who will go on to have an event from those who will not) and 
calibration (i.e. the agreement between predicted and observed risk in groups of individuals) 
are of limited clinical relevance when risk thresholds are in place to guide clinical decision 
making as is the case in the field of primary prevention of CVD.8-10
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1
General introduction
Part II of this thesis focusses on a relatively novel statistical method to quantify improvements 
in risk stratification in the presence of one or more clinically meaningful risk thresholds. This 
method, net reclassification improvement (NRI), summarizes changes in risk classification when 
comparing 2 methods to categorize individuals in different risk strata.16, 17 Generally, NRI is used 
to compare a more parsimonious prediction model to a model that includes a new maker under 
study.
Chapter 5 of this thesis is an overview of practical applications of NRI in research published in 
top-medical journals which highlights a number of challenges and limitations of NRI. These may 
be clear to the statisticians who use NRI in daily practice but are less clear to clinicians writing, 
reviewing or reading articles that make use of this method. Hence, we aimed to construct an 
educational part on NRI specifically for clinicians with examples from the literature and clear 
clinical applications.
Specific challenges and pitfalls in the use of NRI are discussed in the subsequent chapters. 
Chapter 6 delineates how NRI incorporates an implicit weighing factor for the frequency of 
occurrence of the studied outcome. Chapter 7 contains a discussion on the clinical and statistical 
importance of the placement of risk thresholds. Chapter 8 provides an example of how the 
selection of the outcome under the study, in this instance CHD versus a broader CVD outcome, 
can influence the estimates and subsequent interpretation of NRI for a newer risk marker. 
Finally, Chapter 9 of this thesis highlights the role of model calibration on the interpretation of 
NRI.
Part III – Quantifying the burden of cardiovascular disease
CVD has been ever present in the 4000 year history of human kind.18 In fact cardiac symptoms 
were common enough to be mentioned in ancient writings, dating as far back as 1550 BCE: 
“If thou examinst a man for illness in his cardia, and he has pains in his arms, in his breast and 
on one side of his cardia … it is death threatening him”.19 Yet, the burden of CVD on society 
has varied greatly over time with a sharp rise in incidence and mortality in the first half of the 
20th century and a marked decline afterwards, following major advancements in treatment and 
prevention of CVD.20 In order to identify further opportunities for CVD prevention and allocation 
of adequate resources to do so, it is important to have insight into the actual contemporary 
burden of CVD.21
Chapter 10 is an up-to-date compilation of quantitative data on incidence, prevalence, mortality, 
and interventions related to heart disease in the Netherlands, including temporal trends.
Most data on the occurrence of CVD are expressed as 10-year cumulative incidences or age-
specific incidence rates. However, preventive strategies generally aim to reduce long-term 
risk of CVD and pharmacological treatment to reduce blood pressure and LDL cholesterol 
is prescribed for indefinite periods of time. Therefore, it is of interest to both patients and 
clinicians to quantify risk over longer periods of time or even over a lifetime. Attempts to 
estimates such parameters have traditionally been hampered by the amount of follow-up in 
studies, as well as computational challenges on how to adjust for informative censoring due to 
competing non-cardiovascular causes of death in older individuals. In Chapter 11 of this thesis 
18
Chapter 1
the lifetime risk of CVD and the distribution of its first manifestations are presented for men 
and women from the Rotterdam Study. This novel approach allows for unique opportunities 
to study the relative contribution of various types of CVD (i.e. CHD, cerebrovascular disease, 
and heart failure) among the sexes, which may have bearing on prioritizing specific preventive 
efforts in men and women.
Part IV – Improving cardiovascular risk stratification
Optimal prevention of CVD starts with identifying those who are most likely to benefit from it. 
In Chapter 12 of this thesis we present the implications for recommendations on cholesterol-
lowering therapy from current European 8 and American 9 prevention guidelines on a 
contemporary population sample, free of CVD, from the Rotterdam Study.
Over the past 30 years many new risk indicators for CVD have been proposed, including markers 
of blood coagulation, inflammation, and renal function, as well as parameters related to the 
extent of subclinical atherosclerosis. Most research has focused on the contribution of single 
markers, but seldom research aimed to compare the contribution of multiple putative markers 
that might improve CVD risk estimation in a primary prevention setting. In Chapter 13 a total 
of 12 newer risk markers for CHD risk prediction are evaluated within the framework of the 
Rotterdam Study. These blood biomarkers represent a variety of processes contributing to 
atherosclerosis and atherothrombosis, or come from non-invasive measurements that quantify 
the extent of accrued subclinical vascular damage. Both improvements in traditional model 
performance parameters and NRI were used to compare the markers.
Commonly used CVD risk prediction models focus on hard atherosclerotic end points such as 
CHD mortality, myocardial infarction, and stroke. When evaluating the cost-effectiveness of 
newer candidate CVD risk markers for clinical practice, it is important to consider other costly 
CVD outcomes, such as heart failure, that could be prevented with the measurement of these 
candidate markers. Since heart failure is predominantly attributed to coronary atherosclerosis in 
older individuals,22 it is of importance to evaluate whether markers of subclinical atherosclerosis 
can improve heart failure risk prediction. One of the most promising risk indicators to improve 
CVD risk prediction is the coronary artery calcification (CAC) score, obtained from non-contrast 
computed tomography (CT). Chapter 14 contains data on the ability of the CAC score to predict 
future heart failure in individuals free of overt CHD from the Rotterdam Study. Again, both 
improvements in traditional model performance parameters and NRI are presented.
Life expectancy has been increasing at a steady pace for nearly 2 centuries.23 Not only do we live 
longer, but we also live healthier lives with frailty, sickness, and disability increasingly confined 
to the final stages of life.3 As a consequence, cardiology patients nowadays are typically older 
individuals with specific needs associated with advancing age.24 These demographic changes 
have implications for CVD prevention, as traditionally cardiovascular risk calculators have been 
developed for individuals of middle age. However, the aging of the population creates a group 
of healthy elderly individuals, who have been promoted as candidates for primary prevention of 
CVD.25, 26 CVD prediction models for elderly persons should take into account, that with growing 
age and frailty, clinical CVD may be precluded by death from competing non-cardiovascular 
causes.
19
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General introduction
Chapter 15 describes the development and transatlantic validation of the coronary risk in the 
elderly (CORE) model, a CHD prediction model tailored to older populations. The CORE model 
is based on data from participants aged 65 years and older from the Rotterdam Study and the 
Cardiovascular Health Study. Competing risks regression methodology was used throughout in 
order to account for risks of non-coronary causes of death. The risk estimates from the CORE 
model were compared to those from the Adult Treatment Panel III (ATP III) model underlying 
the previous iteration of the American cholesterol treatment guidelines.27 Moreover, since the 
predictive ability of traditional cardiovascular risk factors declines with advancing age,28-30 we 
aimed to evaluate the added value of easily available newer CVD risk markers in this elderly 
population. In line with the other chapters of this part of the thesis, both traditional model 
parameters and NRI are presented.
Part V – General discussion and summary
In Chapter 16 general methodological considerations on the research described in this thesis 
are discussed, as well as future perspectives and challenges for risk-based strategies in primary 
prevention of CVD. In particular, two items are discussed in debt. First, the opportunities for 
a transition from traditional 10-year risk estimates to lifetime risk perspectives. And second, 
the dominant role of age in cardiovascular risk calculators and alternative treatment allocation 
strategies.
20
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1
General introduction
There is sometimes a tendency to regard an experiment as providing the higher form of 
evidence. This seems completely unrealistic. Certainly the classic experiment is a powerful 
tool for investigation, but it can be neither designed nor interpreted except by reference to 
observed unmanipulated reality. The community study provides this kind of reference for 
the investigation of chronic diseases in human populations.
- Tavia Gordon (1917 – 2004)
Some methodological problems in the long-term study of cardiovascular disease:
observations on the Framingham Study.
J Chron Dis 1959;10(3):186-206
PART I
Methodological Considerati ons in 
Cardiovascular Epidemiologic Research

C HAPTER 2
Data Collecti on and Defi niti ons of Cardiac Outcomes 
in the Rott erdam Study
28
Chapter 2
The prevalence of cardiovascular diseases is rising. Therefore, adequate risk prediction 
and identification of its determinants is increasingly important. The Rotterdam Study is a 
prospective population-based cohort study ongoing since 1990 in the city of Rotterdam, the 
Netherlands. One of the main targets of the Rotterdam Study is to identify the determinants 
and prognosis of cardiovascular diseases. Case finding in epidemiologic studies is strongly 
depending on various sources of follow-up and clear outcome definitions. The sources used 
for collection of data in the Rotterdam Study are diverse and the definitions of outcomes 
in the Rotterdam Study have changed due to the introduction of novel diagnostics and 
therapeutic interventions. This chapter gives the methods for data collection and the up-
to-date definitions of the cardiac outcomes based on international guidelines, including the 
recently adopted cardiovascular disease mortality definitions. In all, detailed description of 
cardiac outcome definitions enhances the possibility to make comparisons with other studies 
in the field of cardiovascular research and may increase the strength of collaborations.
Despite major advances in prevention and treatment, the prevalence of cardiovascular diseases 
(CVD) is rising.21, 31 Nowadays, the majority of healthy adults will be confronted with some form 
of CVD during their lifetime and still heart disease is the leading cause of death in the western 
world, claiming approximately 1 out of every 5 lives.31 Therefore, the continued search for 
determinants and predictors of occurrence and prognosis of CVD is of paramount importance.
The Rotterdam Study is a prospective population-based cohort study ongoing since 1990 in 
a suburb of the city of Rotterdam, the Netherlands. The original cohort comprised of 7983 
inhabitants, aged 55 years or older and living in the well-defined Ommoord city district. The 
participants undergo repeated extensive examinations every 3-4 years at the Rotterdam Study 
research center, located in the middle of the study area. They are followed for a variety of 
diseases that are frequent in the general population. At initiation, the study focused on 
cardiovascular, neurological, ophthalmological, and endocrine diseases. The rationale and 
design of the Rotterdam Study have been described extensively 2 decades ago.32 However, 
over the years the original cohort has been extended twice, the scope has been broadened, 
and the characteristics of repeated examinations have changed. As of December 2008, 14,926 
individuals aged 45 years or over comprise the Rotterdam Study cohort (Figure 1.1). Therefore, 
its objectives and design have been updated regularly.33-38 Parallel to extensions in the design 
of the Rotterdam Study, medical technology has advanced and clinical presentation of heart 
disease is evolving.
Within the Rotterdam Study, multiple cardiac outcomes are considered, namely recognized and 
unrecognized myocardial infarction (MI), myocardial revascularization, coronary heart disease 
(CHD) mortality, heart failure, atrial fibrillation (AF), and sudden cardiac death (SCD). The 
sources used for collecting the data are diverse and up until now their corresponding methods 
and the definitions of various cardiac outcomes in the Rotterdam Study have not been reported 
combined together in an overview. Furthermore, implementation of novel diagnostics and 
therapeutic interventions in everyday cardiac care has urged us to change definitions since our 
earliest reports on prevalence and incidence of MI and CHD.39-41 Above all, in today’s era of large 
transatlantic collaborations in epidemiologic research comparability of outcome definitions has 
gained importance.14, 42 In this chapter the methods of data collection and up-to-date definitions 
of the cardiac outcomes in the Rotterdam Study will be presented.
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Methods and definitions in the Rotterdam Study
Methods of data collection
Dutch health care system
In order to understand the methods of data collection used in the Rotterdam Study a brief 
introduction into the Dutch health care system is essential. Primary care, provided by general 
practitioners (GPs), plays a central role in the health care in the Netherlands. In the Netherlands 
there are almost 11,000 practicing GPs, who each have had 3 years of specialist training in 
family medicine. All Dutch inhabitants can register at a single general practice of choice. The 
GPs act as the gatekeepers to hospital care and must give their approval before patients can get 
referred to a medical specialist. In doing so, the vast majority of problems presented in primary 
care are handled by the GPs themselves.43
For decades, emergency and after-hours care is handled by primary care cooperatives. In 
order to provide adequate after-hours care, full electronic exchange of patient data is of great 
importance. Therefore, virtually all GPs in the Netherlands use computer-based GP information 
systems based on requirements set by the professional organizations of Dutch general practice 
(Dutch GP Society [NHG] and Nationwide Association of GPs [LVH]). These computer systems 
have been designed specifically for use in primary care and consist of a set of specific modules 
(e.g. medical, electronic communication, prescription, financial).Using the digital systems, all 
encounters in primary practice are coded using the International Classification of Primary Care 
(ICPC).44, 45 As discussed above, Dutch GPs have a coordinating role in the overall health care 
utilization process of their patients enlisted. They refer their patients to medical specialists and 
are reported back on every hospital admission and results from outpatient contacts with medical 
specialists, preferably using electronic communication.46 Further details on the structure of the 
health care system in the Netherlands and the use of electronic medical records have been 
described in detail.43, 47-50
With regards to concerns of general accessibility to medical care in the Netherlands, insurance 
status is not allowed to be considered in referral of patients. Cardiac hospital care, including 
invasive procedures, is covered by the basic health care insurance plan in the Netherlands, 
which is obligatory by law.47, 48
Assessment of cardiovascular disease status at baseline
Upon entrance in the Rotterdam Study cohort, baseline CVD status of each participant is 
ascertained in the following way. During a baseline home interview, trained non-medical 
interviewers administer a standardized questionnaire to obtain information on medical history 
(e.g. MI, myocardial revascularization) and health status (e.g. chest discomfort, breathlessness), 
and labels of current medication are copied (both prescription and over-the-counter usage). 
Medication use is coded according to the Anatomical Therapeutic Chemical (ATC) classification 
index.51 Questions on indication of cardiovascular medication and breathlessness were lacking 
at the start of the Rotterdam Study, but have subsequently been added. Consequently, these 
questions were asked in most (70%) of the participants at baseline of the original Rotterdam 
Study cohort (RS-I-1; Figure 1.1). After the interview, the participants are invited to visit the 
research center where they undergo a physical examination in some detail by one of the 
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study physicians and various tests are performed (e.g. resting electrocardiogram [ECG], 
echocardiography). In addition to these examinations, information on prevalent disease status 
is obtained by accessing data from the Nationwide Medical Registry (Dutch Hospital Data 
[LMR], Utrecht, the Netherlands). This is a national registration on all primary and secondary 
hospital discharge diagnoses of Dutch inhabitants, with linkage on the basis of zip code, date 
of birth, sex, and GP. Records from this registry are linked to the study database. For potential 
events identified in this registry, copies of hospital discharge letters and ECGs are requested. 
Most importantly, clinical information on prevalent CVD status is obtained from the GPs for 
each participant: the entire medical records of the GPs are hand screened at the GPs’ office by 
trained research assistants. Using the aforementioned sources (interview, examination at the 
research center, Nationwide Medical Registry, and full screening of GPs’ records), disease status 
at baseline is available for all participants of the Rotterdam Study. An overview of the sources 
used for ascertaining disease status at baseline is presented in Table 2.1.
Clinical follow-up
Follow-up starts after the baseline home interview of each individual participant. Data on 
clinical cardiovascular outcomes are collected continuously through an automated follow-up 
system. The follow-up system involves automated digital linkage of the study database to digital 
files from GPs in the study area. On a weekly basis, all ICPC codes of diagnoses of interest made 
by the GPs and medical specialists in study participants are entered to the Rotterdam Study 
database. Moreover, the entire medical record of each participant living in the research area is 
checked by hand on a regular basis at the GPs’ office by trained research assistants for diagnoses 
of interest. This is the primary source of information on CVD events, since all letters of medical 
specialists, discharge reports in case of hospitalization, and ECGs are copied by the research 
assistants. Subsequently, all the collected information is compared to the ICPC codes entered 
to the study database for each individual participant. This is done in order to make sure no 
clinical information on potential events is missed out. Additional information is obtained from 
the hospitals in case the automated follow-up system or medical records contain insufficient 
information. Medical records of the participants under the care of nursing home physicians or 
GPs working outside the study area are checked annually for potential events. Furthermore, 
before every repeat examination the participants are interviewed on the occurrence of cardiac 
events since their last visit to the research center.
With respect to the vital status of all participants, information is obtained on a weekly basis 
from the central registry of the municipality in Rotterdam and through the digital linkage with 
GPs working in the study area. For participants living outside the research area, the GPs are 
the primary source of information, complemented by the municipality records in the place of 
residence. After notification, cause and circumstances of death are established by requesting 
information from the medical records of the GPs or nursing home physicians.
As of January 1991 onwards all drug prescriptions dispensed to participants by 7 fully automated 
pharmacies in the study area are routinely stored in the database. At baseline, nearly all (99.7%) 
participants were registered at 1 of these pharmacies. This data consists of information on the 
date of delivery, the total amount of drug units per prescription, the prescribed daily number of 
units, product name of the drugs, and the ATC code.51, 52
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Table 2.1 provides an overview of the sources used for obtaining information on the occurrence 
of cardiac outcomes during follow-up.
Table 2.1 – Sources of data in the Rotterdam Study
Source Data obtained on disease 
status at study baseline
Data obtained on occurrence of 
outcomes during follow-up
Regular checks of 
medical records at 
the GPs’ office
Full medical history Intercurrent medical history
Hospital discharge letters Intercurrent hospital discharge letters
Reports on outpatient contacts 
with medical specialists
Intercurrent reports on outpatient 
contacts with medical specialists
Previous ECGs Intercurrent ECGs
Cause and circumstances of death
Continuous linkage 
of the study 
database with GPs’ 
digital files
ICPC codes of all diagnoses made
Date of death
Home interviews Medical history Intercurrent medical history
Current health status Current health status
Current medication use Current medication use
Research center 
visits
Resting ECG Resting ECG
Physical examination
Pharmacy 
prescription records
Current medication use Continous monitoring of all 
presciptions filled
Nationwide Medical 
Registry (LMR)
History of hospital discharge 
diagnoses for any outcome of 
interest
Intercurrent hospitalization with AF 
or atrial flutter
Municipality records Date and place of death
Hospitals Hospital discharge letters Hospital discharge letters
Previous ECGs Intercurrent ECGs
GP = general practitioner; ECG = electrocardiogram; ICPC = International Classification of Primary Care; AF = atrial 
fibrillation.
Electrocardiography
At baseline and at each follow-up visit to the research center, every participant has a 10 s 
12-lead resting ECG (on average 8-10 beats) recorded using an ACTA Gnosis IV ECG recorder 
(Esaote Biomedica, Florence, Italy) at a sampling frequency of 500 Hz and stored digitally. All 
ECGs are processed by the standardized Modular ECG Analysis System (MEANS) to obtain ECG 
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measurements and interpretation. The ECGs are analyzed off-line using MEANS. The MEANS 
program has been evaluated extensively and determines common onsets and offsets for 
all 12 leads together on 1 representative averaged beat, with the use of template matching 
techniques.53-57
Event adjudication
For each outcome 2 cardiovascular research physicians independently classify information on 
occurrence, certainty, and date of onset of all data collected on potential events according 
to the corresponding definitions below. Cases on which the research physicians disagree are 
discussed in order to reach consensus in a separate session. Afterwards, a panel of medical 
specialists in CVD reviews potential events for each diagnosis separately. This panel consists of 
a cardiologist, 2 geriatricians, and a GP experienced in cardiac disease. The medical specialist’s 
judgment is considered decisive. The research physicians and the medical specialists base their 
decisions on the same data. This procedure is similar for both prevalent and incident outcomes.
Definitions of cardiac outcomes
Within the Rotterdam Study 8 highly prevalent cardiac outcomes are considered subdivided 
into 3 categories, namely CHD, heart failure, and cardiac arrhythmias (Table 2.2).
Table 2.2 – Cardiac outcomes in the Rotterdam Study
Categories Underlying outcomes
Coronary heart disease MI
Unrecognized MI
Myocardial revascularization
CHD mortality
Overall CHD
Heart failure Heart failure
Cardiac arrhythmia Atrial fibrillation and atrial flutter
Sudden cardiac death
MI = myocardial infarction; CHD = coronary heart disease.
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Coronary heart disease
Myocardial infarction
The triad of chest pain, ECG abnormalities, and rise of cardiac enzymes has been a generally 
accepted definition of acute MI for many years. However, during the past decades development 
of more sensitive and specific blood markers (e.g. creatinin kinase MB, troponins) and enhanced 
imaging techniques allow for detection of smaller MIs. Widespread introduction of troponin 
testing in the Netherlands happened around the turn of the century and took several years 
to be fully implemented in the hospitals in the research area.58 This has had implications for 
adjudication of MIs in the Rotterdam Study. Accordingly, clinical practice, as well as epidemiologic 
research required a more precise definition of MI.59
Methods on follow-up and event adjudication of prevalent and incident MI for the Rotterdam 
Study have been described previously in brief.60 The diagnosis of MI is classified as definite, 
probable, possible or unlikely. Definite MI is defined as pathology findings of an acute MI within 
28 days of death, or a rise/fall in cardiac biomarkers and/or objective indicative ECG changes, 
and preferably the presence of symptoms or signs (e.g. cardiac pain, cardiogenic shock). Also, 
for definite MI, the diagnosis has to have been made by a medical specialist, preferably a 
cardiologist or an internist. If the MI was diagnosed by a GP or a nursing home physician it is 
classified as probable. MI is classified as possible when 1 of the criteria for probable or definite 
MI cannot be met. MI is considered unlikely if symptoms or signs are present, but objective 
evidence showing myocardial necrosis is lacking. Accordingly, diagnoses of unstable angina, 
acute coronary syndromes, and invasive procedure related ischemia are also considered as MI 
events whenever they are accompanied by a significant rise in cardiac biomarkers. Thereby, the 
current definition of MI in the Rotterdam Study includes the clinical type 1, 2, 4a, 4b, and type 5 
MI as defined in the endorsed universal definition of MI.59 In accordance with the international 
epidemiologic CHD case definitions, only definite and probable cases are included in the 
Rotterdam Study definition, unless otherwise noted.61 For participants of the original Rotterdam 
Study cohort, the presence of MI at baseline (RS-I-1; Figure 1.1) is based on verification of either 
self-reported MI or ECG abnormalities indicative of prior MI. In subsequent cohorts, the medical 
records of all participants are screened for prevalent MI, regardless of their self-reported history 
or ECG abnormalities. The presence of MI during follow-up is based on clinical information from 
the medical records. The date of incident MI is defined as the day of the first occurrence of 
symptoms suggestive of MI.
Unrecognized myocardial infarction
Unrecognized MI, although prevalent, is not always considered as an outcome in epidemiologic 
studies on CHD, since determining an exact date of occurrence of the MI is impossible by 
definition.60 Therefore, unrecognized MI is not included as an outcome in studies on the 
occurrence of CHD in the Rotterdam Study, unless otherwise noted. However, separate studies 
within the framework of the Rotterdam Study have been conducted on the prognosis of this 
type of presentation of CHD.62-64
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Methods on definition of prevalent and incident unrecognized MI within the Rotterdam Study 
have been summarized previously.60, 64 This definition is in accordance with the criteria for ‘prior 
MI’ (type 3) defined by the international Task Force for the Redefinition of MI, as follows in 
detail.59 At baseline of the Rotterdam Study all participants were asked whether they had ever 
experienced a heart attack and who established the diagnosis. Afterwards, an ECG was obtained 
and analyzed using MEANS as described above. To determine MI, MEANS uses a comprehensive 
set of criteria that partly derive from The Minnesota Code.65, 66 Pathological Q-waves are 
central in the diagnosis of MI using MEANS, next to auxiliary criteria, such as QR-ratio and 
R-wave progression. A cardiologist with expertise in electrocardiography, whose judgment was 
considered final, reviewed all cases that were classified by MEANS as possible, probable, or 
definite MI. At baseline of the Rotterdam Study, unrecognized MI was considered to be present 
in all participants with confirmed ECG characteristics matching a MI, but without documented 
history or self-reported MI. An incident unrecognized MI is considered to have occurred if there 
is confirmed electrocardiographic evidence of MI on follow-up examinations at the research 
center, given the absence of an incident clinically recognized MI at baseline or during follow-up. 
The unrecognized MI is considered to have occurred in the middle of the time interval between 
the examination at which the unrecognized MI is detected and the examination before that.
Myocardial revascularization
Invasive myocardial revascularization is an established treatment for acute MI, relief of unstable 
angina, and medically intractable stable angina. Furthermore, patients with symptomatic or 
asymptomatic severe coronary artery disease benefit from myocardial revascularization by 
improving survival.67 Especially during the past decade, a great number of novel and hybrid 
cardiac interventions, and other transcatheter interventions have been introduced.67, 68
Within the Rotterdam Study data is collected on incident coronary artery bypass grafting (CABG) 
and percutaneous coronary interventions (PCIs) for atherosclerotic CHD, separately. For PCI, 
previously termed percutaneous transluminal coronary angioplasty, the following interventions 
are considered: coronary stenting, coronary balloon angioplasty, coronary recanalization, 
intracoronary thrombosuction, and (although very rare) intracoronary laser and brachytherapy. 
CABG and PCI are also adjudicated for combined cardiopulmonary surgery and other combined 
or hybrid cardiac procedures.67, 68 Any attempt of revascularization is adjudicated, regardless of 
success, given the indication is still present at the time of the attempt. For participants of the 
original Rotterdam Study cohort (RS-I-1; Figure 1.1), the presence of myocardial revascularization 
at baseline is based on self-reported CABG or PCI, verified by clinical data from the medical 
records. In subsequent cohorts, the medical records of all participants are screened for prevalent 
myocardial revascularization procedures, regardless of their self-reported history. The presence 
of CABG and PCI during follow-up is based on clinical information from the medical records. The 
date of incident myocardial revascularization is obtained from the hospital discharge letters.
As mentioned before, myocardial revascularization procedures are available to everyone in the 
Netherlands, regardless of insurance status. Myocardial revascularization is fully covered by the 
basic health care insurance in the Netherlands, which is obligatory by law.47, 48
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Coronary heart disease mortality
Fatal CHD is often an unheralded presentation of presymptomatic coronary artery disease and 
is mainly attributed to sudden death, ischemic heart failure, and sequelae of a MI.69 Originally, 
the CHD mortality definitions in the Rotterdam Study have been based on the International 
Classification of Diseases, tenth revision (ICD-10) codings.70, 71 Recently, a classification used in 
other large cohort studies with specific focus on CVD has been adopted in order to improve the 
quality of the outcome data and enhance comparability with other epidemiologic studies. This 
system is a marginally adapted classification applied by both the Cardiovascular Health Study 
and the Atherosclerosis Risk in Communities Study.72-75 From 2003 onward, this classification 
Table 2.3 – Cardiovascular mortality classification and definitions for underlying cause of 
death
Mortality categories 
(hierarchical)
Underlying cause of death
1. Coronary heart 
disease
Definite fatal 
MI
No known non-atherosclerotic cause, and definite MI 
within 28 days of death
Definite fatal 
CHD
No known non-atherosclerotic cause, and at least one 
of the following: cardiac pain within 72 h of death 
or a history of ischemic heart disease in the absence 
of significant valvular heart disease or non-ischemic 
cardiomyopathy
Possible fatal 
CHD
No known non-atherosclerotic cause, and mode of death 
consistent with CHD in the absence of significant valvular 
heart disease or non-ischemic cardiomyopathy
2. Cerebrovascular 
disease
Non-traumatic intracerebral hemorrhage or infarction
3. Other 
atherosclerotic 
disease
Atherosclerotic disease other than CHD or 
cerebrovascular disease (including ruptured abdominal 
aortic aneurysm, peripheral vascular disease, and visceral 
vascular disease)
4. Other 
cardiovascular 
disease
CVD other than 1-3 (including valvular heart disease, 
non-ischemic cardiomyopathy, endocarditis, hypertensive 
renal disease, pulmonary embolism, ruptured thoracic 
aortic aneurysm, and complications from cardiovascular 
interventions other than 1-3)
5. Noncardiovas-
cular disease
All other causes of death other than 1-4 (including 
natural, due to trauma, suicide, and death of unknown or 
uncertain cause)
MI = myocardial infarction; CHD = coronary heart disease; CVD = cardiovascular disease.
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has served as a basis for the endorsed international case definition for out-of-hospital CHD 
mortality in epidemiologic studies.61
As a first step, all deaths (both cardiovascular and non-cardiovascular) in the Rotterdam Study 
are adjudicated based on ICD-10 codes. Subsequently, all available clinical information for 
each potential new fatal CHD and CVD case is reviewed by the research physicians in order to 
ascertain the underlying cause of death and adjudicate a CHD or CVD mortality category. The 
underlying definitions for the CHD and CVD mortality categories are presented in Table 2.3. CVD 
mortality is subdivided into the following hierarchical categories: CHD (definite fatal MI, definite 
fatal CHD, and possible fatal CHD), non-traumatic cerebrovascular disease, other atherosclerotic 
disease, and other CVD. Within the Rotterdam Study, none of the deaths are classified as due to 
heart failure. The classification system used in the Rotterdam Study focuses on the underlying 
etiology, rather than the mode of death: i.e. participants dying with decompensated heart 
failure are mostly classified as deaths being from CHD or valvular heart disease. In rare cases 
where no possible underlying etiology of heart failure can be established from the medical 
records, these deaths are classified as being from other CVD. The date of death is established 
from the medical records or municipality records.
Coronary heart disease
The many forms of presentation of CHD make up for many possibilities of combining these into 
an overall disease outcome. The definition of combined CHD outcomes may depend on the 
research question at hand.
Within the Rotterdam Study 2 different combined outcomes have been used as described 
previously.70 First, ‘total CHD’ is defined as a combined outcome of myocardial revascularization 
(as a proxy for significant coronary artery disease), MI (fatal and nonfatal), and fatal CHD. 
Second, ‘hard CHD’ is defined as MI (fatal and nonfatal) and fatal CHD. Heart failure morbidity 
and unrecognized MI are not part of the combined CHD definitions, unless otherwise noted.
Heart failure
The presentation and etiology of heart failure is heterogeneous.76 Strict case definition and 
diagnostic criteria for follow-up studies are therefore of utmost importance.
Methods on event adjudication of prevalent and incident heart failure for the Rotterdam 
Study have been described previously.77, 78 The diagnosis of heart failure is classified as 
definite, probable, possible or unlikely. Definite heart failure is defined as a combination of the 
presence of typical symptoms or signs of heart failure, such as breathlessness at rest or during 
exertion, ankle edema, and pulmonary crepitations, confirmed by objective evidence of cardiac 
dysfunction (chest X-ray, echocardiography). This definition is in accordance with the criteria 
of the European Society of Cardiology (ESC).76 Also, for definite heart failure, the diagnosis 
has to have been made by a medical specialist, preferably a cardiologist or an internist. Heart 
failure is classified as probable when at least 2 typical symptoms suggestive of heart failure 
are present, and at least 1 of the following: history of CVD (e.g. MI, valvular heart disease, 
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hypertension), positive response to initiated treatment for heart failure, or objective evidence 
of cardiac dysfunction, while symptoms cannot be attributed to another underlying disease, 
such as chronic obstructive pulmonary disease. Heart failure is classified as possible when 1 
of the criteria for probable heart failure cannot be met. For both probable and possible heart 
failure, a diagnosis of a GP or a nursing home physician suffices. Heart failure is considered 
unlikely if symptoms or signs are present, but when objective evidence fails to show cardiac 
dysfunction, and if symptoms or signs can be attributed to another underlying disease. In 
accordance with the ESC guidelines, only definite and probable cases are used in the Rotterdam 
Study definition.76 Inclusion of probable heart failure depends on the research question at hand 
and is detailed in the methods of the corresponding analyses. A participant is not considered 
as having heart failure, if heart failure occurs directly postoperative after cardiac surgery. For 
participants of the original Rotterdam Study cohort, the presence of heart failure at baseline 
(RS-I-1; Figure 1.1) is based on clinical information from the medical records for all participants 
and by using a validated score, similar to the definition of heart failure by the ESC.76, 77, 79 In 
subsequent cohorts, the medical records of all participants are screened for prevalent heart 
failure. The presence of heart failure during follow-up is based on clinical information from the 
medical records. The date of incident heart failure is defined as the date of the first occurrence 
of symptoms suggestive of heart failure, obtained from the medical records, or the day of 
receipt of a first prescription for a loop diuretic or an ACE inhibitor, whichever comes first.
Cardiac arrhythmia
Atrial fibrillation and atrial flutter
AF and atrial flutter are the most common sustained cardiac arrhythmia and are well-known risk 
factors for stroke and mortality.80 Within the Rotterdam Study both AF and atrial flutter are a 
single outcome and referred to as AF, given the likewise natural course.81
Methods on follow-up and event adjudication of prevalent and incident AF for the Rotterdam 
Study have been described previously.80 In accordance with the ESC guidelines, an ECG that 
verifies the diagnosis for all potential cases of AF is required.82 A participant is not considered as 
having AF, if AF occurs during the process of dying and is not the cause of death, or if transient 
AF occurs during a MI or directly postoperative after cardiopulmonary surgery. The presence of 
AF at baseline is based on clinical information from the medical records for all participants of the 
Rotterdam Study. Additionally, at baseline a resting ECG is obtained using the aforementioned 
methods and analyses software (MEANS). Notably, MEANS is characterized by a high sensitivity 
(96.6%) and a high specificity (99.5%) in coding arrhythmias.56 To verify the diagnosis of AF, 
all ECGs with a diagnosis of AF or atrial flutter or any other rhythm disorder are recoded 
independently by 2 research physicians who are blinded to the MEANS diagnosis. The judgment 
of a cardiologist is asked and taken as decisive in case of persistent disagreement. The presence 
of AF during follow-up is based on ECG evidence from the medical records. Furthermore, cases 
of newly diagnosed AF are obtained during the follow-up examinations at the research center 
and by accessing the hospital discharge diagnoses data from the Nationwide Medical Registry. 
The date of incident AF is defined as the date of the first occurrence of symptoms suggestive 
of AF with subsequent ECG verification, obtained from the medical records. When diagnosed 
at the research center and no other information on a diagnosis of AF is available from either 
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the GPs’ files and/or the Nationwide Medical Registry, the date of onset of AF is defined as the 
midpoint of the time interval between examination at which AF is detected and the previous 
examination at the research center.
Sudden cardiac death
The term SCD is commonly used for a mode of cardiac death. The clinical presentation of 
sudden cardiac death is frequently used as a surrogate implying that a specific mechanism is 
involved. The underlying etiology can be diverse, but most often results from tachyarrhythmia 
or mechanical complications of MI.83 SCD is an outcome of special interest in studies on genetics, 
certain ECG parameters, and pharmacological adverse effects on the heart.84-86
During the past century there has been some debate on the definition of this clinical presentation 
of heart disease, however Myerburg’s definition has been accepted and endorsed widely: “A 
natural death due to cardiac causes, heralded by abrupt loss of consciousness, within 1 h after 
the onset of acute symptoms or an unwitnessed, unexpected death of someone seen in a stable 
medical condition less than 24 h previously with no evidence of a non-cardiac cause.”83, 87
Within the Rotterdam Study the methods of adjudicating SCD are based on the definition 
supported by the ESC and have been described previously.83, 85 All available information from 
GPs and a copy of the medical records are used to assess if the death can be classified as a 
SCD using the aforementioned definition proposed by Myerburg.83, 87 First, potential cases are 
subdivided on the basis whether the death is witnessed. If death is witnessed and occurs within 
1 h after the start of symptoms (if present) it is assumed to be a SCD, without additional review 
of the medical records for a medical history of CVD. In case of an unwitnessed death, evidence 
of underlying cardiac or non-cardiac causes is searched for. Inclusion of unwitnessed SCD in 
the Rotterdam Study definition depends on the research question at hand. The date of death is 
established from the medical records or municipality records.
Discussion
Comparability
The necessity of research on the etiology and prognosis of heart disease has been obvious for 
many decades. This has resulted in countless epidemiologic studies with a focus on CHD or 
CVD at large. However, multiple, and sometimes inconsistent, definitions of cardiac outcomes 
are in use. For instance, the inclusion of stable or unstable angina pectoris, myocardial 
revascularization procedures, and specific subtypes of CHD mortality varies greatly in overall 
CHD outcome definitions. This may influence the conclusions drawn and impede the overall 
comparability of studies on CHD.
A substantial proportion of the CHD mortality occurs out-of-hospital.69 Classification of out-of-
hospital death is often based on limited information, due to its sudden onset or unwitnessed 
occurrence. Therefore, a clear coding system is of key importance. Various classifications by 
the World Health Organization (WHO), using data from death certificates, or self-developed 
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CHD mortality definitions are used in epidemiologic and clinical research. Within the Rotterdam 
Study, ICD-10 has been the classification of choice during the past decade for fatal and nonfatal 
events.70, 71 However, the ICD-10 causes confusion when coding mortality. ICD-10 contains codes 
for both underlying disease (cause of death), as well as mechanisms and circumstances of dying 
(mode of death). For instance, cardiac arrest (code I46), heart failure (code I50), sudden death 
(code R96), and unattended death (code R98) could very well be attributed to CHD as to other 
conditions, depending on one’s individual medical history. More recently, in order to avoid 
confusion and enhance comparability in our multiple large transatlantic collaborations with 
other epidemiologic studies, a classification used by other large cardiovascular cohort studies 
has been adopted by the Rotterdam Study.14, 42, 88 As mentioned before, this classification has 
been proposed as the international standard for epidemiologic research.61 As a consequence, 
harmonization of the outcome definitions used in our large epidemiologic collaborations will 
strengthen the consistency of future results. Furthermore, the categorization of the events 
as such helps to avoid inaccuracy in the immediate cause of death reporting, complicated by 
the presence of comorbid conditions, particularly in the elderly.73 Therewith, this classification 
allows for more accurate adjudication of the cause of death by underlying etiology and result 
in less misclassification.
Variability
Insight into outcome definitions does not only facilitate comparability between studies, it 
may also explain variability between or even within studies. Reported incidences of CVD vary 
over different geographic areas and may reflect differences in presence of risk factors, active 
treatment, and differences in CVD susceptibility among populations. However, the differences 
may also be a result of differences in coding systems used or differences in clinical practice 
of adjudication of events.89 In a recent report on the WHO Burden of Disease Program the 
incidence of fatal ischemic heart disease varied greatly. For instance, incidence of fatal ischemic 
heart disease was reported to be 54 per 100,000 in the Netherlands, and 98 per 100,000 in the 
U.S., accounting for 11.3% and 17.9% of the total mortality, respectively. Besides transatlantic 
differences, great dissimilarities among neighboring nations in Western Europe were observed. 
Incidences of fatal ischemic heart disease varied from 38 per 100,000 in France to 90 per 100,000 
in both Germany and the United Kingdom.90 Despite the fact that all countries applied the same 
WHO coding system for adjudication of the causes of death, such differences in incidences are 
unlikely to be fully explained just by variation in presence and management of cardiovascular 
risk factors. The precise cause of this variability remains uncertain.
Variability in incidences is also known to occur within the same study. It is well known that 
calendar time is a cause of variability in observed incidences of heart disease in a single study 
population due to changes in prevalence or treatment of risk factors, or introduction of novel 
sensitive diagnostics over time (e.g. creatinin kinase MB, troponins).91 Furthermore, researchers 
may decide on including outcomes of various certainties (e.g. definite, probable). Depending 
on the research question at hand, more or less sensitive criteria may be applied in different 
analyses. Next, one should also be aware that a study population is of higher average health 
status at baseline of a study or shortly after an active repeat research center visit.92 After all, 
those who attend in a visit to a research center are necessarily healthy enough to undergo the 
examinations.
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Quality control
In the Netherlands, many studies on incidence and prognosis of heart disease rely on data 
provided by the Nationwide Medical Registry. This registry includes all discharge diagnoses 
for every hospital admission in the Netherlands and has shown a good sensitivity and good 
positive predictive value for acute CHD diagnoses, but less for chronic conditions such as heart 
failure.93 Within the Rotterdam Study, a validation study for evaluating the clinical follow-up 
event registration of incident MI was performed. This was done by obtaining data on hospital 
discharge diagnoses in Rotterdam Study participants from the Nationwide Medical Registry. 
A total of 100 discharge diagnoses of MI were obtained from the registry. In 59 instances MI 
was the primary discharge diagnosis, and in 41 instances MI was mentioned as a secondary 
discharge diagnosis. These 100 hospitalized MIs were compared to incident events observed 
through our clinical follow-up system and this showed that none of the primary diagnoses were 
missed and only 2 of the secondary discharge diagnoses were not detected, resulting in a 98% 
case finding of hospitalized MIs in our study population.
Strengths and limitations
Within the Rotterdam Study we have over 2 decades of experience in data collection. It is known 
that use of various sources for data collection is needed to achieve complete follow-up in large 
epidemiologic studies.94 Within the Rotterdam Study, multiple sources for potential events are 
consulted, namely the linkage of the medical records and pharmacy data to the study database, 
regular screening of medical records at the GPs’ office, follow-up interviews and examination at 
the research center, and consultation of the central registry of the local municipality (Table 2.1). 
The Rotterdam Study thereby has a virtually complete follow-up with respect to vital status: 
using the sources described above, exactly 22 years after start of the study, less than 1.8% of the 
participants have been lost to follow-up. This is predominantly due to emigration.
At initiation of the Rotterdam Study most GPs in the research area were already using 
standardized digital patient records, resulting in over 85% of the enrolled participants having 
their medical record digitally linked to the study database.50 Still, 22 years after initiation of 
the study, the great majority (79%) of all participants alive are enlisted with a GP with linkage 
to the automated follow-up system. This results in high quality documentation. Furthermore, 
the GPs in the research area have a low threshold to refer patients for community based 
laboratory testing and (exercise) ECGs. However, this does not fully apply to the participants 
living in nursing homes. Predominantly, the oldest of old and diseased participants are less 
likely to undergo diagnostic tests (e.g. ECG, echocardiography, cardiac biomarker testing), or to 
get referred to a medical specialist in comparison to elderly in other European countries.95 This 
is usually due to lack of diagnostic accuracy of physical examination and reduced mobility of the 
nursing home residents.96 Moreover, clinical benefit is uncertain and care for other comorbid 
conditions (such as Parkinson’s disease or advanced dementia) is considered to take priority 
over performing diagnostic procedures outside the nursing home.97, 98 In all, this may result in 
missing non-hospitalized nonfatal events in nursing home residents.
Although nowadays the typical cardiac patient is of old age, elderly persons are still highly 
underrepresented in cardiovascular research.99, 100 The Rotterdam Study has no upper age limit 
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and can thereby study the determinants and outcomes of heart disease in older participants. 
This implies challenges in adjudication of diagnosis of especially chronic diseases (e.g. heart 
failure), which are associated with a wide range of comorbid conditions.101, 102 Symptoms of 
other common disease in older individuals, such as chronic obstructive pulmonary disease 
and chronic venous insufficiency, can be easily misattributed to the failing heart. Strict case 
definitions are therefore insurmountable in order to prevent misadjudication, however this 
may result in missing some cases where limited information is available.
Conclusions
The need for studying occurrence and prognosis of heart disease is obvious. Case finding in 
epidemiologic studies is strongly depending on the availability of various sources of clinical 
follow-up and clear outcome definitions. The presentation of the up-to-date definitions of 
cardiac outcomes in epidemiologic studies will result in enhanced possibilities to compare 
results with other studies in the field of cardiovascular research and may increase the strength 
of future collaborations.

C HAPTER 3
The Healthy Volunteer Eff ect and Cardiovascular Disease Risk
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Most cardiovascular risk prediction functions are developed using data from cohort studies. 
Invariably, a proportion of invitees will not participate in such studies because relatively good 
health status is required for a person to agree to undergo the examinations. This implies that 
persons enrolled in a study requiring active participation are healthier than those who declined 
to participate. It is thus unclear whether the cardiovascular risk distributions among study 
participants adequately reflect the risk distribution of the source population. We aimed to 
quantify the consequences of this ‘healthy volunteer effect’.
Methods
Study design, setting, and population
The Rotterdam Study is a prospective population-based cohort study ongoing since 1990. The 
original cohort comprised of 7983 inhabitants living in a well-defined suburb in the city of 
Rotterdam, the Netherlands (RS-I). Using municipality data, all 10,215 inhabitants aged 55 years 
or over of the Ommoord district were invited to participate (overall participation rate 78%; age 
55 to 59 participation rate 83%; age 90 years and older participation rate 71%).103 No upper age 
limit was set and no exclusion criteria were defined. Over the past 2 decades, the participants 
have been invited to undergo repeated home interviews and examinations at the Rotterdam 
Study research center, located in the middle of the Ommoord district. The rationale and design 
of the Rotterdam Study have been described in detail elsewhere.32-37
We used response data from the third examination of the cohort (RS-I-3; Figure 1.1), conducted 
between 1997 and 1999 (mean 6.3 years after enrollment). This round included both a home 
interview and a subsequent extensive clinical examination at the research center. For the 
present analysis we excluded permanent nursing home residents (n = 105), persons who moved 
out of the Rotterdam area (n = 34), those without follow-up regarding vital status (n = 17), 
persons who did not provide or withdrew informed consent for follow-up data collection (n 
= 35), and those not invited for undefined reasons (n = 29). This left a total of 5423 persons 
available for analyses.
We classified these persons on the basis of their response as participating in both the home 
interview and extensive clinical examination at the research center, participating in the home 
interview only, or nonparticipating. Formal invitations for the third examination were sent by 
mail and participants were subsequently contacted by trained interviewers through telephone 
during the following week. During the call, an appointment for home interviewing was made if 
the invitee agreed to participate or reasons for declining the invitation were asked. At the end 
of the home interview, appointments for the clinical examination at the research center were 
made. Repeated attempts were undertaken if invitees could not be reached. Ultimately, in rare 
instances where the invitees could not at all be reached by the interviewers a letter was sent 
with a request to contact the study center to make an appointment.
Assessment of coronary risk
The nature of nonparticipation in population research makes it inherently difficult to investigate. 
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Therefore, we examined nonparticipation during a follow-up visit rather than at study enrollment. 
This ensured that we had data on cardiovascular risk factors for all persons, including the 
nonparticipants of the third examination. For each person, we estimated the predicted absolute 
10-year coronary heart disease risk at enrollment (RS-1-I; 1990 to 1993; Figure 1.1) based on 
traditional cardiovascular risk factors under the Adult Treatment Panel III guidelines.27 Coronary 
risk was expressed in percentage-points (range between 1 and 30%) of the Framingham point 
score as originally published and in the recommended clinical risk categories (< 10% low-risk, 10 
to 20% intermediate-risk, and > 20% high-risk).27 The cardiovascular risk factors were measured 
in a standardized fashion at study enrollment as described in detail previously.104
Assessment of outcome
In order to minimize the possibility of asymmetrical follow-up data collection between those 
who participated and those who did not participate in the third examination, we focused on 
all-cause mortality as the outcome of interest. With respect to the vital status of all persons 
enrolled in the Rotterdam Study, information is obtained on a weekly basis from the central 
registry of the municipality of the city of Rotterdam, through direct digital linkage of the study 
database with the electronic medical records of the general practitioners working in the study 
area, and through active follow-up as described in more detail elsewhere.105 Follow-up data 
collection was done irrespective of participation during follow-up examinations.
Statistical analysis
All analyses were performed for 2 different comparisons. First, nonparticipation in the home 
interview was compared to participation in the home interview (reference category). Second, 
nonparticipation in the center visit was compared to participation in the center visit (reference 
category).
We studied the association between predicted coronary risk and participation during the third 
examination by logistic regression models adjusted for age at the date of invitation, sex, and 
level of education. P for trend was obtained by entering coronary risk categories into the logistic 
models as a continuous variable. Since it is the difference in coronary risk distributions between 
the study participants and the entire underlying population that is of interest,106 we compared 
distributions of predicted coronary risks between all invitees and subgroups of participants 
using χ2 test for categorical data.
Hazard ratios (HRs) adjusted for age at start of follow-up, sex, and level of education (in 7 
categories) were computed using Cox proportional hazards models.107 In order to assess 
changes of the hazards over time since the start of follow-up the proportional hazards 
assumption was tested, by entering interaction-terms of log-transformed follow-up time with 
participation status, and violated (P < 0.001). Therefore, the HRs over the 10-year follow-up 
are to be interpreted as a weighted average over this period.108 Start of follow-up was defined 
as follows: participants in the center visit were followed from the date of examination at the 
research center onwards; participants in the interview only were followed from the date of 
home interview onwards; and the nonparticipants were followed from the date of declining the 
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invitation onwards.
Missings in cardiovascular risk factors (0.2 to 5.7%) were handled by single imputation using an 
expectation-maximization algorithm.109 With the exception of the baseline characteristics (Table 
3.1), results are reported for imputed data. All estimates of relative risk are presented with 95% 
confidence intervals (CIs). Exact 95% CIs using a Poisson distribution were calculated for the 
absolute mortality rates. Data were analyzed using the IBM SPSS Statistics version 20.0.0.1 (IBM 
Corp., Somers, NY, U.S.) and R version 2.15.1.110
Results
Of 5423 eligible invitees (mean age 73.5 years; 39% men), 87% participated, of whom 76% 
visited the research center (Table 3.1). Nonparticipants had lost interest (50%), had physical 
complaints (34%), or considered themselves too old to participate (12%; mean age 86.9 
years). Persons who were elderly, women, less educated, and with higher levels of specific 
cardiovascular risk factors were less likely to participate (Table 3.1).
Nonparticipation was strongly associated with mortality (HR 1.71; 95% CI 1.56-1.88]). This 
was most pronounced shortly after invitation (0-3 months, HR 4.85; 95% CI 2.43-9.71), with a 
diminishing healthy volunteer effect during follow-up (P for trend < 0.001) (Table 3.2).
Every percentage-point increase in coronary risk yielded an approximately 3% lower probability 
of participating (Table 3.3). Those categorized as high-risk were least likely to participate (odds 
ratio 0.56; 95% CI 0.45-0.71) (Table 3.3). There was a slightly lower proportion of high-risk 
persons among the examined participants compared with all invitees (23% versus 24%) (Table 
3.4).
Discussion
More than 5 decades ago, investigators from the Framingham Heart Study observed higher 
mortality rates in those who refused to participate.12 They speculated that mortality in 
participants and nonparticipants might converge later during follow-up. We indeed noticed 
declining differences in mortality rates at long-term follow-up. The large difference shortly after 
invitation is presumably attributable to clinical or subclinical disease that makes invitees less 
likely to volunteer.92 Residual differences at long-term follow-up could reflect a health-care-
aversive attitude or a lower awareness of health in general.106 However, long-term benefits of 
participation in population-based research cannot be ruled out because most studies (including 
the Rotterdam Study) disclose results from measurements (e.g. blood pressure and cholesterol 
levels) and incidental findings (e.g. aneurysms and indolent cancers) to the participants.106, 111
Methodological considerations
Follow-up examinations of many cohort studies extend over decades to accrue repeated 
measurements on changes in risk factors or to introduce state-of-the-art diagnostics as the 
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Chapter 3
study progresses. These follow-up examinations often serve as new baselines for analysis. The 
healthy volunteer effect may be different during follow-up compared to study enrollment. All 
persons enrolled have demonstrated a positive attitude towards population-based research and 
subsequent drop-outs might be more likely for reasons of health or disease, rather than lack of 
interest. Conversely, highly committed persons might be less likely to decline an invitation, even 
if they face problems with their health.
We would have preferred to have measurements on cardiovascular risk factors at the time of 
invitation. Using measurements obtained at enrollment (mean 6.3 years prior to the invitation 
for the third examination) will most likely result in an underestimation of the association 
Table 3.2 – Risk of mortality associated with nonparticipation in the third examination, by 
time since invitation
Follow-up time Deaths Participants Non-participants HR (95% CI) b
Mortality rate (95% CI) a Mortality rate (95% CI) a
Home interview:
  0-10 years 2175 45.3 (43.3-47.6) 88.7 (80.5-97.4) 1.44 (1.29-1.60) c
  0-3 months 41 21.4 (13.8-31.5) 88.3 (50.4-143.3) 2.79 (1.45-5.36) d
  3-6 months 40 24.1 (16.0-34.8) 67.9 (35.1-118.5) 2.16 (1.07-4.35) d
  6-12 months 108 31.7 (24.9-39.9) 101.8 (70.9-141.6) 2.18 (1.44-3.32) d
  1-2 years 214 36.6 (31.2-42.6) 77.9 (57.8-102.7) 1.44 (1.04-1.99) d
  2-5 years 645 40.5 (37.0-44.2) 86.1 (72.5-101.6) 1.53 (1.27-1.85) d
  5-10 years 1127 56.4 (52.9-60.1) 94.1 (80.8-108.9) 1.23 (1.05-1.45) d
Center visit:
  0-10 years 2175 39.5 (37.5-41.7) 94.4 (87.9-101.2) 1.71 (1.56-1.88) c
  0-3 months 41 12.6 (6.7-21.6) 87.2 (57.9-12.6) 4.85 (2.43-9.71) d
  3-6 months 40 14.6 (8.2-24.1) 79.8 (51.7-117.8) 4.57 (2.32-8.97) d
  6-12 months 108 23.6 (17.4-31.2) 98.7 (75.3-127.1) 2.83 (1.89-4.26) d
  1-2 years 214 29.8 (24.7-35.7) 83.5 (67.6-102.1) 1.82 (1.37-2.43) d
  2-5 years 645 34.3 (30.9-37.9) 90.4 (79.8-102.1) 1.81 (1.53-2.14) d
  5-10 years 1127 51.4 (47.9-55.1) 103.1 (92.3-114.9) 1.44 (1.26-1.64) d
a Per 1000 person-years.
b Adjusted for age at start of follow-up, sex, and level of education; participants are the reference category.
c Proportional hazards assumption violated (P < 0.001); interpret HR as weighted average over 10-year follow-up time.
d HR is interpreted to be conditional on the survival until the start of the time interval.108
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between predicted coronary risk and nonparticipation. Alternatively, we could have used data 
from the local general practice registries where no active participation is required. However, 
the data stored in such databases were collected for clinical purposes rather than research 
purposes and therefore incompleteness and lack of standardization of measurements would be 
bring forward other important limitations.
We explicitly chose to study the effects associated with nonparticipation on all-cause 
mortality, rather than cardiovascular end points. This decision was driven by the exploration 
of the available data on cause-specific mortality showing that a cause of death could not be 
adjudicated in 59 (3.4%) persons who died after the home interview and 32 (7.4%) persons who 
died after declining the home interview (P < 0.001). Follow-up on vital status on the other hand 
was virtually complete (n = 17 lost to follow-up at 10 years, predominantly due to emigration; 
99.7% complete for participants versus 99.6% for nonparticipants, P = 0.61). Patterns and point 
estimates were, however, almost identical for all-cause and cardiovascular mortality (data not 
shown).
Last, the participation rates, as observed in our elderly study population (mean age at invitation 
73.5 years) (Table 3.1), may mitigate the underestimation of the mortality rates and the 
distributions of predicted cardiovascular risk in the underlying population. In order to attain 
such participation figures, we visit invitees for extensive home interviews and have built a 
dedicated research center in the Ommoord district prior to the start of the Rotterdam Study. As 
a consequence, our results may not be generalizable to studies with much lower participation 
rates.112, 113
Table 3.3 – Participation during follow-up, by levels of predicted coronary heart disease risk
NCEP ATP III FPS Participation in home 
interview
Participation in center 
visit
OR (95% CI) a OR (95% CI) a
Per percentage-point increase 0.974 (0.961-0.987) 0.970 (0.959-0.980)
Risk categories:
  Low (< 10%) 1.00 (reference) 1.00 (reference)
  Intermediate (10-20%) 0.72 (0.58-0.90) 0.68 (0.57-0.82)
  High (> 20%) 0.59 (0.45-0.77) 0.56 (0.45-0.71)
  P for trend < 0.001 < 0.001
Predicted 10-year coronary heart disease risks were derived from the FPS and categorization of risk was based on the 
NCEP ATP III guidelines.27
FPS = Framingham point score.
a Adjusted for age at invitation for the third examination, sex, and level of education.
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Implications
Our focus on distributions of absolute cardiovascular risk is new information. This is important 
in light of the recent shift in cardiovascular epidemiologic research toward evaluating new risk 
markers on the basis of their clinical utility in risk prediction (i.e. whether the predicted risks with 
addition of a new marker change sufficiently to alter recommended therapy) rather than the 
marker’s association with cardiovascular disease expressed as an odds ratio or HR.114 In contrast 
to the study of associations, the risk distribution in the study population affects the magnitude 
of measures of risk reclassification, such as net reclassification improvement.115 Given that most 
people have a low predicted cardiovascular risk (Table 3.4), underrepresentation of persons at 
higher cardiovascular risk will usually mean that smaller proportions of persons are reclassified, 
resulting in lower estimates of net reclassification improvement;115 therefore, the contribution 
of emerging risk markers could be underestimated. We observed a small underrepresentation 
of persons at high cardiovascular risk (1.2% less at high risk) (Table 3.4); thus, results from 
analyses on absolute cardiovascular risk are not likely to be severely affected. However, future 
simulation studies could quantify the degree of bias on measures of risk reclassification.
Table 3.4 – Distributions of predicted 10-year coronary heart disease risk, by degrees of 
participation during follow-up
NCEP ATP III risk 
categories
All invitees Participants in home 
interview
Participants in center 
visit
n = 5423 n = 4692 n = 4126
Low (< 10%) 2318 (42.7) 2070 (44.1) 1867 (45.2)
Intermediate (10-20%) 1783 (32.9) 1514 (32.3) 1302 (31.6)
High (> 20%) 1322 (24.4) 1108 (23.6) 957 (23.2)
P value a Reference < 0.001 < 0.001
Values are counts (percentages). Predicted 10-year coronary heart disease risks were derived from the Framingham 
point score and categorization of risk was based on the NCEP ATP III guidelines.27
a P value for comparison in distributions of risk over clinical risk categories between all invitees (reference) and 
participants in home interview or visit to the research center.
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Chapter 4
Hippisley-Cox and colleagues noticed a nearly 2-fold higher lifetime risk of cardiovascular disease 
(CVD) in the Rotterdam Study 116 as compared to results from the QResearch database.117 In this 
chapter we discuss how these differences might be explained.
Part of the discrepancies in results may arise from the difference in CVD definitions used in 
the 2 studies. Other differences in study design should also be highlighted. Population-based 
cohort studies are generally smaller than administrative databases and will inevitably lack 
information on invitees unwilling or unable to participate. However, cohort studies collect 
baseline information on risk factors (e.g. smoking and cholesterol levels) in a standardized way 
for every participant, whereas availability of information in administrative databases depends 
on healthcare-seeking behavior of patients and not all important risk factors are assessed and 
registered in every patient. Moreover, due to the use of multiple data sources,105 follow-up in 
prospective cohort studies is more detailed and may include more outcomes as compared to 
studies solely relying on administrative data.
The Rotterdam Study is a prospective population-based cohort study of an unselected sample 
of the population of the city of Rotterdam, the Netherlands (Figure 1.1).32-37 Population-based 
cohort studies, including in the Rotterdam Study,118 have repeatedly been shown to represent 
a lower risk population than the underlying eligible source population due to selective non-
participation of individuals with a poorer health status. This results in somewhat lower event 
rates rather than an overestimation of cardiovascular risk and thus does not explain the 
difference observed by Hippisley-Cox and colleagues. Besides, the Netherlands is considered 
a low risk country by the European Society of Cardiology.8 Recent work from the Rotterdam 
Study has shown that established cardiovascular risk calculators, including the SCORE calculator 
for low risk countries,5 overestimate risk in the Rotterdam Study.104, 119 This indicates that the 
Rotterdam Study population is not a particular high-risk population. Finally, lifetime risks of 
CVD in the Rotterdam Study are comparable to those found in a recent meta-analysis on 5 
prospective population-based cohort studies from the U.S.120
What then may explain the observed difference in results? For one, the comparison of crude 
incidence rates over the studies are hampered by differences in age distribution. Mean (SD) 
age was 67.6 (8.9) in the Rotterdam Study 116 and 48.1 (14.3) in QResearch.117 A comparison of 
prevalence of diabetes mellitus is similarly flawed, since glucose levels were measured in all 
Rotterdam Study participants at baseline, whereas these were missing for many individuals in 
QResearch.
Lifetime risk of death from cardiovascular causes is a uniform way to compare cardiovascular 
risk between populations. A greater burden of CVD will be reflected by a greater proportion 
of deaths attributable to CVD. We calculated lifetime risk of death due to CVD using the 
data described in Chapter 11.116 When applying a broad definition that also included non-
atherosclerotic end points and sudden deaths,105 remaining lifetime risk of death due to CVD 
was 34.3% (95% CI 32.6-35.8%) at age 55; using a stricter definition based on International 
Classification of Diseases, tenth revision (ICD-10; codes I00-I99), we estimated this to be 28.7% 
(95% CI 27.2-30.2%). These results are in line with nationwide data from Statistics Netherlands 
(CBS) on the second decade of our study period (2003-2010; 31% for ages 18 and over),121, 122 as 
well as the data presented in the 2012 statistics report from the British Heart Foundation (33% 
for ages 55 and over).123
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In this context it is remarkable that the lifetime risks at age 55 in QResearch (37% in men and 
28% in women for fatal and non-fatal CVD combined) are similar to or lower than the 33% 
probability of dying from CVD according the British Heart Foundation.123 This makes one wonder 
whether the striking difference in results might be due to an underestimation of lifetime risks in 
QResearch rather than an overestimation in the Rotterdam Study.
Mortality from CVD is declining in Western societies. Yet the prospect that 2 out of 3 healthy 
adults at age 55 will face some form of CVD during their lifespan should reinforce efforts to 
motivate people to adopt a healthy lifestyle and underscores the importance of primordial and 
primary prevention.
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- Jay S. Kaufman and Miguel A. Hernán
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Chapter 5
The net reclassification improvement (NRI) is an increasingly popular measure for evaluating 
improvements in risk predictions. This chapter details a review of 67 publications in high-
impact general clinical journals that considered the NRI. Incomplete reporting of NRI 
methods, incorrect calculation, and common misinterpretations were found. To aid improved 
applications of the NRI, the chapter elaborates on several aspects of the computation and 
interpretation in various settings. Limitations and controversies are discussed, including the 
effect of miscalibration of prediction models, the use of the continuous NRI and ‘clinical NRI’, 
and the relation with decision analytic measures. A systematic approach toward presenting 
NRI analysis is proposed: detail and motivate the methods used for computation of the NRI, 
use clinically meaningful risk cut-offs for the category-based NRI, report both NRI components, 
address issues of calibration, and do not interpret the overall NRI as a percentage of the study 
population reclassified. Promising NRI findings need to be followed with decision analytic or 
formal cost-effectiveness evaluations.
Since the introduction of the term risk factor more than 50 years ago,11 many such factors 
have been identified. Risk factors have been incorporated into statistical models to predict 
occurrence of disease, to more adequately diagnose patients, and to predict outcomes after 
disease has been diagnosed. A substantial number of clinical guidelines have incorporated risk 
prediction models to aid clinicians in everyday decision making in various fields of medicine, 
including cardiology, oncology, and respiratory medicine.8, 27, 124-128
Many markers, such as biomarkers, genetic factors, and imaging results, have been proposed 
to improve these prediction models. In the past 3 decades, the most commonly used measure 
to quantify these improvements has been the change in the c-statistic, also known as the 
area under the receiver operating characteristic curve (AUC). Studies have emphasized the 
limitations of the AUC, including the difficulty in interpreting the usually small changes in this 
statistic and the relation of the magnitude of improvement to the performance of the baseline 
model.17, 129-131 A more relevant criterion may be to assess whether the addition of the marker 
to an existing model will influence clinical practice,114 which is the case if the newly predicted 
risk crosses a clinically meaningful threshold for an individual. This has led to the introduction 
of the concept of risk reclassification,132 which involves cross-tabulating categories of predicted 
risk for 2 models—usually one with the new marker under study and the other without it—
to see how persons are classified differently when these models are used. The subsequent 
changes in risk classification can be quantified by the net reclassification improvement (NRI).16 
Risk reclassification analysis with the NRI has become popular: more than 1000 publications 
have cited the 2008 article that introduced the NRI.16 However, reporting of the methods used 
is of heterogeneous quality,133 and misconceptions are common in interpreting the NRI.134
In this chapter, we aim to provide a systematic assessment of the reporting practices in analyses 
involving the NRI and address some controversies relating to its use and interpretation. We also 
make recommendations on how to report and interpret the NRI.135
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Overview of current reporting
Literature search and data extraction
We systematically collected studies that computed the NRI or discussed results from NRI analysis. 
We used the Thomson Reuters Web of Knowledge (version 5.9) to identify all publications that 
cited 1 of 4 methodological articles by Pencina and colleagues 16, 136-138 or a methodological 
review on reclassification measures by Cook and Ridker.139 The search was last updated on 23 
April 2013 and yielded 1250 unique citations (Figure 5.1). We selected all 67 citations in the 4 
general clinical journals with the highest impact factors (New England Journal of Medicine, The 
Lancet, Journal of the American Medical Association, and Annals of Internal Medicine) for data 
extraction (Appendix Tables 5.1 and 5.2).104, 139-204 Our rationale was that these articles may be 
expected to have broad impact and be used as examples for others.
Figure 5.1 – Summary of literature search and selection of articles
Figure 5.1 
 Citations to articles of interest (n = 1479) 
 Pencina et al 2008 (n = 1119) 
 Pencina et al 2010 (n = 39) 
 Pencina et al 2011 (n = 168) 
 Pencina et al 2012 (n = 18) 
 Cook and Ridker 2009 (n = 135) 
Unique publications (n = 1250) 
Selected publications (n = 66) 
 New England Journal of Medicine (n = 15) 
 The Lancet (n = 7) 
 Journal of the American Medical Association (n = 28) 
 Annals of Internal Medicine (n = 16) 
Publications included in the review (n = 67) 
Duplicates excluded (n = 266) 
Added through hand-search (n = 1) 
The search was last updated on 23 April 2013.
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Two evaluators independently extracted data from the publications. Cases on which the 
evaluators disagreed were discussed with a third evaluator to reach consensus. All publications 
were searched for NRI calculations or results. If these were found, we checked which version of 
the NRI was used: the category-based NRI 16 or the continuous (category-free) NRI 137 (Table 5.1). 
Next, we reviewed all articles to determine whether risk categories corresponding to diagnostic 
or treatment thresholds from clinical guidelines were used to evaluate the category-based NRI 
or whether other categorization was justified. We determined which NRI components were 
reported: solely the overall NRI, or the event NRI and the nonevent NRI (Table 5.1). Moreover, 
we categorized studies that reported estimates of the overall NRI on the basis of whether they 
reported it as a unitless statistic or a percentage.
Table 5.1 – Formulas and interpretation of the net reclassification improvement
NRI type Formula and interpretation
Category-based: a
  Event NRI  =  Pr(up|event) – Pr(down|event)
 = (number of events classified up – number of events classified down) / 
number of events
The net percentage of persons with the event of interest correctly 
classified upwards
The category-based event NRI can be interpreted as a percentage with a 
range of -100% to +100% b
  Nonevent NRI  =  Pr(down|nonevent) – Pr(up|nonevent)
 = (number of nonevents classified down – number of nonevents 
classified up) / number of nonevents
The net percentage of persons without the event of interest correctly 
classified downwards
The category-based nonevent NRI can be interpreted as a percentage 
with a range of -100% to +100% b
  Overall NRI  = [Pr(up|event) – Pr(down|event)] + [Pr(down|nonevent) – 
Pr(up|nonevent)]
 = event NRI + nonevent NRI
The sum of the net percentages of correctly reclassified persons with 
and without the event of interest
Thereby, the category-based overall NRI is a statistic that is implicitly 
weighted for the event-rate and cannot be interpreted as a percentage
The theoretical range of the category-based overall NRI is -2 to +2
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Results
The predominant reason for citing any of the methodological articles was the computation of 
NRI estimates (n = 39) (Table 5.2). In 2 (5%) articles, only the continuous NRI was computed. In 
5 articles, the NRI was used to compare 2 different models instead of the nested addition of 1 
or more new risk markers to a simpler model.
Of the 37 articles that computed category-based NRI results, 34 (92%) detailed the cut-offs for 
the risk categories chosen. The number of risk categories defined in the computation of the NRI 
Table 5.1 (continued)
NRI type Formula and interpretation
Continuous: c
  Event NRI  =  Pr(higher|event) – Pr(lower|event)
 = (number of events with increased predicted risk – number of events 
with decreased predicted risk) / number of events
The net percentage of persons with the event of interest correctly 
assigned a higher predicted risk
The continuous event NRI can be interpreted as a percentage with a 
range of -100% to +100% b
  Nonevent NRI  =  Pr(lower|nonevent) – Pr(higher|nonevent)
 = (number of nonevents with decreased predicted risk – number of 
nonevents with increased predicted risk) / number of nonevents
The net percentage of persons without the event of interest correctly 
assigned a lower predicted risk
The continuous nonevent NRI can be interpreted as a percentage with a 
range of -100% to +100% b
  Overall NRI  = [Pr(higher|event) – Pr(lower|event)] + [Pr(lower|nonevent) – 
Pr(higher|nonevent)]
 = event NRI + nonevent NRI
The sum of the net percentages of persons with and without the event 
of interest correctly assigned a different predicted risk
Thereby, the continuous overall NRI is a statistic that is implicitly 
weighted for the event-rate and cannot be interpreted as a percentage
The theoretical range of the continuous overall NRI is -2 to +2
NRI = net reclassification improvement; Pr = probability.
a Assumes that clinically meaningful categories of predicted risk can be defined.
b Negative percentages are interpreted as a worsening in risk classification (i.e. the number of incorrectly reclassified 
events [or nonevents] exceeds the number of correctly reclassified events [or nonevents]).
c Does not consider any categorization.
64
Chapter 5
Table 5.2 – Results from the literature review on reporting of the net reclassification 
improvement
Reporting of NRI feature Studies, n (%)
Reason for citing methodological article on NRI:
   Claimed to have calculated NRI 39 (58.2) a
   Discussed NRI results from previous analysis 4 (6.0) a
   Suggested alternative methods for quantifying predictive abilities 16 (23.9) a
   Computed other (non-NRI) measures elaborated on in this article 8 (11.9) a
Risk categorization:
   Only continuous (category-free) NRI computed 2 (5.1) b
   Categorization for computing NRI detailed 34 (91.9) c
   Categorization for computing NRI justified in text 10 (27.0) c
   Reference given for NRI categorization 14 (37.8) c
   Categorization for computing NRI corresponded to diagnostic or 
therapeutic implications in clinical guidelines
4 (10.8) c
Time horizon and follow-up:
   Predicted horizon detailed 30 (78.9) d
   Observed follow-up detailed (mean, median, or maximum) 37 (97.4) d
   Predicted time horizon longer than observed follow-up 7 (23.3) e
Components:f
   Overall NRI 36 (92.3) b
   Event NRI and nonevent NRI in text or tables 11 (28.2) b
   Reclassification table for main findings 25 (67.6) c
Unit:f
   Reported as a percentage 24 (66.7) g
   Interpreted as a percentage or proportion 8 (22.2) g
NRI = net reclassification improvement.
a Of all 67 publications included in the literature review.
b Of 39 studies that calculated the NRI.
c Of 37 studies that calculated the category-based NRI.
d Of 38 prospective studies that calculated the NRI.
e Of 30 prospective studies that calculated the NRI and detailed the predicted horizon and follow-up.
f Table 5.1 provides more details.
g Of 36 studies that reported the overall NRI.
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varied between 2 and 6, with 3 being the most common number (Appendix Table 5.1). These 
risk categories were justified in the text, by references, or both ways in 15 (41%) instances and 
fully matched clinically meaningful categories with clear implications from guidelines in 4 (11%) 
instances (Table 5.2). For outcomes other than atherosclerotic cardiovascular disease (CVD), 
the rationale for the risk categorization could not be traced in 10 of 12 instances. Another 8 
studies on the prediction of various manifestations of CVD used cut-offs for the NRI that are the 
subject of ongoing debate 145, 176, 186, 205, 206—for example, a 10-year risk cut-off of 6% (rather than 
10%) for low risk for coronary heart disease. Fourteen publications applied cut-offs for coronary 
risk stratification to broader definitions of CVD (Appendix Table 5.1).
Among 38 prospective studies that calculated the NRI, 30 (79%) clearly reported the time 
horizon at which the risk predictions were evaluated. In 7 of 30 (23%) instances where both 
predicted horizon and observed follow-up were detailed, we could infer that the authors studied 
a predicted horizon beyond the observed follow-up time (Table 5.2). We identified another 7 
studies that used events occurring beyond the predicted horizon in the reclassification analysis.
Nearly all studies reported the overall NRI. Only 11 (28%) articles presented its components—
the event NRI and the nonevent NRI—in the results section. However, 25 (68%) presented 
reclassification tables stratified for events and nonevents (Table 5.2), which allowed for 
computation of both NRI components by a knowledgeable reader. By combining the 
components presented in the text and the reclassification tables, we identified 29 (74%) studies 
with information on the event NRI and nonevent NRI presented for at least 1 reclassification 
analysis. Of note, 1 study claimed to have calculated the NRI, but no such results could be 
traced. Another study presented P values but no point estimates of the NRI.
Of the 36 studies presenting estimates of the overall NRI, 24 (67%) expressed it as a percentage 
(Table 5.2). Eight (22%) articles in our review interpreted the overall NRI as a percentage or 
proportion of the entire study population that was correctly reclassified or used similar wording, 
such as interpreting an overall NRI of 0.29 as “29% of patients were correctly reclassified”.134, 156
NRI computation, components, and interpretation
Predicted time horizons and follow-up
When prospective data are involved, such as cardiovascular events occurring during follow-up, 
the time horizon used to calculate the predicted risks should be clear. Because virtually every 
prospective study has some loss to follow-up, it is important to adequately handle observations 
with incomplete follow-up in the analysis. In our review, we found that studies published shortly 
after the introduction of the NRI often did not report how incomplete follow-up was handled. 
Some studies classified censored observations as nonevents (‘naive extrapolation’) or excluded 
persons with incomplete follow-up. Better methods have been proposed to limit loss of useful 
information, including Kaplan-Meier estimates of the expected number of events and nonevents 
(‘prospective NRI’)137, 194 and inverse-probability weighting.207 Similarly, not every study has 
sufficient follow-up available for the predicted time horizons used in clinical guidelines (for 
example, 10-year risk for coronary heart disease 205). In the articles we reviewed, authors made 
various attempts to overcome this problem, such as using Weibull extrapolation,165, 170 adjusting 
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the predicted risk cut-offs by the ratio of actual to desired follow-up,141 or extrapolating the 
observed rates on the Kaplan-Meier survival estimates to the predicted time horizon for 
presentation purposes.139
Risk categories
The NRI was introduced with the example of the added value of high-density lipoprotein 
cholesterol level to coronary risk prediction in the Framingham Heart Study.16 Current clinical 
guidelines on primary prevention of CVD recommend clear cut-offs for initiation of statin 
treatment.8, 27, 205, 206 These recommendations are supported by cost-effectiveness analyses. The 
NRI captures the change in a person’s predicted risk that crosses one of such cut-offs and thus 
translates into a clinically meaningful change in treatment recommendations.
Our review of the literature confirms the findings of Tzoulaki and colleagues: selected risk cut-
offs are generally poorly motivated and rarely correspond to therapeutic implications. Both 
shortcomings have been shown to yield significantly higher NRI estimates.133, 197 In some cases, 
the existing clinical cut-offs may result in limited reclassification. For example, in a study of a 
population at very low risk for CVD, only a small number of participants would be considered 
to be at high risk; therefore, few will cross the recommended risk thresholds after the addition 
of a new marker.208 Using the existing cut-offs illustrates the limited utility of a new marker in 
real-life application to such a low-risk population. Choosing a priori clinically meaningful cut-
offs has been frequently emphasized.16, 133, 136, 137, 176, 179, 197, 208-214 In addition, the estimates of 
the NRI and its components increase with the number of categories.211, 215 Limiting analysis to 
clinically meaningful categories will forestall authors from presenting results from the cut-offs 
with the highest magnitude of NRI in their data. Moreover, consistent use of cut-offs enhances 
comparability of results on the same markers between studies provided that the same outcome 
definition and time horizons are used.
Although many risk prediction algorithms are described in the medical literature, a limited 
number of clinical guidelines outside the field of cardiology explicitly recommend risk thresholds 
for use in clinical practice. In the fields where meaningful cut-offs are lacking or evolving, 
various options have been suggested to overcome this problem. Each has its own caveats. First, 
in some cases, classification thresholds exist for related outcomes. For example, a 20% 10-year 
risk for ‘hard coronary heart disease’ corresponds to a 25% 10-year risk for ‘total coronary 
heart disease’.216 In these situations, a conversion factor based on the ratio of event rates—in 
this example, a ratio of 1.25—can be used to translate cut-offs from one application to another. 
Such conversion assumes that the associated clinical implications are similar for the different 
outcome definitions, which may not always be true. For example, the protective effect of statins 
on the occurrence of cardiovascular manifestations other than coronary heart disease, such as 
heart failure, may be less.217 Similarly, conversion factors can be used to define risk cut-offs for 
different predicted time horizons (for example, 30-year versus 10-year risks 218). In the absence 
of published conversion factors, the data under study can be examined to define the relative 
occurrence of the outcomes. Second, some researchers have suggested defining risk categories 
based on the event rate. A cut-off equal to the event rate would be used for binary classification, 
and cut-offs equal to half the event rate, the event rate, and twice the event rate would be used 
when more than 2 categories are desired.215, 219 Such cut-offs, however, have no direct clinical 
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interpretation. The appropriateness of risk cut-offs should be related to the anticipated use of 
the prediction model. As an example, myocardial infarction risk thresholds for a model used to 
select patients with chest pain for early discharge from an emergency department will be much 
lower than those for a model used to identify patients with chest pain who will benefit from 
early invasive coronary angiography. Third, the continuous NRI was introduced as an alternative 
in the absence of any categorization (Table 5.1).137 However, it does not quantify the clinical 
impact of risk reclassification (see limitations and controversies section). The relation between 
cut-offs and the risk distribution in the data can be elegantly visualized in reclassification graphs 
with superimposed cut-offs (Figure 5.2 220).
Figure 5.2 – Example of a reclassification graph with superimposed cut points of predicted risk
Figure 5.2 
 
The graph shows 10-year risk for incident CHD in women from the Atherosclerosis Risk in Communities (ARIC) Study 
predicted by a model containing only the Framingham risk score variables (horizontal axis) against risk predicted by a 
model containing Framingham risk score variables and retinal arteriolar caliber (vertical axis). Lines at predicted risks 
of 10% and 20% are superimposed to show reclassification over clinically relevant cut points 27, 205 and thereby create 
a visual representation of a reclassification table (e.g. Tables 13.3 and 13.4 165, 221). Of note, most women in this study 
have a low (< 10%) predicted risk for CHD, both with the Framingham variables and with the model that includes retinal 
arteriolar caliber. The graph also shows that a limited number of women are reclassified over the cut points (i.e. only 
a small proportion of dots lies in the off-diagonal cells of the graph). CHD = coronary heart disease. Reproduced from 
McGeechan and colleagues 220 with permission of the American Journal of Cardiology.
Case-control studies
Because of cost and feasibility, the predictive value of new biomarkers is often studied in subsets 
of persons with events and nonevents from larger prospective studies, especially when the event 
rates are low. The NRI can be used in both cohort studies and (nested) case-control studies.137 
In the latter, the researcher determines the ratio of events (cases) to nonevents (controls) by 
selective oversampling of cases, which implies artificial weighting by the investigators.160 This 
should not lead to different estimates in magnitude of the NRI compared with results derived 
from a full cohort provided that the cases and controls are randomly selected.137, 222 However, 
difficulties arise when selected controls are not representative of the entire underlying subset 
68
Chapter 5
they were drawn from, as in the case when matching on certain risk factors (even as simple as 
age and sex) is done.222-224 This can be overcome by weighting for the inverse of the sampling 
probability for cases and controls.217, 222
Components and interpretation
Although the article that introduced the NRI recommended reporting the components of the 
overall NRI,16 we noticed in our review that a limited number of studies did so. The components 
are easier to interpret than the combined number: when only 1 cut-off is being evaluated, the 
event NRI equals the improvement in sensitivity and the nonevent NRI equals the improvement 
in specificity.16 The NRI components then express the net percentages of persons with or 
without events correctly reclassified (Table 5.1). Negative percentages for the components 
are interpreted as a net worsening in risk classification. The overall NRI is the sum of these 
2 underlying components; as a result, an identical point estimate of this statistic may have 
different interpretations depending on its components.178, 209 Large positive values of the event 
NRI indicate that the investigated marker aids in the detection of persons with the outcome of 
interest. This enables clinicians to initiate targeted treatment and thereby prevent events. On 
the other hand, an overall NRI driven by the nonevent NRI indicates the marker’s property of 
correctly decreasing risk estimates for nonevents and is thus useful for reducing overtreatment. 
However, such markers will have limited contribution to decreasing the burden of disease. This 
illustrates the difficulty of interpreting the overall NRI without knowledge of its components.225 
Although it is tempting to do so, the overall NRI cannot be interpreted as the “net percentage of 
persons correctly reclassified” 165 in a straightforward manner because of the implicit weighting 
by the event rate: the overall NRI is the sum of 2 fractions with different denominators (the 
number of events and nonevents).134 Such misinterpretations may have contributed to the 
popularity of the overall NRI, which therefore should not be presented as a percentage but 
as a unitless statistic.134 Moreover, the components of the overall NRI may be reasonably well 
interpretable, whereas their sum is less so because of the implicit weighting related to the event 
rate (the costs of misclassification are assumed to be proportional to the odds of nonevents) 
(Table 5.1).226
As with most summary statistics, the NRI should not be interpreted on its own but in the context 
of complementary statistical measures. If a marker is not associated with the outcome or does 
not yield an increase in the AUC, a positive NRI should not be expected.210 In rare instances 
where this does occur, random chance or differences in calibration between the models are 
the most likely causes. Also, presenting reclassification tables (in tabular or graphical form) will 
aid in the broader interpretation of summarized reclassification statistics (e.g. Figure 5.2 220 and 
Tables 13.3 and 13.4 165, 221).
Limitations and controversies
Miscalibration
Unlike such rank-based statistics as the AUC, the NRI is affected by miscalibration of a model 
(that is, the average predicted risk is not close to the event rate).226-228 Systematic miscalibration 
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does not occur when the performance of models is assessed on the same data set that 
was used to develop them but is often present when prediction models are validated in 
other populations. A well-recognized example of this phenomenon is the application of the 
Framingham cardiovascular risk models to European populations.104, 229, 230 When performing 
a head-to-head comparison between a Framingham function (using the published coefficients 
and baseline hazard) and a new risk function developed from the data under study, one might 
find an NRI that favors the new model and no difference in the AUCs.231, 232 This discrepancy can 
be avoided by deriving both the reference model and the model including the marker under 
investigation from the same data set that is used to compute the NRIs or by recalibrating both 
models in case of independent validation.233
The traditional Hosmer-Lemeshow goodness-of-fit test is strongly dependent on the sample 
size of the study.234 Therefore, calibration might better be assessed graphically in a plot with 
predicted risks on the horizontal axis and observed event rates on the vertical axis (e.g. Figure 
15.2 104). For perfectly calibrated models, the plot forms a diagonal line where the observed 
event rates equal the predicted risks. Such graphs can show systematic underestimation or 
overestimation as well as issues of overfitting (which can be quantified using the calibration 
slope 235).
Classification or reclassification?
Some researchers have argued that before addressing the issue of reclassification, one should 
first focus on risk classification and examine the margins of a reclassification table.160 Accordingly, 
examining reclassification is useful only to the extent to which it quantifies change in the size 
of these margins. This might be of particular relevance in head-to-head comparisons of non-
nested models with substantial reclassification (that is, if the 2 models have low correlation). 
In this case, knowing how many persons are classified in the clinically relevant subgroups is of 
greater interest than the exact reclassification within the inner cells of the table (e.g. Table 15.2 
104).209, 212 Therefore, when choosing between competing models for clinical practice, the main 
question is which one leads to better classification (which relates to both discrimination and 
calibration of the models). On the other hand, when the focus is primarily on the potential of a 
new marker, the improvements in discrimination and subsequent risk reclassification that it can 
induce are of primary interest.
Continuous NRI
The continuous NRI was originally proposed to overcome the problem of selecting categories 
in applications where they do not naturally exist.137 It does not require any risk categorization 
and considers all changes in predicted risk for all events and nonevents. This has several 
consequences. First, most changes in predicted risk do not translate into changes in clinical 
management; for example, a middle-aged woman whose 10-year predicted coronary risk doubles 
from 1% to 2% will probably not be treated differently.208, 236 Therefore, the interpretation of the 
continuous NRI is different from that of the category-based NRI (Table 5.1).130 Second, when 
the addition of a normally distributed marker is considered, the continuous NRI is less affected 
by the performance of the baseline model and can therefore be seen as a rescaling of the 
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measures of association (for example, an odds ratio of 1.65 per standard deviation corresponds 
to a continuous NRI of 0.395).130, 138 Consequently, the continuous NRI is often positive for 
relatively weak markers.130 Moreover, it is strongly affected by miscalibration, especially in the 
setting of external validation.228
As such, the continuous NRI is less suitable for head-to-head comparisons of competing models 
unless these models have been developed from the same data or are correctly calibrated. The 
most appealing application of the continuous NRI comes in quantifying the effect of an added 
predictor in settings where the distributions of other risk factors may not be representative of 
the population.237 For example, when the same marker for coronary risk prediction is evaluated 
in 2 populations, one with wide and the other with narrow age ranges, the conclusions about its 
usefulness might be different if based on the increment in AUC.131 The continuous NRI, however, 
would give a consistent message and is therefore marker-descriptive rather than model-
descriptive. Furthermore, its magnitude should be assessed on its own scale 130 and should not 
be compared with that of the category-based version.
Clinical NRI
Reclassification measures, including the NRI, can be used to evaluate markers in specific 
subgroups of the study population defined by the reference model. Specifically, the added value 
of new risk markers may be of greater importance in persons with a risk categorization that has 
more uncertainty about the clinical implications (for example, persons at intermediate risk for 
coronary heart disease 150, 165, 178, 188, 189, 202). This ‘clinical NRI’,238 however, has been found to be 
biased because it does not take into account incorrect reclassification from other risk categories 
into the intermediate-risk category.178 Adding randomly generated non-informative markers to 
existing prediction models leads to positive clinical NRIs more frequently than expected on 
the basis of chance.215, 239 A method for correcting this systematic overestimation has been 
published.239
Decision analytic measures
The overall NRI implicitly weights for the event rate, p, with 1 / p and 1 / (1 ─ p) serving as costs 
for false-negative results (events classified downward) and false-positive results (nonevents 
classified upward), respectively.226, 240 However, a different weighting of false-positive and false-
negative results is often more clinically appropriate.214 This can readily be incorporated in a 
weighted version of the NRI if the event NRI and nonevent NRI are presented separately or 
when a reclassification table is provided.137, 241 In its broadest form, the weighted NRI can be 
interpreted as the average savings (for example, in dollars or quality-adjusted life-years) per 
person resulting from using the new model instead of the old one.137
The weighted NRI is a decision analytic measure and is mathematically a transformation of 
changes in net benefit and relative utility.241 These measures use the harm-benefit ratio to 
define an optimum decision threshold for binary classification as high risk versus low risk.242 The 
harm-benefit ratio also defines the weights of true-positive and false-positive classifications to 
calculate a single summary measure.241-243 However, the use of such decision analytic measures 
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is limited by the fact that weights for harms and benefits are not firmly established in most 
fields of medicine,243 although a range of decision thresholds can be considered in a sensitivity 
analysis with visualization in a ‘decision curve’.244
The non-weighted category-based NRI analysis is regarded as an early-stage analysis in the 
evaluation of new markers or prediction models. For assessment of the potential clinical utility 
of promising markers, decision analytic approaches are needed in the next step, after the NRI 
analyses but before a full formal cost-effectiveness analysis that incorporates changes in costs 
and clinical outcomes in more detail.114
Recommendations
In our literature review, we encountered several common flaws in the presentation and 
interpretation of the NRI and insufficient documentation of the computational methods. On 
the basis of our observations, we make the following recommendations for clinical research 
(Table 5.3).135
Clearly defining which type of NRI is used is essential because their applicability and relevance 
vary substantially. The most appropriate NRI type and cut points depend on several factors, 
as discussed in this review. We recommend separate reporting of the NRI for events and 
nonevents in all circumstances. Also, the sum of the NRI components should not be interpreted 
as a percentage. If authors choose to present the category-based NRI, they should discuss the 
implied costs of misclassification by the event rate. The cut-offs selected for the NRI analyses 
should preferably match risk thresholds that have clear clinical implications or can be motivated 
on clinical grounds. In general, the category-based NRI is directly applicable in settings where 
meaningful risk categories exist and models are well calibrated. If either of these conditions is 
not satisfied, one must carefully determine what information the NRI offers and whether it can 
be interpreted meaningfully. Using cut- offs that have no direct clinical meaning impedes the 
interpretation of the category-based NRI. Several methods have been proposed to define cut 
points in situations where meaningful thresholds do not exist, but each has its own caveats. 
Presenting graphical displays similar to a decision curve 244 for a range of cut-offs could be 
considered as an alternative. The continuous NRI can be recommended in only a few settings, 
including those where the primary focus is on the strength of the marker rather than model 
performance. Authors must be careful not to overinterpret the magnitude of the continuous 
NRI, which is usually much larger than that of the category-based NRI, and must ascertain 
that the models are well calibrated. Finally, for mathematical reasons, we recommend against 
calculating P values for any of the forms of the NRI when the contribution of a new marker is 
being evaluated.245, 246 Instead, after a marker has been shown to be statistically significantly 
associated with the outcome, only CIs for the NRI should be presented.
Our recommendations are meant to improve completeness, transparency, and clinical relevance 
of research involving risk reclassification. However, because the scientific debate on the NRI and 
related performance measures is ongoing, our recommendations may be subject to advances 
or additions in the future.
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Table 5.3 – Recommendations for reporting the net reclassification improvement
Article section Recommendation
Methods:
  Type of NRI Specify the type of NRI computed (category-based and/or continuous NRI).
  Follow-up Specify the horizon of risk prediction if the NRI was computed for 
prognostic evaluations (e.g. 10-year risk).
Describe how censored observations (e.g. persons lost to follow-up before 
the specified horizon) were handled.
Use the event status at the predicted time horizon and ignore events 
occurring beyond the predicted time horizon (e.g. when predicting 10-year 
risk of CHD consider participants with a myocardial infarction occurring 
after 10-year of follow-up as nonevents).
  Cut-offs For category-based NRI ideally the categorization should ideally have clear 
consequences in clinical practice.
Where possible, give references to formal clinical guidelines used to define 
the risk categories for the computation of the NRI.
If alternative cut-offs were used, clearly motivate them.
Results:
  Components Report the NRI for events and nonevents separately.
Reclassification tables stratified for persons with and without the event of 
interest are informative beyond the NRI (e.g. Tables 13.3 and 13.4).
  Unit The event and nonevent NRI can be presented as percentages. However, 
the overall NRI has no unit and should therefore not be presented as a 
percentage (see Table 5.1).
  Calibration Provide information on the calibration of the models being compared.
Discussion:
  Interpretation The components of the overall NRI can be interpreted as a net percentage 
of the number of persons with or without events.
However, the overall NRI should not be interpreted as a net percentage of 
the study population correctly reclassified.
  Comparisons Do not draw strong comparative conclusions based on direct comparisons 
of NRIs obtained in different populations or using different outcomes or 
cut-offs.
CHD = coronary heart disease; NRI = net reclassification improvement.
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Appendix Table 5.2 – Summary characteristics of the 67 articles included in the literature 
review
Characteristic Studies, n (%)
Journal:
  New England Journal of Medicine 15 (22.4)
  Lancet 7 (10.4)
  Journal of the American Medical Association 28 (41.8)
  Annals of Internal Medicine 17 (25.4)
Year of print publication:
  2008 8 (11.9)
  2009 13 (19.4)
  2010 16 (23.9)
  2011 12 (17.9)
  2012 15 (22.4)
  2013 3 (4.5)
Cited methodologic article:
  Pencina et al, 2008 56 (83.6)
  Pencina et al, 2010 3 (4.5)
  Pencina et al, 2011 9 (13.4)
  Pencina et al, 2012 0 (0)
  Cook and Ridker, 2009 11 (16.4)
Country of address for correspondence:
  Australia 1 (1.5)
  Canada 2 (3.0)
  Finland 1 (1.5)
  Germany 2 (3.0)
  Greece 1 (1.5)
  The Netherlands 6 (9.0)
  Norway 1 (1.5)
  South Africa 1 (1.5)
  Sweden 4 (6.0)
  Switzerland 1 (1.5)
  U.K. 8 (11.9)
  U.S. 39 (58.2)

C HAPTER 6
Net Reclassifi cati on Improvement: 
Expression and Interpretati on
82
Chapter 6
Gulati and colleagues examined whether information about the presence of myocardial fibrosis 
aided in the prediction of mortality and major arrhythmia in 472 patients with non-ischemic 
dilated cardiomyopathy.156 The predictive ability of fibrosis over left ventricular ejection fraction 
was quantified using the net reclassification improvement (NRI).16
The NRI is the sum of net percentages of patients with and without the outcome of interest 
reclassified correctly. The patients are assigned to more appropriate risk categories that ideally 
correspond with diagnostic or treatment thresholds from clinical guidelines. The NRI has a 
range of -2 to 2.We believe that the authors misinterpreted the NRI results and consequently 
overestimated the contribution of myocardial fibrosis in risk reclassification for mortality and 
arrhythmias.
The authors erroneously simplified the interpretation of the NRI of 0.29 for the arrhythmic 
composite outcome by stating “Overall, 29% of patients were correctly reclassified after adding 
midwall fibrosis status to the risk model (NRI 0.29; 95% CI 0.11-0.48, P = 0.002)”. Presumably 
this misinterpretation comes from the implicit weighting of patients with and without the 
outcome by the event rate in the summation of 2 percentages with different denominators (i.e. 
the number of patients with and without events).16, 137, 240
The NRI is computed by adding up the improvement for patients with major arrhythmia ([23 
─ 11] / 65) and improvements in patients without arrhythmia ([89 ─ 46] / 407), which indeed 
equals 0.29. However, for the entire study population, a total of 23.7% ([23 + 89] / 472) of the 
patients were correctly reclassified, offset by the 12.1% ([11 + 46] / 472) of patients who were 
incorrectly reclassified. As a result, only 11.7% of all patients were net correctly reclassified after 
adding midwall fibrosis status, rather than the stated 29%. Similarly, for predicting mortality 
in these patients (Table 6.1 156), the NRI of 0.26 corresponds to a net of 15.5% of the study 
population with improved categorization rather than the suggested “26% of patients”.
The NRI aims to reflect changes in clinical decision making as opposed to more traditional 
measures of model performance.208 The example above, however, shows that the NRI is difficult 
to interpret and how it is tempting to express the NRI as the percentage of the study population 
correctly reclassified. We would like to raise awareness that the overall NRI should neither be 
expressed nor interpreted as a percentage.
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Table 6.1 – Risk reclassification with the addition of midwall fibrosis status to a risk model 
based on left ventricular ejection fraction
Risk based on LVEF Risk based on LVEF and midwall fibrosis
0-15% > 15%
Patients with arrhythmia (n = 65):
  0-15% 12 23
  > 15% 11 19
Patients without arrhythmia (n = 407):
  0-15% 218 46
  > 15% 89 54
Values represent the number of patients with non-ischemic dilated cardiomyopathy in each risk category according to 
the risk model based on LVEF alone and the risk model based on LVEF and midwall fibrosis status (presence or absence) 
for patients who had an arrhythmic event or did not have an arrhythmic event. LVEF = left ventricular ejection fraction. 
Adapted from Gulati and colleagues.156

C HAPTER 7
Net Reclassifi cati on Improvement: the Importance of 
Cut-off  Selecti on
A Link Between Stati sti cs and Clinical Practi ce
86
Chapter 7
A little over a decade ago, European 247 and U.S. guidelines 27 on cardiovascular disease (CVD) 
prevention first recommended the use of various global risk assessment models. These 
guidelines directly aid clinicians in making decisions on consultation of a healthy lifestyle and 
initiation of drug treatment. The recommendations to use risk scoring algorithms invigorated 
researchers to improve on these existing functions and thereby heralded the current upswing 
in risk prediction research. Ever since a plethora of additional risk factors have been proposed, 
ranging from simple questions on familial predisposition and laboratory measures, to state-
of-the-art vascular imaging. In order to provide guidance the American Heart Association 
issued a comprehensive statement on the stepwise evaluation of the value of novel markers.114 
The expert panel suggested that a new marker should be prospectively associated with the 
outcome, it should add predictive information over established risk factors, the addition of the 
marker should have the potential to modify an individual’s risk sufficiently to change treatment 
recommendations, and finally whether this improves clinical outcomes in a cost-effective 
manner.
For many years, the main criterion used in evaluating and comparing prediction models was 
the c-statistic, or the area under the receiver operating characteristic curve (AUC) for binary 
data.248, 249 This measure, however, is quite insensitive to the addition of strong markers.129, 
130 Its typically small changes in value can be difficult to interpret, especially in the presence 
of other strong predictors.17 Various new statistical methods have been introduced to gauge 
the effect of the addition of a biomarker on clinical decision making. One such method is risk 
reclassification,17 which has gained immediate widespread use and has resulted in a paradigm 
shift, at least in preventive cardiology, from reporting measures of association to changes in 
clinical management. The most commonly used measure for this is the net reclassification 
improvement (NRI).16 The NRI summarizes the net changes of allocation in clinical meaningful 
risk categories for events and nonevents when extending an existing prediction model with a 
novel marker. It can be computed by summing up the proportions of correctly upward classified 
events (correctly qualifying for treatment) and downward classified nonevents (correctly 
abstaining from treatment), subtracted by the proportions of incorrectly downward classified 
events (incorrectly abstaining from treatment) and upward classified nonevents (unnecessarily 
qualifying for treatment). The relative simplicity of the NRI has undoubtedly contributed to its 
popularity.
The NRI, however, has several properties that may impede its clinical interpretation. Recently, 
Mühlenbruch and colleagues clearly illustrate the dependency of the NRI on the number of risk 
categories chosen and the cut points of these categories.211 They use empirical data from the 
EPIC-Potsdam study which was previously used to develop the German Diabetes Risk Score, a 
model designed to predict the absolute 5-year risk of developing type 2 diabetes. The authors 
show that increasing the number of risk categories results in an increase of the NRI. Moreover, 
the placement of the cut points of absolute risk categories has a substantial influence on the 
magnitude of the NRI. The most extreme values of the 2-category NRI occur at thresholds at 
the edge of the data. Few individuals, for example, have predicted diabetes risk > 9%, resulting 
in a limited number of participants getting reclassified when higher cut-offs are chosen. Others 
have similarly shown that the value of the NRI changes as threshold cut points change.210, 236, 
250 Mealiffe and colleagues, however, found that while the NRI tends to be larger when the cut 
points are widely spaced and smaller when the cut points are close together, it was otherwise 
only weakly dependent on the precise placement of the cut points.250
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In fields other than CVD, established meaningful risk categories with direct consequences for 
clinical practice may be sparse. Therefore the results from the present study by Mühlenbruch 
and colleagues are important in that they clearly underline the recommendations to compute 
the NRI only in the setting of a priori meaningful risk categories that have a clear consequence 
for patient care.16 As the authors acknowledge, care should be taken to identify categories that 
have clinical relevance, which would ideally correspond to treatment thresholds or clinical risk 
strata.
A suggested alternative in the absence of firmly established cut-offs is to consider the continuous 
version of the NRI.137 In settings of population prevention, however, typically the majority of 
the population is at low risk, and the purpose of the model is to screen and identify a smaller 
subset that needs clinical attention. For example, in the U.S. Women’s Health Study cohort over 
85% of women had a very low estimated 10-year cardiovascular risk of less than 5% using the 
Framingham risk score variables.139 These women are of limited clinical concern and would 
not generally be followed closely. Small changes in the estimated risk for these women, even a 
doubling from 1 to 2%, would not have clinical impact. Continuous measures, particularly the 
rank-based AUC and continuous NRI, are based on the observed distribution in the entire study 
population, and the lower 85% would have a large impact. While these have advantages with 
respect to avoiding the need to prespecify categories, they may not be as relevant clinically 
since they give weight to regions that may not be clinically important. The continuous NRI 
has also been found to exhibit unusual behavior in particular situations.236, 251 Unlike the AUC, 
it does not depend on the performance of the baseline model and is thus not a measure of 
model improvement.130 This limits the interpretation of the continuous NRI as a model specific 
performance improvement indicator, but it may help evaluate the discriminatory potential of a 
new predictor.130
In analyzing the diabetes data from Potsdam, the German Diabetes Risk Score offered less 
incremental benefit in model fit over a simpler model containing age, anthropometrics, and 
hypertension status. This was reflected by the substantially lower values of the NRI and minimal 
increase in AUC.211 Another way of demonstrating this is by computing the reclassification 
calibration statistic,139 a derivative of the Hosmer-Lemeshow goodness of fit test 252 that 
compares the observed and expected number of events in each cell of the reclassification table 
rather than deciles of predicted risk, thus focusing on calibration rather than discrimination. 
While this test is also affected by the threshold cut-offs chosen, these have less impact than 
in the calculation of the NRI.215, 236 Since sufficient numbers of participants in each cell are a 
prerequisite to get reasonable estimates of the observed rates, in most circumstances 3 or 4 
risk strata are appropriate, with a focus on the area of the risk distribution that is of most clinical 
relevance.
Besides calibration, model validation must also be considered. Because these models are 
nested and fit in the same data, the fit can only improve when assessed in the derivation data 
set. This is true for the difference in AUC, all versions of the NRI, as well as the reclassification 
calibration statistic. The comparison of the AUC for such models has been shown to be biased 
by several authors with overly conservative P values.215, 245, 253, 254 While the other measures have 
been shown to have an appropriate probability of false positive findings,215 the estimates of 
fit will still be optimistic. It is only in other populations or adjustment through resampling that 
proper estimates can be derived.233
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In addition, in many fields, including cardiovascular risk prediction, treatment implications 
are clear for those considered at high risk or low risk of the outcome, but less so for those 
considered at intermediate risk. Often additional testing is ordered to guide decision making 
and to gain insight at what side of the risk spectrum an individual resides. Such cascaded 
testing can be more cost-effective and potentially have the greatest impact on clinical practice. 
Researchers have recently shown interest in examining reclassification properties for additional 
tests within subgroups of the population defined by the reference model.202 The ‘clinical NRI’ 
based on those at intermediate risk only has been suggested as a relevant criterion.238 This, 
however, has been found to be inflated even under the null hypothesis,215 and a solution has 
been offered to correct the bias.215, 239
Thus, as pointed out by Mühlenbruch and colleagues, care must be taken when computing and 
interpreting the NRI in all its forms. The number of categories, the placement of cut points, and 
the distribution of risk in the population of interest all need to be taken into account. As a result, 
the various ways of quantifying risk reclassification all have advantages and caveats. While the 
continuous NRI is attractive, it is not a panacea since it is based on ranks rather than changes 
in magnitude of predicted absolute risk. The categorical NRI, moreover, can be very useful 
when evaluating improvement in assignment to clinically relevant risk strata. Risk stratification 
already exists in a variety of settings,255 and is often incorporated into clinical guidelines.27, 125-127, 
247 While care must be taken in its interpretation, reclassification analysis, including the NRI, can 
be a useful step toward evaluating utility of risk prediction models for use in clinical practice.
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Yeboah and colleagues compared the ability of several risk markers to improve prediction 
of coronary heart disease (CHD) and cardiovascular disease (CVD) among individuals at 
intermediate risk in the Multi-Ethnic Study of Atherosclerosis (MESA).202 They reported that 
coronary artery calcification (CAC) provided superior reclassification compared with other 
novel risk markers and recommended CAC as a tool for refining cardiovascular risk prediction in 
individuals at intermediate risk. While the added predictive ability of CAC in CHD risk prediction 
was substantial and confirmed previous findings,165 supporting CAC as a candidate for CVD 
screening based on the results is less grounded.
While it is straightforward to define an intermediate-risk group for CHD, this is not the case for 
CVD because accepted thresholds are lacking. Yeboah and colleagues 202 included persons at 
intermediate risk for CHD and therefore the results might not necessarily apply to persons at 
intermediate risk for CVD.256
While CAC has been shown to accurately predict CHD in different populations, CAC has not 
been proven to be a useful predictor for stroke.257 In the study by Yeboah and colleagues,202 
addition of CAC to the Framingham risk score provided overall net reclassification improvement 
of 0.659 for CHD and 0.466 for CVD risk categorization. The net percentage correctly reclassified 
in the group without events hardly changed after adding a non-CAC-related outcome such as 
stroke (40.4% for CHD and 36.0% for CVD) (Table 8.1 202). However, the net percentage correctly 
reclassified for those with events, which reflects the ability to identify persons who will benefit 
from intensive treatment, dropped from 25.5% for CHD and 10.6% for CVD (Table 8.1 202).
The net 25.5% correctly reclassified persons with CHD events in the current study 202 and 24.0% 
previously reported 165 imply that adding CAC to risk prediction models moves a substantial 
proportion of persons initially at intermediate risk to the high-risk group, in which they qualify 
for more intensive preventive treatment. This supports the incorporation of CAC in CHD risk 
assessment. However, whether the net 10.6% correctly reclassified persons with CVD events 
provided by CAC is sufficiently large to warrant recommending CAC as a screening tool for CVD 
is doubtful.
The general trend in developing new guidelines on CVD prevention is moving toward focusing on 
broader CVD risk rather than on CHD risk only.258 However, before considering new markers for 
CVD risk prediction, all components of this broad outcome should be considered and limitations 
for stroke risk prediction should be recognized.
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Table 8.1 – Net reclassification improvement for incident coronary heart disease and 
cardiovascular disease with the addition of coronary artery calcification to the Framingham 
risk score in MESA participants at intermediate-risk of coronary heart disease
Outcome Risk category based on FRS 
predictors and CAC
Low
(< 5%)
Intermediate
(5-20%)
High
(> 20%)
Net correctly 
reclassified
Overall
NRI
CHD 0.659
  Persons with event (n = 94) 12 46 36 25.5%
  Persons without event (n = 1236) 589 557 90 40.4%
CVD 0.466
  Persons with event (n = 123) 16 78 29 10.6%
  Persons without event (n = 1207) 493 655 59 36.0%
Values represent the number of MESA participants at intermediate CHD risk by the FRS alone reclassified in risk 
categories according to the model based on FRS plus CAC for participants who had a CHD (or CVD) event or did not have 
a CHD (or CVD) event. CAC = coronary artery calcification; CHD = coronary heart disease; CVD = coronary heart disease; 
FRS = Framingham risk score; MESA = Multi-Ethnic Study of Atherosclerosis; NRI = net reclassification improvement. 
Adapted from Yeboah and colleagues.202
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For the last 3 decades, clinical prediction models have mainly been evaluated on the basis of 
their ability to discriminate between persons who develop the event of interest and persons 
who do not, as quantified by the c-statistic or area under the receiver operator characteristic 
curve (AUC).248, 249 The AUC considers sensitivity and specificity of the model over all possible 
cut points of predicted risk. However, prediction models are often used to classify patients into 
risk categories that correspond to diagnostic or therapeutic decisions. This provoked the idea of 
comparing models according to their ability to adequately assign clinical risk categories based on 
absolute risk estimates.16, 17, 132, 137 Analyses of risk reclassification have hit the ground running: 
uptake of measures such as net reclassification improvement (NRI) has been enormous,115 and 
guidance documents on evaluations of markers and prediction models embraced it as a step 
prior to full-blown cost-effectiveness analysis.114 More recently, several researchers reviewed 
the current applications of reclassification analysis and expressed concerns about inappropriate 
use.115, 133, 134, 210, 251, 259-261
In the introductory article on NRI and integrated discrimination improvement (IDI), Pencina and 
colleagues point out that “IDI (and by extension NRI as well) depends on model calibration” 
because “the discrimination slope suffers from the drawback of being dependent on model 
calibration, the same might also affect the IDI” and “When evaluating the performance of 
a model after addition of a new marker, it is essential to check for improvement (or at least 
no adverse effect if other measures improve) in calibration”.16, 226 Recently, Hilden and Gerds 
warned “not (to) rely on IDI and NRI” and that these measures “offer guidance that cannot be 
trusted” when evaluating the added value of markers to prediction models.228 They employ 
theoretical examples and sophisticated mathematical developments to conclude that “If IDI 
and NRI are used to measure gain in prediction performance, then poorly calibrated models 
may appear advantageous, and in a simulation study, even the model that actually generates 
the data (and hence is the best possible model) can be improved on without adding measured 
information”.228 This puts IDI and continuous NRI in the category of metrics that are “nonproper”, 
in contrast with AUC or Brier score.
One can easily reach the same conclusion as Hilden and Gerds without simulations and 
mathematical developments. For example, when simply doubling predicted risks for all 
individuals in a study, usually a substantial proportion will be reclassified to other risk categories, 
and differences in predicted risks will be inflated. The question regarding the relevance of these 
findings is not convincingly answered in the article by Hilden and Gerds: should we indeed no 
longer trust the conclusions from the over 1000 scientific publications presenting NRI or IDI 
results?
Theoretical example
The example by Hilden and Gerds 228 illustrates the consequences of miscalibration on NRI and 
IDI: a population is broken down into 3 groups sized 50%, 30%, and 20%. The observed event 
rates are 30%, 60%, and 80% in each respective group. Hilden and Gerds compare 2 models: 
the first model correctly assigns a risk of 30%, 60% and 80% to each respective group, while 
the second model assigns a risk of 0% to all persons in the first group and a risk of 100% to all 
persons in the second and third group. Continuous NRI and IDI are positive when comparing the 
second model to the first model (0.76 and 0.22, respectively), suggesting that the second model 
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is better, whereas using the ‘proper’ metrics of AUC and Brier score one observes decreased 
model performance (AUC goes down from 0.71 to 0.69, and Brier score goes up from 0.21 to 
0.31).
We consider a third model to show that even ‘proper’ measures do not have to agree: the model 
assigns a constant predicted risk to everyone, equal to the event rate in the entire population 
(49%) or randomly assigns risks from the interval 48% to 50%. When comparing the third model 
with the second model, we obtain negative continuous NRI and IDI of substantial magnitude 
(-0.76 and -0.38, respectively), suggesting that the third model, which has no discriminatory 
capacity, is much worse than the second. Inference based on AUC concurs (0.69 for the second 
versus 0.50 for the third model). Yet, Brier scores suggest that the third model is better (0.31 for 
the second versus 0.25 for the third model).
This paradox can be explained. Brier score is a combined measure of discrimination and 
calibration, whereas AUC, continuous NRI, and IDI are measures intended to evaluate 
discrimination only. Furthermore, AUC is not affected by calibration whereas NRI and IDI are. 
Our extension of Hilden and Gerds’ example shows how it can be challenging (and confusing) to 
try to summarize both discrimination and calibration with a single metric.
Marker versus model perspective
We consider 2 perspectives on the evaluation of prediction models: one with the primary 
focus on quantifying the contributions of an added marker (‘marker perspective’, focus on the 
intrinsic predictive value of the marker), and another more general perspective on comparing 
the predictions of various candidate models to support clinical decision making (‘model 
perspective’).
Marker perspective
By far, the most common way of evaluating improvements in predictions by a new marker is 
by fitting 2 nested models on the same data set—one model without the marker and one with 
the marker under study—and subsequently compare the predictions from these models.17 In 
such situations, both models are expected to fit the data well without miscalibration, where 
calibration is defined in the weak sense: if the event rate is p among persons whose calculated 
risks are equal to p, then the model risk p(covariables) is considered well calibrated.262 Markers 
are typically added to models which contain a limited number of well-known predictors.133 
Therefore, with adequate sample sizes, miscalibration due to overfitting is unlikely, and NRI 
or IDI hence do not suffer from the suggested bias and spurious inference in this context.138, 233 
Although Hilden and Gerds question “What can happen in real applications?”,228 they do not 
bring up any examples from the literature, because the setting of validating unaltered nested 
models in an external population is not how markers are assessed in medical research. It is 
common practice to refit both models in studies that attempt to verify the value of a marker, 
hence focusing on replication of the previous marker assessment.
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Miscalibration would be a relevant concern when the 2 nested models are applied unaltered to 
an external validation population as studied by Hilden and Gerds.228 Pepe and Janes suggest that 
calibration should be assessed first, and any lack of calibration needs to be corrected before one 
can decide whether a marker holds sufficient promise.262 This can be done by recalibrating the 
model, for example by adjusting the intercept and calibration slope to the external population.233 
We note that such recalibration does not guarantee calibration in a stronger sense, i.e. by 
each covariable pattern.263 Evaluating biomarker’s value using miscalibrated models can lead 
spurious practical recommendations. Imagine a study on whether a new expensive blood 
biomarker should be added to the Framingham risk score. The Framingham and Framingham-
plus-biomarker models are applied to a population in Europe, where the Framingham risk 
score is known to overestimate absolute risks of cardiovascular disease (CVD).104, 229, 230 Without 
recalibration, we could end up with a recommendation to measure the biomarker in the entire 
population because it might improve apparent model performance by improving calibration. 
Such a conclusion is merely of theoretical interest, because a more sensible strategy would be 
to use available resources to recalibrate the Framingham risk score or develop and validate a 
new prediction model.
Model perspective
When comparing several distinct candidate models, it may be relevant to assess which of them 
provides the best risk classification (and concomitant decision-making) for a specific population 
or patient group (e.g. 104, 217, 232). Direct head-to-head comparison of a new model versus an 
existing model or comparison of 2 existing models with coefficients and intercepts applied 
as published (i.e. without refitting or recalibrating) mimics the application of risk models in 
everyday clinical practice. Systematic underestimation or overestimation of established 
risk functions is a fact of life and a well-recognized phenomenon in CVD prediction models 
(e.g. 104, 217, 229, 230, 232, 264).
In this context, a careful assessment of both calibration and discrimination of the models is 
necessary. This can, for example, be accomplished by using AUC for discrimination and the 
slope-and-intercept approach for calibration (or graphically by calibration plots)235, 243, or by 
decomposing a summary measure such as the Brier score.265 In situations where clinically 
meaningful risk categories exist, the components of the category-based NRI can be used to 
quantify differences in risk classification due to both discrimination and calibration. It should be 
noted that, in these situations, NRI needs to be interpreted in the context of the complementary 
measures of calibration and discrimination.115 Decision analytic summary measures, such as the 
change in net benefit,244 relative utility,266 or weighted NRI,137 may however be most appropriate 
for head-to-head comparisons of prediction models used for classification purposes. Findings 
on substantive miscalibration of established risk functions may inspire efforts to recalibrate or 
adapt these models.217, 229, 230
We note that IDI 16 and continuous NRI 137 were not proposed for the ‘model perspective’. 
However, differences in discrimination between candidate models can be quantified by 
continuous NRI or IDI but only after ascertaining adequate calibration.
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Conclusions
Appropriate application and interpretation of the NRI and IDI are imperative to avoid spurious 
claims of improved prediction and erroneous clinical inference.115, 133 Like most other summary 
statistics, NRI and IDI should not to be interpreted on their own, but combined with metrics 
such as the change in AUC, calibration measures, and decision analytic measures in order to 
assess increments in clinical usefulness.114, 115, 133, 210, 259 Depending on the perspective, model 
calibration is a necessary condition for the evaluation of the intrinsic value of an added marker 
or can be an inherent part of head-to-head comparisons of candidate models. We do not see 
this property as limiting the applicability of NRI and IDI, especially not when examining the 
potential of a new marker using nested models that are fitted on the same study population.
Heart attacks were recognized as a public health problem only in this century.
They are likely to lose this notoriety early in the next.
- Michael S. Brown and Joseph L. Goldstein
Heart attacks: Gone with the century?
Science 1996;272(5262):629
PART I I I
Quanti fying the Burden of Cardiovascular Disease

C HAPTER 10
Heart Disease in the Netherlands
A Quanti tati ve Update
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In this chapter we discuss cardiovascular mortality, incidence and prevalence of heart 
disease, and cardiac interventions and surgery in the Netherlands. We combined most 
recently available data from various Dutch cardiovascular registries, Dutch Hospital Data 
(LMR), Statistics Netherlands (CBS), and population-based cohort studies, to provide a 
broad quantitative update. The absolute number of people dying from cardiovascular 
diseases is declining and cardiovascular conditions are no longer the leading cause of death 
in the Netherlands. However, a substantial burden of morbidity persists with 400,000 
hospitalizations for cardiovascular disease involving over 80,000 cardiac interventions 
annually. In the Netherlands alone, an estimated 730,000 persons are currently diagnosed 
with coronary heart disease, 120,000 with heart failure, and 260,000 with atrial fibrillation. 
These numbers emphasize the continuous need for dedicated research on prevention, 
diagnosis, and treatment of heart disease in the Netherlands.
This chapter provides an update on the current number of persons with cardiovascular and 
cardiac disease manifestations in the Netherlands. Although the mortality from cardiovascular 
disease (CVD) in our country has declined, its disease burden remains high. Therefore, recent 
data on the number of patients with specific clinical cardiac disease entities, those having 
undergone surgical or percutaneous procedures, as well as estimates of the number of 
hospitalizations for cardiac reasons, are also given.
Data have been derived from various sources. Because it was not possible to obtain 
information from the year 2012 in every instance, exact present-day numbers of procedures or 
hospitalizations may be slightly dissimilar from those provided herein. Still, we hope that our 
numbers will provide some insight into the actual burden of heart disease in the Netherlands 
and its management.
Cardiovascular mortality
Since its peak in the late 1950s (in women) and the early 1970s (in men), cardiovascular mortality 
in the Netherlands has gradually declined. This reduction has occurred despite the larger number 
of elderly persons as well as the more advanced age of contemporary Dutch citizens. After 
correction for these changes (standardization), the drop in cardiovascular mortality that has 
taken place, a reduction of about 70%, is considerable.122, 267 Cardiovascular mortality from 1950 
to 2012 is delineated in Figure 10.1. After 1980, the cardiovascular mortality rates in women 
and men tend to converge.267 Currently, CVD accounts for 27% of all deaths. This percentage 
was 33% 10 years ago, 37% in 1992 and between 45 and 50% in earlier decades. In the year 
2012, 39,048 persons (20,733 women and 18,315 men) died from a primary cardiovascular 
cause (Table 10.1).122 The number of persons dying from CVD amounted to 46,942 in 2003, and 
thus a drop in absolute numbers of deaths from CVD has taken place concomitantly with the 
relative decrease in fatal CVD. Cardiovascular mortality as a fraction of total mortality in the last 
10 years is presented in Table 10.1. The specific causes of cardiovascular mortality in the year 
2012 are presented in Table 10.2.122
Inspection of the data makes it clear that most cardiovascular deaths result from atherosclerotic 
disease affecting the coronary, cerebral, and other arterial vessels. Women die more often from 
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more ‘mature’ atherosclerotic manifestations such as stroke and heart failure than men: the 
latter die in larger numbers from myocardial infarction (MI). However, one should appreciate 
that the primary cause of death is often difficult to ascertain and, in particular in persons 
over 80 years of age, may not be accurate.73, 89 For instance, the number of 766 individuals 
supposedly dying from infectious CVD could well be false, since neither the incidence of 
Figure 10.1 – Standardized cardiovascular mortality per 100,000 inhabitants in the Netherlands 
from 1950 through 2011
Figure 10.1 
 
 
Adapted from the National Public Health Compass (National Institute for Public Health and the Environment [RIVM]).267
Table 10.1 – Total and cardiovascular mortality in the Netherlands from 2003 through 2012
Year Cardiovascular mortality Non-cardiovascular mortality Total
n (%) n (%) n
2003 46,942 (33) 94,994 (67) 141,936
2004 44,638 (33) 91,915 (67) 136,553
2005 43,350 (32) 93,052 (68) 136,402
2006 41,720 (31) 93,652 (69) 135,372
2007 40,849 (31) 92,173 (69) 133,022
2008 40,129 (30) 95,007 (70) 135,136
2009 38,897 (29) 95,338 (71) 134,235
2010 39,009 (29) 97,049 (71) 136,058
2011 38,132 (28) 97,609 (72) 135,741
2012 38,371 (27) 102,442 (73) 140,813
Source: Statistics Netherlands (CBS). Adapted from Vaartjes and colleagues.122 Reproduced with permission of the 
Dutch Heart Foundation.
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bacterial endocarditis (estimated to be approximately 300 cases per year in the Netherlands) 
nor its clinical course (estimated case fatality less than 20%) are able to account for the numbers 
reported.268 Although the incidence of infective endocarditis has been stable in other parts of 
Europe over the past decades,269 it must be noted that contemporary data from the Netherlands 
are lacking.
On their own, atrial fibrillation (AF) and hypertension represent unlikely primary causes of 
death, yet thousands of deaths are attributed to these morbid conditions. Also, the mortality 
statistics combine causes and modes of death. For instance, heart failure is not a disease entity 
in itself, but merely a symptom of underlying cardiac conditions. Presumably many more 
persons die from the consequences of heart failure,270 but these deaths are attributed to for 
instance coronary, valvular, or congenital heart disease. This is likewise also the case for sudden 
cardiac death, which now only constitutes a minor part of the cause of death statistics (‘Other 
heart diseases’ in Table 10.2), whereas Dutch population-based studies have demonstrated that 
approximately 10% of all deaths in adults fulfill the criteria for sudden cardiac death.85, 271
Table 10.2 – Cardiovascular causes of death in the Netherlands in 2012
Cause of death Men Women Total
n (%) n (%) n (%)
Ischemic heart disease 5691 (31) 4029 (19) 9720 (25)
  Myocardial infarction 3514 2681 6195
Cerebrovascular disease 3302 (18) 5222 (25) 8524 (22)
Congenital heart disease 64 (< 1) 46 (< 1) 110 (< 1)
Rheumatic and valvular heart disease 698 (4) 1023 (5) 1721 (4)
Infectious heart disease 331 (2) 435 (2) 766 (2)
Other heart diseases 5778 (32) 7543 (36) 13,321 (34)
  Heart failure 2625 4136 6761
  Atrial fibrillation 538 939 1477
Arterial vascular disease 1067 (6) 714 (3) 1781 (5)
Atherosclerosis and/or hypertension 1023 (6) 1227 (6) 2250 (6)
Other vascular disease 361 (2) 494 (2) 855 (2)
Total 18,315 (100) 20,733 (100) 39,048 (100)
Source: Statistics Netherlands (CBS). Adapted from Vaartjes and colleagues.122 Reproduced with permission of the 
Dutch Heart Foundation.
107
10
Heart disease in the Netherlands
Coronary heart disease
On the basis of estimates from registries in the general population from 2007, 648,300 Dutch 
citizens had coronary heart disease (CHD) (estimated prevalence in women 3%, and 5% in men). 
Combined with the incidence of CHD in the same year (82,100 persons), the total number of 
women and men with CHD was estimated to be 730,400. Of these, an estimated 298,100 had 
angina.267 Although men and women are struck by cerebrovascular disease at about the same 
age (data not shown), women develop CHD disease approximately 10 years later than their 
male counterparts (Figure 10.2).
Figure 10.2 – Coronary heart disease incidence per 1000 inhabitants in the Netherlands in 
2007
Figure 10.2 
 
 
Source: general practice registry. Adapted from the National Institute for Public Health and the Environment (RIVM).267
Myocardial infarction
In 2012, 3514men and 2681 women died from an MI (Tables 10.2 and 10.3).122 Their absolute 
numbers in the years between 1980 and 2012 are presented in Table 10.3. MI-associated 
mortality declined significantly by more than 70% over time in both men and women. Age-
standardized mortality declined even further. The number of hospitalizations for MI in 2012 
was 20,025 in men and 9653 in women. Between 1980 and 2012, the age-standardized MI 
admission rate (year of standardization: 2012) declined by 42% in men and by 23% in women. 
However, the absolute number of hospitalizations for MI has not changed much.122
Significant discordance in mortality statistics based on self-reports of hospitals (performance 
indicators) and data from clinical registries is noted. Hospital mortality from MI is between 5 and 
10% according to data from Statistics Netherlands (CBS), with age being the main determinant 
of adverse outcomes. The incidence of first MI has been declining by about 3 to 4% per year in 
the last decade, both in men and women. Total incidence declined by 38% in men and by 32% 
in women between 1998 and 2007.272, 273
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Table 10.3 – Absolute number of fatal myocardial infarctions in the Netherlands from 1980 
through 2012
Year Men Women
n (%) Per 100,000 inhabitants n (%) Per 100,000 inhabitants
1980 12,634 180 7718 108
1985 12,486 174 8082 110
1990 10,002 135 7300 97
1995 8888 116 6800 87
2000 7291 93 5668 70
2005 5361 66 4141 50
2010 3840 47 2983 36
2012 3514 42 2681 32
Data are not standardized. Source: Statistics Netherlands (CBS). Adapted from Vaartjes and colleagues.122 Reproduced 
with permission of the Dutch Heart Foundation.
Surgical procedures
The total number of surgical procedures, including pediatric surgery, has gradually increased 
over the years to 17,293 operations in 2012, performed in 16 surgical centers (Figure 10.3).122 
Seven percent of these interventions are ‘urgent’ (i.e. take place before the start of the next 
working day after the decision to operate has been taken).274
About two-thirds of the 16,262 operations in adults in 2012 involved coronary artery bypass 
grafting (CABG), while half of all surgical procedures are represented by isolated CABG 
(source: Supervisory Committee for Cardiac Interventions in the Netherlands [BHN]). In these 
procedures, the use of only arterial grafts has increased from 15% in 1995 to nearly 26% in 
2011.274 The 30-day mortality of isolated CABG in 2010 was 1.2%.122
In 2012, a total of 3020 operations were related to diseases of the aortic valve, and in 41% of 
these procedures coronary bypass grafts were implanted (source: Supervisory Committee for 
Cardiac Interventions in the Netherlands [BHN]). The type of prostheses implanted has gradually 
changed from mainly mechanical prostheses in the 1990s to the use of bioprostheses in nearly 
80% of the operations nowadays. In addition to CABG and aortic valve surgery, mitral valve 
surgery is the most common indication for cardiac surgery with approximately 1750 operations 
annually. Concomitant CABG is performed in 36% of these operations.122 The proportion of 
mitral valve repairs has increased to over 75%. Active endocarditis is reported in less than 200 
surgical procedures per year.274 Overall the 30-day mortality associated with valvular surgery in 
2010 was 3.6%.122
Mainly as a result of varying availability of donor hearts, the number of yearly heart transplants 
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has varied considerably over the years. On average, about 40 to 50 transplants are performed 
each year in 3 academic medical centers.275
Other procedures include aortic surgery (approximately 1000 operations per year), transcatheter 
aortic valve implantation, and less frequently performed procedures such as surgical left 
ventricle reconstruction, ventricular septal rupture repair, rhythm surgery (as a concomitant or 
as a stand-alone procedure), surgery for correction of congenital heart disease, or management 
of cardiac trauma.276, 277
Percutaneous coronary interventions
While the number of surgical procedures has only risen gradually in the last decade, this has not 
been the case with the percutaneous interventions (PCIs). Their number has risen much more 
quickly in recent years. For instance, in 2012, 45,305 PCIs were performed in 30 centers, and 
this number represents more than a doubling of these procedures in a time frame of only 10 
years (Figure 10.3).122, 278 The most frequent indications for PCI were stable angina (42%), acute 
MI (33%) and unstable angina (22%). Over 90% of the procedures involved stent placement.275
ICD and pacemaker implants
There has been a substantial increase in the number of implantable cardioverter-defibrillator 
(ICD) implants in the last 10 years. Symptomatic patients with advanced heart failure (e.g. 
left ventricular ejection fraction < 30%) are the main recipients. Currently, their number is in 
Figure 10.3 – Absolute number of surgical procedures and percutaneous coronary interventions 
in the Netherlands from 1983 through 2012
Figure 10.3 
 
 
Source: Supervisory Committee for Cardiac Interventions in the Netherlands (BHN). Adapted from Vaartjes and 
colleagues.122 Reproduced with permission of the Dutch Heart Foundation.
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the order of about 5000 new implants per year (Table 10.4). Registration of indications is not 
complete, but most (approximately 80%) implants are prophylactic, i.e. implanted in patients 
at high risk for sudden cardiac death. The other patients receive an ICD after successful 
resuscitation. In addition to the new ICD implants, their replacement currently adds over 1000 
procedures to the numbers presented in Table 10.4.275 ICDs now have the ability to perform 
biventricular pacing in patients with heart failure and conduction abnormalities in order to 
emulate physiological cardiac function (i.e. cardiac resynchronization therapy). Biventricular 
systems are becoming more popular and now account for almost 40% of all procedures. The 
average age of the patients is 66 years and 23% of them are women. Relatively few (6%) ICDs 
are implanted beyond the age of 80 years.
Based on the Dutch ICD and Pacemaker Registry (DIPR), an additional 10,389 pacemakers 
(excluding cardiac resynchronization therapy) were implanted in 92 contributing hospitals in 
2011. A fourth of the pacemaker implantations were replacements of another device.
Table 10.4 – Absolute number of new implantable cardioverter-defibrillator implants based 
on 29 centers in the Netherlands from 2003 through 2012
Year Non-CRT CRT Total
n (%) n (%) n
2003 800 (82) 180 (18) 980
2004 1237 (79) 327 (21) 1564
2005 1724 (72) 665 (28) 2389
2006 2005 (67) 967 (33) 2972
2007 2590 (72) 1030 (28) 3620
2008 2644 (69) 1175 (31) 3819
2009 2890 (68) 1385 (32) 4275
2010 2986 (62) 1804 (38) 4790
2011 3192 (61) 2007 (39) 5199
2012 3051 (63) 1830 (37) 4881
CRT = cardiac resynchronization therapy. Source: Netherlands Heart Rhythm Association (NHRA). Adapted from Vaartjes 
and colleagues.275 Reproduced with permission of the Dutch Heart Foundation.
Heart failure
As with most other CVD, the presence of heart failure casts a shadow over the last phase of life 
in a considerable number of Dutch individuals. Between 20 and 30% of the general population 
will develop some form of heart failure, usually when they are over 70 years of age.78 Incidence 
rates in the Netherlands increase steeply from about 1 per 1000 person-years below 60 years of 
age to almost 50 per 1000 person-years in those aged 90 years and over.
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Due to the ageing of the population, an increase in the number of patients with heart failure 
in the Netherlands was already predicted in the 1990s.279 Contemporary data have confirmed 
that forecast, and an estimated 120,000 individuals with heart failure, about 1% of the adult 
Dutch population, were reportedly present in 2008. The continuing ageing of the population is 
expected to raise their numbers to an approximate 200,000 in the coming decade.270
The majority of heart failure is diagnosed in chronic stages, but episodes of acute cardiac 
decompensation can lead to hospitalization. In 2011, 29,916 hospital admissions were 
registered in the Netherlands with heart failure as the primary discharge diagnosis (source: 
Dutch Hospital Data [LMR]).273 The numbers are equally distributed over both sexes. This 
number includes readmissions which are known to be frequent in patients with heart failure. 
Recent Dutch data on the ratio of first admissions to readmissions is lacking, but studies from 
U.S. registries consistently report 30-day readmission rates up to 25%.280 Between 1980 and 
1990, the number of hospitalizations for heart failure increased by about 50%. Thereafter, a 
decrease was observed but, as of 2002, the number of hospitalized patients increased again, 
although the total number of days spent in hospital has more or less stabilized.270
The prognosis of patients with heart failure has been described as being more ‘malignant’ 
than that of many common cancers.281 Five-year survival after the initial diagnosis ranges from 
approximately 25 to 35% in population-based studies.78 The in-hospital mortality associated 
with decompensated heart failure is poor, even for first occurrences, and has been reported 
to be in the order of 15% in the Netherlands.78 This is worse than the currently observed in-
hospital mortality associated with acute MI.
Figure 10.4 – Absolute number of deaths attributed to myocardial infarction or heart failure 
as the primary cause of death in the Netherlands from 1980 through 2012Figure 10.4  
 
Source: Statistics Netherlands (CBS). Adapted from Vaartjes and colleagues.122 Reproduced with permission of the 
Dutch Heart Foundation.
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The absolute number of Dutch citizens dying either from MI or heart failure has been depicted 
in Figure 10.4, and clearly shows the direction of the change in both causes of death. Since 
2012, the number of deaths from heart failure (n = 6761) has surpassed the mortality from MI 
(n = 6195) (Table 10.2 and Figure 10.4).122
Atrial fibrillation
AF is the most common sustained cardiac arrhythmia. The condition carries serious health 
consequences, including increased risk for stroke and heart failure. AF is found to be present 
in about a quarter of patients presenting with an ischemic stroke. The presence of many other 
cardiometabolic disorders, such as coronary and valvular heart disease, cardiomyopathies, 
hypertension, and diabetes, predispose to the development of AF.
Estimates from a Dutch population-based cohort study indicate that the lifetime risk of AF is 
in the order of 20 to 25%. As with heart failure, its occurrence strongly increases with age: 
the incidence rate of AF below 60 years of age is less than 1 per 1000 person-years, but rises 
to almost 20 per 1000 person-years in persons over 85 years of age.80 These estimates may 
underestimate the true incidence since the presence of AF, either permanent or paroxysmal, 
may go undetected clinically.
On the basis of the best available data, an estimated 260,000 Dutch individuals are currently 
affected by AF.282 These were responsible for 42,188 hospital admissions in 2011 with AF as the 
primary discharge diagnosis (source: Dutch Hospital Data [LMR]).273 Between 1994 and 2006, no 
major changes in its prevalence were observed but, given current demographic developments, 
an increase in the number of persons with AF in the coming years is projected.282
Hospitalizations for cardiovascular disease
During the last years, the number of hospitalizations associated with CVD has stabilized at 
around 400,000 (2400 per 100,000 inhabitants). Almost 115,000 (29%) of these comprise 1 day 
admissions related to diagnostic or therapeutic procedures, or observations of cardiovascular 
symptoms. In the remaining cases, the mean duration of hospital stay is about 6 days (source: 
Statistics Netherlands [CBS]). Admission rates for rhythm disturbances are on the rise.273
Discussion
With plausible estimates of 730,000 patients with CHD, of 120,000 persons with heart failure, 
and of 260,000 men and women with AF, the total count of Dutch individuals with some 
manifestation of heart disease could be as high as 1 million. In addition, a substantial number 
of women and men have other forms of atherosclerotic disease, either of the cerebral and/or 
the peripheral arterial system. However, since atherosclerosis is usually not limited to one organ 
system and many cardiac and vascular diseases co-exist, the simple summation of the various 
disease manifestations will likely overestimate the number of individuals with cardiovascular 
and/or heart disease. In view of the high CVD prevalence, it is striking that actual mortality 
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from CVD has declined so much. Currently, 27% of all deaths result from CVD, and cancer has 
overtaken CVD as the main cause of death in the Netherlands in both women and men (source: 
Statistics Netherlands [CBS]). Cardiovascular mortality in the Netherlands is low in international 
comparisons. The current Dutch age-standardized mortality from CVD is 147 per 100,000, and 
only Spain and France have lower cardiovascular mortality rates (143 and 126 per 100,000, 
respectively). In all other European countries, including for instance Switzerland and Greece, 
cardiovascular mortality is higher.283
The number of cardiac procedures in the Netherlands, in particular that of PCI and CABG, is 
below the Organisation for Economic Cooperation and Development (OECD) average. As in most 
other European countries, the rate of PCI versus CABG is in the order of 2.5. Both the numbers 
of percutaneous and surgical cardiac procedures in the Netherlands are 50% lower than in our 
affluent neighboring countries, Belgium and Germany.283 Patients with an acute MI are the 
main PCI target population with about 13,000 procedures in 30,000 patients hospitalized for 
MI. The 15,000 PCIs performed for stable angina constitute a relatively large proportion of PCI 
procedures, although the large number of patients with angina in the population must be taken 
into account.
Throughout our review we have cited various sources from which we obtained data on CVD 
in the Netherlands. However, data from different sources can be conflicting due to differential 
participation of hospitals in registries or due to the outcome definitions used. As an example, 
cardiovascular mortality is defined differently in the statistical updates from the Dutch Heart 
Foundation 272 compared to Statistics Netherlands (CBS). This results in minor discrepancies 
in the annual number of deaths attributable to CVD, in this case related to the inclusion or 
exclusion of congenital and perinatal heart disease and vascular autoimmune disorders (e.g. 
Tables 10.1 and 10.2).
Future projections are always fraught with uncertainty, but demographic trends undeniably 
suggest an increase in the number of patients with heart disease and other forms of CVD in the 
not too distant future. Still, these trends are not dissimilar to the circumstances observed in the 
last decades, during which time cardiovascular mortality decreased so markedly. Most likely, 
these developments will continue, and high morbidity (and high prevalence) but relatively low 
mortality from CVD remains the most plausible scenario for the foreseeable future.
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Objective
To evaluate differences in first manifestations of cardiovascular disease (CVD) between men 
and women in a competing risks framework.
Design
Prospective population-based cohort study among persons living in the community in 
Rotterdam, the Netherlands.
Participants
8419 participants (60.9% women) aged 55 years or older and free from CVD at baseline.
Main outcomes
First diagnosis of coronary heart disease (CHD; myocardial infarction, revascularization, 
and coronary death), cerebrovascular disease (stroke, transient ischemic attack, and 
carotid revascularization), heart failure, or other cardiovascular death; or death from non-
cardiovascular causes. Data were used to calculate lifetime risks of CVD and its first-incident 
manifestations adjusted for competing non-cardiovascular death.
Results
During follow-up of up to 20.1 years, 2888 participants developed CVD (826 CHD, 1198 
cerebrovascular disease, 762 heart failure, and 102 other cardiovascular death). At age 55, 
overall lifetime risks of CVD were 67.1% (95% CI 64.7-69.5%) for men and 66.4% (95% CI 64.2-
68.7%) for women. Lifetime risks of first-incident manifestations of CVD in men were 27.2% 
(95% CI 24.1-30.3%) for CHD, 22.8% (95% CI 20.4-25.1%) for cerebrovascular disease, 14.9% 
(95% CI 13.3-16.6%) for heart failure, and 2.3% (95% CI 1.6-2.9%) for other deaths from CVD. 
For women the figures were 16.9% (95% CI 13.5-20.4%), 29.8% (95% CI 27.7-31.9%), 17.5% 
(95% CI 15.9-19.2%), and 2.1% (95% CI 1.6-2.7%), respectively. Differences in the number of 
events that developed over the lifespan in women compared with men (per 1000) were 7 
fewer for any CVD, 102 fewer for CHD, 70 more for cerebrovascular disease, 26 more for heart 
failure, and 1 fewer for other cardiovascular death; all outcomes manifested at a higher age 
in women. Patterns were similar when analyses were restricted to hard atherosclerotic CVD 
outcomes, but absolute risk differences between men and women were attenuated for both 
CHD and stroke.
Conclusions
At age 55, though men and women have similar lifetime risks of CVD, there are considerable 
differences in the first manifestation. Men are more likely to develop CHD as a first event, 
while women are more likely to have cerebrovascular disease or heart failure as their first 
event than men, although these manifestations appear most often at older ages.
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For both men and women, cardiovascular disease (CVD) remains among the leading causes 
of death and disability in Western societies.284, 285 Considerable sex differences exist, however, 
in the occurrence of the various manifestations of CVD. Men have a higher risk of CHD than 
women, especially at younger ages.286 Women, on the other hand, have a similar or greater 
propensity for developing stroke 287 and heart failure.78, 288 Because strategies for prevention of 
stroke and heart failure might differ from strategies for prevention of coronary heart disease 
(CHD), knowledge about the first manifestation of CVD is important for primary prevention 
purposes. Population-based data on sex differences in CVD are scarce for the various first 
manifestations of CVD.
Women have a higher life expectancy than men and consequently have more time to develop 
CVD. Cardiovascular risk factors, such as smoking, not only increase the susceptibility for 
CVD but are also associated with an increased risk of dying from non-cardiovascular causes 
before the development of CVD.289, 290 Therefore, in comparisons of first manifestations of CVD, 
competing risks among the different manifestations and death from non-cardiovascular causes 
cannot be neglected. To date no studies have compared multiple first manifestations of CVD 
between men and women in a competing risks framework.
We used long term follow-up data from the prospective population-based Rotterdam Study to 
calculate the lifetime risks of CVD and the first-incident manifestations of CVD in middle-aged 
and elderly men and women.
Methods
Study design, setting, and population
This study was performed within the Rotterdam Study, a prospective population-based cohort 
designed to study the occurrence and determinants of age related diseases in the general 
population. Details regarding the objectives and design have been reported previously.32-37 
Briefly, for the initial cohort (RS-I-1; Figure 1.1) all inhabitants aged 55 years or older from a 
well-defined suburb in the city of Rotterdam, Netherlands, received an invitation to participate, 
and 7983 (78.1%) were enrolled. Levels of participation at baseline did not differ for men and 
women but were lower with increasing age.103 Between 1990 and 1993, baseline data were 
collected during standardized home interviews and 2 visits to the research center. Starting in 
2000, the Rotterdam Study was extended with a second cohort (RS-II-1; Figure 1.1) of inhabitants 
who reached the age of 55 and persons who migrated into the research area since the start of 
RS-I-1. A total of 3011 (67.3%) were enrolled, and baseline data were collected between 2000 
and 2001. Besides the minimum age, there were no other criteria for eligibility for participation 
in either of the cohorts.
For the present analysis, we excluded all participants with a history of CVD (CHD, cerebrovascular 
disease, or heart failure) at baseline (n = 1421), those who did not visit the research center at 
baseline for assessment of cardiovascular risk factors (n = 1034), those who did not provide, 
or withdrew, informed consent for collection of follow-up data (n = 76), and those without 
any available follow-up data (n = 44). This left a total of 8419 persons eligible for the present 
analysis.
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Data collection during follow-up
Follow-up started at the date of assessment of cardiovascular risk factors at the research center. 
Methods for the follow-up and data collection in the Rotterdam Study have been described in 
detail elsewhere.105, 291 Briefly, data on clinical outcomes are collected continuously through 
an automated follow-up system involving digital linkage of the study database to medical 
records maintained by general practitioners working in the research area. Moreover, well-
trained research assistants affiliated with the study regularly check the medical records of each 
participant by hand for diagnoses of interest. Notes, outpatient clinic reports, hospital discharge 
letters, electrocardiograms, and imaging results are collected from general practitioner records 
and hospital records. Subsequently, research physicians independently adjudicate all data on 
potential events. Afterwards, medical specialists whose judgments are considered decisive 
review the potential cases. Information on vital status is additionally obtained from the central 
registry of the municipality of the city of Rotterdam.
Assessment of cardiovascular disease outcomes
All participants were followed up for the occurrence of incident CHD, cerebrovascular disease, 
heart failure, other cardiovascular death, and non-cardiovascular death. Definitions and 
procedures on the adjudication of cardiovascular outcomes have been described in detail 
previously.78, 105, 291, 292 Briefly, CHD was defined as fatal or non-fatal myocardial infarction (MI), 
surgical or percutaneous coronary revascularization procedure (as a proxy for unstable or 
incapacitating angina), or death from CHD.105 Cerebrovascular disease was defined as stroke,291 
transient ischemic attack,292 or carotid revascularization procedure. In accordance with the 
guidelines of the European Society of Cardiology heart failure was defined as the combination 
of typical symptoms and signs, confirmed by objective evidence of cardiac dysfunction or a 
positive response to initiated treatment.78, 105 Other deaths from CVD included all cardiovascular 
mortality other than fatal CHD or fatal stroke, such as deaths from aortic aneurysms, peripheral 
vascular disease, valvular heart disease, and pulmonary embolisms.105
Hard CHD was defined as fatal and non-fatal MI or definite coronary mortality. Hard 
cerebrovascular disease was defined as non-hemorrhagic stroke. Other atherosclerotic 
cardiovascular deaths mainly encompassed deaths from abdominal aortic aneurysms and 
peripheral vascular disease. These definitions of hard atherosclerotic CVD correspond with the 
endpoints used in clinical trials and guidelines for primary prevention of atherosclerotic CVD.
Assessment of cardiovascular risk factors
Standardized assessment of anthropometrics, cardiovascular risk factors, and medication use 
at baseline has been described in detail for both RS-I-1 104 and RS-II-1.165 In RS-I-1, diabetes 
mellitus was defined as a random or post-load serum glucose concentration ≥ 11.1 mmol/L, 
or the use of blood glucose-lowering medication. In RS-II-1, diabetes mellitus was defined as a 
fasting serum glucose concentration ≥ 7.0 mmol/L, a non-fasting serum glucose concentration 
≥ 11.1 mmol/L (only if fasting serum was unavailable), or the use of blood glucose-lowering 
medication. A family history of premature MI was defined as having a parent, sibling, or child 
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who experienced a MI before the age of 65. Use of blood pressure-lowering medication was 
defined as the use of antiadrenergics, diuretics, β blockers, calcium channel blockers, or renin-
angiotensin system modifying agents.
Statistical analysis
We used linear regression models or Mann-Whitney U tests for continuous data and χ2 tests for 
categorical data to compare baseline characteristics between men and women.
We calculated remaining lifetime risks for first-incident CVD and its components (CHD, 
cerebrovascular disease, heart failure, and other cardiovascular death) for men and women 
at age 55, 65, 75, and 85. When older individuals are followed for longer time periods, death 
from non-cardiovascular causes precludes the occurrence of CVD in many. Similarly, when first 
manifestations of CVD are studied, the occurrence of one manifestation precludes consideration 
of any subsequent CVD event. The preclusion of disease-specific outcomes of interest by death 
or other outcomes are referred to as competing risks.293, 294 Standard application of survival 
analysis, such as Cox regression and Kaplan-Meier estimates, do not take competing risks into 
account as those who develop competing events are censored. Consequently, absolute risks 
are overestimated.293, 294 We therefore used a method that takes into account the occurrence of 
competing events to compute lifetime cumulative incidences in left truncated data with age as 
time scale.295 This enabled us to compute lifetime risks with only 20.1 years of follow-up. Lifetime 
risk estimates reflect the cumulative incidences to the age of last observation: in the present 
analysis the maximum age was 106.4 years for men and 107.0 years for women. In the setting of 
competing risks analysis, the sum of the lifetime risks of CVD and competing non-cardiovascular 
death equals 1; the sum of the lifetime risks of the different first manifestations of CVD equals 
the lifetime risk of CVD.293, 294 We computed the excess number of events occurring over the 
lifespan in women compared with men (per 1000) by subtracting the lifetime risk in men from 
the lifetime risk in women for each of the manifestations of CVD and multiplying it by 1000.
To evaluate the effect of adjustment for cardiovascular risk factors on sex differences, we 
quantified the association of sex with the subdistribution hazard of CVD (or the specific first 
manifestations) and non-cardiovascular death using the method proposed by Fine and Gray.296 
Results are presented for models that were unadjusted (model 1); adjusted for age (as a linear 
covariable) and level of education (model 2); and additionally adjusted for systolic and diastolic 
blood pressure, concentrations of total and high-density lipoprotein cholesterol, diabetes 
mellitus, smoking status, family history of premature MI, body mass index (BMI), C-reactive 
protein concentration, use of blood pressure-lowering medication, and use of statins (model 3).
Next, we used the data augmentation proposed by Lunn and McNeil to enable direct comparisons 
between the effect estimates of sex on specific first manifestations of CVD by traditional Cox 
regression.297 This allows inference on the difference in cause-specific hazard ratios (HRs) of 
sex on particular manifestations of CVD in the presence of competing manifestations and non-
cardiovascular death.294 We present P values from the fully adjusted models (model 3).
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To exclude the influence of differences in the inclusion of ‘softer’ events in CHD and 
cerebrovascular disease, we then limited the analysis to first-incident hard atherosclerotic 
cardiovascular events.
As a secondary analysis, we also repeated the main analysis with CVD categorized as fatal or 
non-fatal. A first manifestation of CVD was considered fatal if death occurred within 28 days of 
the event and death was attributed to CVD.
As participants of RS-II-1 were enrolled 6 to 8 years after the baseline examination of the 
participants of RS-I-1, we allowed for strata of cohorts in the regression analyses and repeated 
all the analysis in each cohort separately. A total of 476 (5.7%) individuals had missing values 
for 1 or more traditional cardiovascular risk factors (range 0-2.5% per risk factor) and other 
covariables were missing in up to 3.5% of the participants. These missing values were handled 
separately for each cohort by a single imputation with an expectation-maximization algorithm.109 
We used the level of significance of P < 0.05. All measures of association are presented with 
95% confidence intervals (CIs). Data were handled and analyzed with the IBM SPSS Statistics 
version 21.0.0.1 (IBM Corp., Somers, NY, U.S.), R version 3.0.0 and its libraries cmprsk, etm, and 
mstate.110
Results
Baseline characteristics
On average women were older than men and had lower levels of attained education (Table 
11.1). Cholesterol concentrations and BMI were generally higher in women, whereas men had 
higher diastolic blood pressure and were more often smokers. Several baseline characteristics 
differed between both cohorts, including an overall increase in the level of highest attained 
education, higher blood pressure, lower concentrations of total cholesterol, more frequent use 
of statins, and higher BMI in RS-II. Also, although still significant, sex differences in smoking 
status were less pronounced in RS-II.
Lifetime risk of cardiovascular disease
During a total of 81,276 person-years (median 13.5 years for persons censored alive) of follow-
up, 2888 participants developed a CVD event, which corresponds to an incidence rate of 35.5 
(95% CI 34.2-36.9) per 1000 person-years for any first manifestation of CVD. Of these 2888 
events, 826 were CHD, 1198 were of cerebrovascular origin, 762 were heart failure, and 102 
were other cardiovascular deaths. Of the first CVD events, 608 (21.1%) were fatal. Another 
1532 individuals died from non-cardiovascular causes, and 20 participants were lost to follow-
up over the course of the study (mainly from emigration). In the analysis restricted to hard 
atherosclerotic outcomes, we included 1700 cardiovascular events, of which 766 were hard 
CHD, 869 non-hemorrhagic stroke, and 65 other atherosclerotic cardiovascular deaths. Details 
regarding the amount of follow-up and the number of specific events observed in men and 
women of each cohort are shown in Table 11.2 and the online supplement of the original 
publication.116
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Table 11.3 – Remaining lifetime risks of first-incident manifestation of cardiovascular disease 
by age
Lifetime risk
Men Women P value Excess eventsa
Risk at 55 years of age: n = 3293 n = 5126
  Cardiovascular disease 67.1% (64.7-69.5) 66.4% (64.2-68.7)    0.34 -7
    Coronary heart disease b 27.2% (24.1-30.3) 16.9% (13.5-20.4) < 0.001 -102
    Cerebrovascular disease c 22.8% (20.4-25.1) 29.8% (27.7-31.9) < 0.001  70
    Heart failure 14.9% (13.3-16.6) 17.5% (15.9-19.2)    0.014  26
    Other cardiovascular death d 2.3% (1.6-2.9) 2.1% (1.6-2.7)    0.39 -1
Risk at 65 years of age: n = 3001 n = 4832
  Cardiovascular disease 63.4% (61.1-65.7) 65.6% (63.7-67.5)    0.077  22
    Coronary heart disease b 21.6% (19.6-23.6) 14.7% (13.3-16.2) < 0.001 -69
    Cerebrovascular disease c 22.7% (20.7-24.7) 30.3% (28.4-32.1) < 0.001  76
    Heart failure 16.8% (15.0-18.5) 18.2% (16.7-19.7)    0.113  14
    Other cardiovascular death d 2.4% (1.6-3.1) 2.4% (1.8-3.0)    0.49  0
Risk at 75 years of age: n = 1648 n = 3180
  Cardiovascular disease 58.7% (55.8-61.6) 63.4% (61.2-65.6)    0.006  48
    Coronary heart disease b 15.4% (13.2-17.5) 12.5% (11.0-14.0)    0.014 -29
    Cerebrovascular disease c 21.9% (19.4-24.3) 28.9% (26.8-31.0) < 0.001  70
    Heart failure 18.3% (16.0-20.6) 19.4% (17.6-21.2)    0.24  11
    Other cardiovascular death d 3.1% (2.1-4.2) 2.7% (2.0-3.5)    0.26 -4
Risk at 85 years of age: n = 438 n = 1296
  Cardiovascular disease 52.0% (46.6-57.3) 57.1% (53.9-60.3)    0.054  51
    Coronary heart disease b 11.0% (7.6-14.3) 11.6% (9.6-13.7)    0.38  6
    Cerebrovascular disease c 19.3% (15.1-23.5) 24.8% (22.0-27.6)    0.017  55
    Heart failure 17.3% (13.2-21.3) 17.9% (15.5-20.4)    0.40  6
    Other cardiovascular death d 4.4% (2.2-6.6) 2.8% (1.7-3.9)    0.095 -16
Values are remaining lifetime risks (95% confidence intervals) of first-incident cardiovascular event adjusted for 
competing non-cardiovascular death.
a Excess number of events per 1000 women was computed as the absolute difference in remaining lifetime risk between 
men and women multiplied by 1000.
b Coronary heart disease was defined as myocardial infarction, coronary revascularization, or death from coronary heart 
disease.
c Cerebrovascular disease was defined as stroke, transient ischemic attack, or carotid revascularization.
d Other cardiovascular death was defined as all cardiovascular mortality other than fatal coronary heart disease or stroke.
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The overall lifetime risk of CVD was similar for men and women at the age of 55 (Table 11.3, 
Figure 11.1), with 67.1% (95% CI 64.7-69.5%) for men and 66.4% (95% CI 64.2-68.7%) for women. 
Remaining lifetime risks of CVD decreased with advancing age as the incidence of competing 
non-cardiovascular death increased. The decrease was larger for men than for women: for 
those aged 85 without CVD the remaining lifetime risk of CVD was 52.0% (95% CI 46.6-57.3%) 
in men and 57.1% (95% CI 53.9-60.3%) in women. The cumulative incidence of CVD in men 
increased steadily with age, whereas in women up to the age of 70 the cumulative incidence 
remained low and increased steeply thereafter (Figure 11.1).
Figure 11.1 – Cumulative incidence of cardiovascular disease and competing non-
cardiovascular death for men and women aged 55Figure 11.1 
 
First manifestation of cardiovascular disease
Although the overall lifetime risks of developing any CVD were similar for men and women, 
the first manifestations were different (Table 11.3, Figure 11.2). At age 55, lifetime risks of the 
first manifestations of CVD in men were 27.2% for CHD, 22.8% for cerebrovascular disease, and 
14.9% for heart failure versus 16.9%, 29.8%, and 17.5%, respectively, for women. For every 
1000 women, this would translate into 102 fewer first manifestations with CHD developing 
over the lifespan, but 70 more with cerebrovascular disease and 26 more with heart failure 
when compared with men. With increasing age, excess risk remained about the same for 
cerebrovascular disease but decreased for CHD and heart failure. Cerebrovascular disease and 
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heart failure became the most common initial manifestations for men free from CVD at age 75 
or higher. In women, cerebrovascular disease was the most common first manifestation in the 
remaining lifespan at every age. The cumulative incidences for the various CVD manifestations 
are shown in Figure 11.2. In men, the cumulative incidence of CHD is higher than that of 
cerebrovascular disease and heart failure at all ages with the cumulative incidences of the latter 
2 catching up until age 70 and all curves running about parallel thereafter. In women, the curves 
were steeper for cerebrovascular disease and heart failure than for CHD, especially at higher 
ages, indicating that most cases of cerebrovascular disease and heart failure occurred in the 
later part of the lifespan. Women were on overage older than men when CVD manifested, 
which was the case for each of the separate CVD outcomes (Table 11.4). In both men and 
women, those with CHD as the first manifestation were the youngest, followed by those in 
whom CVD manifested with cerebrovascular disease and heart failure; those who died from 
other cardiovascular causes were the oldest.
Figure 11.2 – Cumulative incidence of first cardiovascular disease manifestations adjusted for 
competing non-cardiovascular death for men (left) and women (right) aged 55Figure 11.2 
 
Coronary heart disease was defined as myocardial infarction, coronary revascularization, or death from coronary heart 
disease. Cerebrovascular disease was defined as stroke, transient ischemic attack, or carotid revascularization. Other 
cardiovascular death included all cardiovascular mortality other than fatal coronary heart disease or stroke.
In line with the pattern of later onset of CVD in women shown in Figure 11.1, hazards (i.e. 
instantaneous risks) were lower for women than men with respect to any first cardiovascular 
event or death from non-cardiovascular causes (Table 11.5). The adjusted cause-specific HR 
of sex for development of CVD was not significantly different from the HR for competing non-
cardiovascular death (Lunn and McNeil P = 0.33 for model 3), which corroborates with the 
comparable lifetime risk of CVD. There was a large sex difference in the unadjusted hazards for 
the development of CHD as a first manifestation of CVD. Also, despite the overall lower hazards 
of CVD, women had a somewhat higher hazard than men for developing cerebrovascular 
disease but not for heart failure. The age adjusted HRs (model 2) were generally similar to 
the ones additionally adjusted for traditional and newer cardiovascular risk factors (model 3). 
Even after adjustment for these risk factors, cause-specific HRs for the sex differences remained 
significantly lower for CHD than cerebrovascular disease (Lunn and McNeil P < 0.001 for model 
126
Chapter 11
3) or heart failure (Lunn and McNeil P = 0.010 for model 3). Competing risk regression, with Fine 
and Gray models, yielded smaller HRs than traditional Cox models for all associations except 
for cerebrovascular disease (Table 11.5). Estimates were similar in both cohorts. These are 
presented in the online supplement of the original publication.116
Hard atherosclerotic cardiovascular disease
Lifetime risks for hard atherosclerotic CVD were substantially lower than with the broad 
definition of CVD (Table 11.6 and the online supplement of the original publication).116 For 
those aged 55, the lifetime risk of atherosclerotic CVD was 43.2% (95% CI 40.7-45.6%) for men 
and 38.1% (95% CI 36.2-40.1%) for women. For men and women free from atherosclerotic 
CVD at age 85, remaining lifetime risks were about 31%. Again sex differences were apparent 
in the first manifestation of atherosclerotic CVD (Table 11.6, Figure 11.3). At age 55, lifetime 
risks of first manifestations of atherosclerotic CVD were 23.5% for hard CHD and 17.8% for 
non-hemorrhagic stroke in men versus 14.4% and 22.5%, respectively, in women. For every 
1000 women, this translates into 91 fewer first manifestations of CHD over the lifetime and 48 
more first manifestations of stroke compared with men. In men CHD was the most common 
first manifestation in the remaining lifespan except for those aged 85 years and older, whereas 
in women stroke was the predominant presentation during the remaining lifespan at all ages, 
especially in older individuals. Identical patterns of the first occurrence of atherosclerotic CVD 
outcomes by rising age were observed as were seen for the broad CVD outcome, although the 
cumulative incidence of cerebrovascular disease crossed that of CHD in women at a somewhat 
higher age (Table 11.6, Figure 11.3).
Table 11.4 – Age of first-incident cardiovascular event or non-cardiovascular death
First-incident event Men Women
n = 3293 n = 5126 P-value a
Cardiovascular disease 75.8 (8.3) 80.2 (8.9) < 0.001
  Coronary heart disease b 73.1 (8.1) 78.7 (9.5) < 0.001
  Cerebrovascular disease c 76.4 (8.0) 79.8 (8.8)    0.009
  Heart failure 78.1 (7.8) 81.7 (8.2)    0.006
  Other CVD death d 80.0 (8.4) 84.0 (7.4)    0.17
Non-cardiovascular death 78.8 (8.4) 82.7 (9.5) < 0.001
Values are mean (standard deviation) age in years of occurrence of first-incident cardiovascular event or competing 
non-cardiovascular death during follow-up among men and women.
a Adjusted for age at start of follow-up and cohort.
b Coronary heart disease was defined as myocardial infarction, coronary revascularization, or death due to coronary 
heart disease.
c Cerebrovascular disease was defined as stroke, transient ischemic attack, or carotid revascularization.
d Other cardiovascular death included all cardiovascular mortality other than fatal coronary heart disease or stroke.
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Table 11.5 – Hazard ratios for cardiovascular disease and non-cardiovascular death for women 
compared to men
Traditional Cox model Competing risks model a
HR (95% CI) HR (95% CI)
Model 1 (unadjusted):
Cardiovascular disease 0.75 (0.70-0.81) 0.81 (0.76-0.88)
  Coronary heart disease b 0.48 (0.42-0.55) 0.52 (0.46-0.60)
  Cerebrovascular disease c 0.99 (0.88-1.12) 1.15 (1.02-1.29)
  Heart failure 0.83 (0.72-0.96) 0.95 (0.82-1.09)
  Other cardiovascular death d 0.67 (0.45-1.00) 0.79 (0.53-1.17)
Non-cardiovascular death 0.68 (0.61-0.75) 0.78 (0.71-0.86)
Model 2:e
Cardiovascular disease 0.62 (0.57-0.67) 0.73 (0.67-0.79)
  Coronary heart disease b 0.42 (0.37-0.49) 0.50 (0.43-0.58)
  Cerebrovascular disease c 0.83 (0.73-0.93) 1.06 (0.94-1.20)
  Heart failure 0.62 (0.53-0.72) 0.79 (0.68-0.93)
  Other cardiovascular death d 0.53 (0.35-0.80) 0.72 (0.48-1.09)
Non-cardiovascular death 0.51 (0.46-0.57) 0.67 (0.60-0.74)
Model 3:f
Cardiovascular disease 0.68 (0.62-0.75) 0.76 (0.69-0.83)
  Coronary heart disease b 0.45 (0.37-0.53) 0.51 (0.43-0.60)
  Cerebrovascular disease c 0.96 (0.83-1.11) 1.16 (1.00-1.33)
  Heart failure 0.62 (0.52-0.75) 0.73 (0.61-0.88)
  Other cardiovascular death d 0.73 (0.44-1.19) 0.96 (0.61-1.50)
Non-cardiovascular death 0.63 (0.55-0.71) 0.76 (0.66-0.87)
Values are hazard ratios (95% confidence intervals) for the risk of a first-incident cardiovascular event or competing 
non-cardiovascular death; men served as the reference category; all regression analyses used follow-up time as time 
scale and were stratified on cohort (see the online supplement of the original publication for results per cohort).116
a Fine and Gray method for subdistribution regression with competing risks.296
b Coronary heart disease was defined as myocardial infarction, coronary revascularization, or death due to coronary 
heart disease.
c Cerebrovascular disease was defined as stroke, transient ischemic attack, or carotid revascularization.
d Other cardiovascular death was defined as all cardiovascular mortality other than fatal coronary heart disease or 
stroke.
e Adjusted for age (as a linear covariable) and level of education.
f Adjusted for age (as a linear covariable), level of education, systolic and diastolic blood pressure, concentrations of 
total and high-density lipoprotein cholesterol, diabetes mellitus, smoking status, family history of premature myocardial 
infarction, body mass index, concentration of C-reactive protein, use of blood pressure-lowering medication, and use 
of statins.
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Table 11.6 – Remaining lifetime risks of first-incident manifestation of hard atherosclerotic 
cardiovascular disease by age
Lifetime risk
Men Women P value Excess events a
Risk at 55 years of age: n = 3293 n = 5126
   Hard cardiovascular disease 43.2% (40.7-45.6) 38.1% (36.2-40.1) < 0.001 -51
     Hard coronary heart disease b 23.5% (21.4-25.6) 14.4% (13.0-15.8) < 0.001 -91
     Non-hemorrhagic stroke 17.8% (15.8-19.7) 22.5% (20.8-24.2) < 0.001  48
     Other atherosclerotic 
cardiovascular death c
1.9% (1.3-2.6) 1.2% (0.8-1.6)    0.037 -7
Risk at 65 years of age: n = 3159 n = 5003
   Hard cardiovascular disease 40.3% (38.0-42.7) 37.8% (35.8-39.7)    0.050 -26
     Hard coronary heart disease b 20.8% (18.8-22.7) 13.7% (12.3-15.1) < 0.001 -70
     Non-hemorrhagic stroke 17.7% (15.8-19.5) 22.8% (21.0-24.5) < 0.001  51
     Other atherosclerotic 
cardiovascular death c
1.9% (1.3-2.6) 1.3% (0.8-1.7)    0.057 -6
Risk at 75 years of age: n = 1934 n = 3560
   Hard cardiovascular disease 35.5% (32.7-38.3) 36.2% (34.1-38.4)    0.34  7
     Hard coronary heart disease b 16.8% (14.6-18.9) 11.9% (10.5-13.4) < 0.001 -48
     Non-hemorrhagic stroke 16.7% (14.5-18.8) 22.9% (21.0-24.8) < 0.001  62
     Other atherosclerotic 
cardiovascular death c
2.1% (1.3-2.9) 1.4% (0.9-1.9)    0.093 -6
Risk at 85 years of age: n = 594 n = 1619
   Hard cardiovascular disease 31.4% (26.9-35.8) 31.6% (28.9-34.4)    0.46  3
     Hard coronary heart disease b 14.1% (10.8-17.4) 10.3% (8.5-12.1)    0.023 -38
     Non-hemorrhagic stroke 15.9% (12.4-19.4) 20.2% (17.8-22.5)    0.026  42
     Other atherosclerotic 
cardiovascular death c
1.3% (0.3-2.4) 1.2% (0.5-1.8)    0.41 -1
Values are remaining lifetime risks (95% confidence intervals) of first-incident hard atherosclerotic cardiovascular event 
adjusted for competing non-atherosclerotic death.
a Excess number of events per 1000 women was computed as the absolute difference in remaining lifetime risk between 
men and women multiplied by 1000.
b Hard coronary heart disease was defined as myocardial infarction or death from coronary heart disease.
c Other atherosclerotic cardiovascular death was defined as all atherosclerotic cardiovascular mortality other than fatal 
coronary heart disease or non-hemorrhagic stroke.
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Figure 11.3 – Cumulative incidence of first hard atherosclerotic cardiovascular disease 
manifestations adjusted for competing non-atherosclerotic death for men (left) and women 
(right) aged 55Figure 11.3 
 
Figure 11.3 
 
Hard coronary heart disease was defined as myocardial infarction or death from coronary heart disease. Other 
atherosclerotic cardiovascular death included all atherosclerotic cardiovascular mortality other than fatal coronary 
heart disease or non-hemorrhagic stroke.
Case fatality
In both men and women, fatality of the first manifestation of CVD increased with age, with 
women being slightly more likely to have their CVD presenting with a fatal event (18.0% of 
first events in men aged 55 years or older versus 20.9% in women, P = 0.047), but this was 
predominantly because of more fatal events in women at old age. Data are presented in the 
online supplement of the original publication.116 Fatal first manifestations of CVD other than 
CHD, cerebrovascular disease, or heart failure were rare in all age and sex groups (Tables 11.3 
and 11.6).
Discussion
Within a contemporary prospective population-based cohort of the general population, 
we used competing risks analysis to appropriately quantify lifetime risk of CVD and its first 
manifestations in both sexes. At age 55, the risk of developing any CVD over the lifespan was 
similar for men and women. We found large sex differences in the initial manifestation of CVD. 
Men are more likely to develop CHD as a first event, while women are more likely to develop 
cerebrovascular disease or heart failure as a first event, although these manifestations appear 
most often at older age.
According to data from various American cohort studies, about 60% of middle-aged men and 
little over half of the middle-aged women develop CVD during their remaining lifespan.120 We 
report higher estimates of lifetime cardiovascular risk. These differences can be explained by 
130
Chapter 11
our inclusion of ‘softer’ cardiovascular manifestations, such as transient ischemic attack and 
arterial revascularization procedures. Such manifestations generally have less impact on the 
lives of the patients, but do significantly contribute to the overall burden of consumption of 
healthcare and its associated costs.
An important point to consider is that within the Rotterdam Study one of the soft coronary 
events, non-invasively managed angina, was not adjudicated. Angina can constitute 34% of first 
diagnoses of CHD in men and 42% in women, though the contribution of new onset isolated 
angina to the incidence of CHD is small after age 70.286 Angina is difficult to adjudicate, but based 
on these estimates of angina, we covered about half of the angina events with the inclusion of 
coronary revascularizations. These represent the more definite and severe cases of unstable or 
incapacitating exertional angina. The lack of non-invasively managed angina could have reduced 
absolute risk difference for CHD between men and women. We therefore also conducted an 
analysis restricted to hard cardiovascular outcomes. In this analysis, overall lifetime risk of CVD 
was somewhat lower in women than in men (38.1% versus 43.2% at age 55) and excess risk 
attenuated for both CHD and cerebrovascular disease compared with the broad CVD endpoint. 
The pattern of sex differences, however, remained the same: CVD presented more often with 
CHD in men and more often with cerebrovascular disease in women.
The results of our regression analysis of the sex differences for the various cardiovascular 
manifestations were not materially affected by adjustment for cardiovascular risk factors (Table 
11.5). This indicates that variation in risk factors between men and women does not explain 
the observed differences in risk. The pattern of sex differences was less pronounced for first 
manifestations of cerebrovascular disease based on the HRs compared with lifetime risks, 
while the sex difference in hazards for heart failure even reversed in the adjusted models. This 
might be explained by the fact that HRs have a more limited interpretation for the lifetime 
perspective 108 and even more so after adjustment for age as higher life expectancy in women is 
one of the driving forces behind a high lifetime risks.
Implications
The recently released British and American guidelines on primary prevention of CVD recognize 
the importance of assessment of lifetime risk.6, 298 Most middle-aged women, even those with 
a moderate to high burden of risk factors, are at (often falsely reassuring) low short term risk of 
developing CVD and thereby might still not qualify for intensive preventive measures based on 
their global 10-year cardiovascular risk.217, 299, 300 Our results indicate that many women have a 
lifetime risk of CVD that is similar to that of men. Clinicians should therefore be aware that the 
risk of CVD rises more steeply in women at older age than in men and that a low 10-year risk 
might come with a high lifetime risk. On the other hand, CVD manifests at higher ages in women 
than in men. Onset of CVD at older age might not have the same impact as onset at younger 
age, which is not accounted for by the use of lifetime risks.
The global cardiovascular risk scoring algorithms that are currently recommended in the 
prevention guidelines no longer include only CHD as the outcome of interest.5, 6, 8, 9, 298 The 
British and American guidelines now recommend consideration of the risk of stroke besides 
CHD to identify individuals at high risk of CVD.6, 9, 298 Compared with the older guidelines based 
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on coronary risk, substantially more women will be considered at high risk under these new 
guidelines and thereby qualify for more intensive risk factor control.119 Our results on lifetime 
risk of hard atherosclerotic CVD (hard CHD and stroke) support this as the estimates were only 
somewhat lower in women than in men (Table 11.6). Despite that most attention on current 
prevention guidelines has focused on the indications for lipid lowering treatment, adequate 
control of the main modifiable causes of stroke – hypertension and smoking 301 – should remain 
top priorities for clinicians and policy makers to reduce the population burden of cerebrovascular 
disease.
We noticed that heart failure constitutes about a quarter to a third of the first manifestation of 
CVD in both men and women. This is a substantial proportion, especially given that by definition 
none of the cases of heart failure in our study were preceded by overt CHD, which is considered 
to be the most important cause of heart failure in older persons.22 The high risks and similarity in 
men and women is in agreement with the results from 3 American population-based cohorts.302 
In the light of primary prevention of CVD this finding once more emphasizes the need to also 
focus on risk factors other than hyperlipidemia, as lipid lowering treatment has so far not been 
proved beneficial to reduce the risk of non-ischemic heart failure. Lifestyle modification and 
blood pressure control are the main targets for prevention of heart failure, especially in women, 
in whom blood pressure is known to play a more prominent role in the development of heart 
failure than in men.303
Up to age 75, first manifestations of CVD were rarely fatal in our study, and case fatality of the 
first manifestation of CVD increased with age. The European guidelines for prevention of CVD 
recommend the use of the SCORE algorithm, which can be used to estimate the 10-year risk of 
fatal CVD.5, 8 A consequence of the use of fatal events only is that treatment allocation, based on 
absolute risk thresholds from the SCORE algorithm, disproportionately increases the likelihood 
for older individuals to be considered as candidates for preventive treatment. Unfortunately, 
the expected absolute benefit from prevention wanes with advancing age because of the 
increased risk of competing non-cardiovascular death.304, 305
Limitations
Our study has some limitations that need to be considered. Various different manifestations 
of CVD were adjudicated according to standardized definitions. We did not have adjudicated 
events available on incident angina that was managed with non-invasive treatment, non-fatal 
peripheral vascular disease, and non-fatal abdominal aortic aneurysms. Within a subset of the 
RS-I cohort, surgery for abdominal aortic aneurysms has been adjudicated, which represented 
only 1.3% of the first manifestations of CVD. Second, as our results were obtained from a 
population aged 55 years and over our results cannot be directly generalized to younger 
individuals who might have an even higher lifetime risk of CVD. Third, the Rotterdam Study 
cohorts are predominantly of European descent (97.8% white). This is relevant because lifetime 
risk of CVD and its manifestations vary by race.306 Fourth, as the incidence of CVD has decreased 
substantially over the past decades, estimates of lifetime risk are subject to birth cohort effects. 
We used data from a broad age range (age 55.0-106.2 at baseline) with long follow-up (over 
20 years) to ensure that individuals from various birth cohorts contribute to different age-
specific cumulative incidences and thereby reduce these effects.289 Also, the long follow-up will 
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mitigate the ‘healthy volunteer effect’ that is known to cause an underestimation of the actual 
incidence of most diseases shortly after baseline in population-based studies that require active 
participation.118 Participation rates at enrolment were similar for men and women in all age 
groups,103 therefore this is unlikely to explain the sex differences we observed. Nonetheless, 
the lifetime risks of CVD in our study could be somewhat underestimated. Fifthly, we did not 
take into account changes in treatment and risk factors during follow-up in the multivariable 
regression models. Finally, in younger women MI more often presents without the hallmark 
symptom of chest pain.307 This compromises optimal recognition of CHD in women and might 
thereby explain part of the observed sex differences in first manifestation of CVD in our study.
Conclusions
Men and women of middle age have similar overall lifetime risks of CVD, with 2 out of 3 facing 
some form of CVD during their life. These numbers underline that primary prevention of 
CVD is of paramount importance in both men and women. There are, however, considerable 
differences in the first manifestation of CVD, with men being more likely to develop CHD as a 
first event, while women are more likely to have cerebrovascular disease or heart failure as 
their first event, although these manifestations appear most often at older age. Our results 
underscore the importance of adequate control of risk factors for stroke and heart failure in 
primary prevention of CVD.
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As with any risk classification system, perfect prediction will not be achieved, but an overall 
improvement in the targeting of prescription drugs to those with the most appropriate
levels of risk should help maximize benefits while minimizing cost and toxicity.
- Paul M. Ridker and Nancy R. Cook
Algorithms for assessing cardiovascular risk in women
JAMA 2007;298(2):177-8
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Importance
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines 
introduced a prediction model and lowered the threshold for treatment with statins to a 
7.5% 10-year hard atherosclerotic cardiovascular disease (ASCVD) risk. Implications of the 
new guideline’s threshold and model have not been addressed in non-U.S. populations or 
compared with previous guidelines.
Objective
To determine population-wide implications of the ACC/AHA, the Adult Treatment Panel III 
(ATP III), and the European Society of Cardiology (ESC) guidelines using a cohort of Dutch 
individuals aged 55 years or older.
Design
We included 4854 Rotterdam Study participants examined between 1997 and 2001. We 
calculated 10-year risks for hard ASCVD events (including fatal and nonfatal coronary heart 
disease [CHD] and stroke) (ACC/AHA), hard CHD events (fatal and nonfatal myocardial 
infarction, CHD mortality) (ATP III), and atherosclerotic CVD mortality (ESC).
Main outcomes
Per guideline, we calculated proportions of individuals for whom statins would be 
recommended and determined calibration and discrimination of risk models.
Results
The mean age was 65.5 (SD 5.2) years. Statins would be recommended for 96.4% (95% CI 95.4-
97.1%; n = 1825) of men and 65.8% (95% CI 63.8-67.7%; n = 1523) of women by the ACC/AHA, 
52.0% (95% CI 49.8-54.3%; n = 985) of men and 35.5% (95% CI 33.5-37.5%; n = 821) of women 
by the ATP III, and 66.1% (95% CI 64.0-68.3%; n = 1253) of men and 39.1% (95% CI 37.1-41.2%; 
n = 906) of women by ESC guidelines. With the ACC/AHA model, average predicted risk versus 
observed cumulative incidence of hard ASCVD events was 21.5% (95% CI 20.9-22.1%) versus 
12.7% (95% CI 11.1-14.5%) for men (192 events) and 11.6% (95% CI 11.2-12.0%) versus 7.9% 
(95% CI 6.7-9.2%) for women (151 events). Similar overestimation occurred with the ATP III 
model (98 events in men and 62 events in women) and ESC model (50 events in men and 37 
events in women). The c-statistic was 0.67 (95% CI 0.63-0.71) in men and 0.68 (95% CI 0.64-
0.73) in women for hard ASCVD (ACC/AHA), 0.67 (95% CI 0.62-0.72) in men and 0.69 (95% CI 
0.63-0.75) in women for hard CHD (ATP III), and 0.76 (95% CI 0.70-0.82) in men and 0.77 (95% 
CI 0.71-0.83) in women for CVD mortality (ESC).
Conclusions
In this European population aged 55 years or older, proportions of individuals eligible 
for statins differed substantially among the guidelines. The ACC/AHA guideline would 
recommend statins for nearly all men and two-thirds of women, proportions exceeding those 
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with the ATP III or ESC guidelines. All 3 risk models provided poor calibration and moderate 
to good discrimination. Improving risk predictions and setting appropriate population-wide 
thresholds are necessary to facilitate better clinical decision making.
Prevention of cardiovascular disease (CVD), the leading cause of death worldwide,284, 285 
remains feasible yet suboptimal.308 The common approach in CVD primary prevention is to 
identify individuals at high enough risk for cardiovascular events to justify targeting them for 
more intensive lifestyle interventions, pharmacological interventions, or both.
The CVD prevention guidelines developed by the National Cholesterol Education Program 
expert panel,27 succeeded by the American College of Cardiology/American Heart Association 
(ACC/AHA) task force,9 and the European Society of Cardiology (ESC)309 are the major guidelines 
influencing clinical practice. While the Adult Treatment Panel III (ATP III) guidelines were based 
on the 10-year risk of coronary heart disease (CHD) only,27 the ACC/AHA guidelines broaden 
to comprise risk of all hard atherosclerotic CVD (ASCVD), including CHD and stroke,9 using the 
Pooled Cohort equations.6 An additional substantial change in the U.S. guideline is a lower risk 
threshold for statin treatment in asymptomatic individuals from 20% CHD risk in the ATP III 
guidelines 27 to 7.5% ASCVD risk in the new guidelines.9 The potential implications of the ACC/
AHA guidelines in largely widening the populations endorsed for treatment and the accuracy of 
the ACC/AHA risk calculator have received much attention.264, 310-313
To be clinically useful, risk prediction models should provide good discrimination. Because 
decisions for statin treatment are based on an individual’s absolute risk, calibration of the risk 
prediction models as well as the risk threshold for treatment are important. Varying approaches 
to CVD risk estimation and application of different criteria for therapeutic recommendations 
would translate into substantial differences in proportions of individuals qualifying for treatment 
at a population level. We therefore aimed to determine implications of the ACC/AHA, the ATP III, 
and the ESC guidelines in a prospective cohort of Dutch individuals aged 55 years or older. Our 
first aim was to determine what proportion of the population would be treated based on each 
guideline. We then sought to examine discrimination and calibration of the 3 risk prediction 
models underlying these guidelines.
Methods
Study design, setting, and population
Analyses were performed within the framework of the Rotterdam Study, a prospective 
population-based cohort study among persons aged 55 years or older in the Ommoord district 
of Rotterdam, the Netherlands. The rationale and design of the Rotterdam Study have been 
described elsewhere.32-37 The baseline examination took place between 1990 and 1993 (RS-I-
1). In 2000, the cohort was extended to include inhabitants who reached the age of 55 years 
between 1990 and 2000 and persons aged 55 years or older who migrated into the research 
area (RS-II-1; Figure 1.1).
The present study used data from the third examination of the original cohort (RS-I-3; examined 
140
Chapter 12
between 1997 and 1999) and the first examination of the extended cohort (RS-II-1; recruited 
between 2000 and 2001; Figure 1.1). Among the participants aged 75 years or younger, there 
were 2209 men and 2645 women with measurements required for the analyses. Among these 
individuals, 315 men and 330 women were receiving statin treatment at baseline and therefore 
were excluded from the population for whom the eligibility for treatment based on each 
guideline was assessed. For further analyses on examining the performance of each risk scoring 
model, exclusions were made using the criteria from each guideline.
Main outcome and follow-up
The main outcome measures were incident hard ASCVD, hard CHD, and atherosclerotic CVD 
mortality. ASCVD composed of fatal and nonfatal myocardial infarction (MI), CHD mortality, 
and stroke. Hard CHD was composed of fatal or nonfatal MI, or CHD mortality.105 Strokes were 
adjudicated based on rapidly developing typical clinical signs of focal (or global) neurological 
deficits lasting 24 h or longer or leading to death.291 Atherosclerotic CVD mortality was defined 
as death due to CHD, cerebrovascular disease, or other atherosclerotic disease (including 
abdominal aortic aneurysms, peripheral vascular disease, and visceral vascular disease).105 
Prevalent CVD was defined as a history of MI, coronary or other arterial revascularization 
procedure, stroke, focal transient ischemic attack, or heart failure.
Events were adjudicated until January 1, 2012. Only first-incident events were included in the 
analyses. The information on study outcomes was gathered from general practitioners and 
from letters and discharge reports from medical specialists. Events were adjudicated by study 
physicians and medical specialists as described previously.105, 291 Total number of events for each 
outcome and number of individuals who were lost to follow-up are presented in the online 
supplement of the original publication.119 As is the overall Clark’s C of completeness of follow-
up, which was calculated for each particular outcome.314
Cardiovascular risk factors and medication use
Information on medication use and smoking behavior was collected by trained interviewers 
during a computerized home interview. Anthropometric measures were obtained during the 
visit at the research center. Blood pressure was measured at the right brachial artery with a 
random-zero sphygmomanometer with the participant in sitting position, and the mean of 2 
consecutive measurements was used. Hypertension was defined as systolic blood pressure ≥ 
140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or use of antihypertensive medication. Serum 
glucose and serum total and high-density lipoprotein (HDL) cholesterol levels were measured 
with standard laboratory techniques. Diabetes mellitus was defined as a fasting blood glucose 
level of ≥ 7.0 mmol/L, or nonfasting blood glucose levels of ≥ 11.1 mmol/L (only if fasting serum 
was unavailable), or use of blood glucose-lowering medication. Serum creatinine levels were 
measured by using an enzymatic assay (Roche Diagnostics, Basel, Switzerland), which was 
calibrated by isotope dilution mass spectrometry. We recalibrated our creatinine measures. 
For this purpose, mean creatinine values from the Rotterdam Study, by sex-specific age groups 
(< 60, 60 to 69, and ≥ 70 years), were aligned with the corresponding corrected means from 
the Third National Health and Nutrition Examination Survey (NHANES III) participants, as 
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described previously.315 The NHANES III creatinine measures were calibrated to the Cleveland 
Clinic Laboratory (Cleveland, OH, U.S.).316 The glomerular filtration rate was estimated by the 
abbreviated Modification of Diet in Renal Disease equation 317, 318 as recommended by the 
National Kidney Foundation.319 Chronic kidney disease was defined as estimated glomerular 
filtration rate of less than 60 mL/min per 1.73 m2. Family history of MI was defined as a self-
reported history of MI occurring before the age of 65 in first degree family members.
Data on dispensing of statins during follow-up were obtained from all 7 fully computerized, 
pharmacies in the Ommoord district. We used the WHO Anatomical Therapeutic Chemical 
codes C10AA and C10B for statins.51
Statistical analysis
We calculated the 10-year risk of hard ASCVD events for each individual based on age, systolic 
blood pressure, treatment of hypertension, total and HDL cholesterol levels, current smoking, 
and history of diabetes mellitus, using the sex-specific parameters from the ACC/AHA Pooled 
Cohort equations.6 We used the recommended 5% and 7.5% risk thresholds for categorization 
of the 2 respective categories of discussion on initiation of ‘treatment considered’ and 
discussion on initiation of ‘treatment recommended’.9 To comply with the ACC/AHA guideline,9 
the risk estimation for hard ASCVD was calculated among individuals who were not receiving 
lipid-lowering medication, were free of CVD at baseline, and had low-density lipoprotein (LDL) 
cholesterol levels < 190 mg/dL (4.9 mmol/L).
Using the continuous ATP III risk prediction model based on age, systolic blood pressure, 
treatment of hypertension, total and HDL cholesterol levels, and current smoking (Online 
calculator: http://www.framinghamheartstudy.org/risk-functions/coronary-heart-disease/
hard-10-year-risk.php). We also calculated the 10-year risk of hard CHD for the individuals who 
were not receiving lipid-lowering medication and were free of CVD and diabetes mellitus, to 
comply with the ATP III guideline.27 The risk thresholds used for categorization were 10% and 
20%, corresponding to the cut-off points for defining the intermediate- and high-risk categories 
by the ATP III guideline.27
The 10-year risk of CVD mortality for each participant was based on age, systolic blood 
pressure, total cholesterol levels, and current smoking using the sex-specific intercepts and 
regression coefficients from the Systematic Coronary Risk Evaluation (SCORE) equation for 
low-risk European countries.5 We used the recommended 1%, 5%, and 10% risk thresholds, 
corresponding to the cut-off points for defining the moderate-risk, high-risk, and very-high-
risk groups, respectively, based on the ESC guideline.8, 309 To comply with the ESC guideline, 
the SCORE risk estimation was performed among the individuals who were not receiving lipid-
lowering medication at baseline and were free of CVD, diabetes mellitus, and chronic kidney 
disease.309 Figure 12.1 describes the inclusion and exclusion criteria for different risk prediction 
models.
Based on each guideline, we formed 3 categories of treatment: ‘treatment recommended’, 
‘treatment considered’, and ‘no treatment’. The criteria used to form these 3 treatment 
categories by each guideline are described in Tables 12.3 to 12.5.
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We assessed the discrimination and calibration of each risk prediction model in our population. 
Discrimination refers to probability of the model to assign a higher risk to individuals who 
develop the outcome of interest compared with those who remain free of disease. The 
discriminative performance of each risk-scoring model was assessed using the c-statistic.28 
Calibration is the agreement between the predicted probabilities of disease, based on the risk 
prediction model, and the actual incidence of events in the population. To assess the calibration 
of each risk prediction model, the average predicted 10-year risks for each risk function were 
compared with the average 10-year observed risks (i.e. cumulative incidence of the event). 
Calibration plots were generated to assess the agreement between the predicted and observed 
risks over the entire range.
Results
Baseline characteristics of the participants are presented in Table 12.1. The mean age of the 
participants was 65.5 (SD 5.2) years and 54.5% were women.
Table 12.1 – Characteristics of the study population
Men Women
n = 2209 n = 2645
Age, y 65.5 (5.3) 65.4 (5.2)
Systolic blood pressure, mmHg 143 (21) 140 (21)
Diastolic blood pressure, mmHg 79 (11) 76 (11)
Use of blood pressure-lowering medication 486 (21.2) 643 (24.3)
Body mass index, kg/m2 26.7 (3.3) 27.3 (4.5)
Total cholesterol, mmol/L 5.6 (1.0) 6.0 (0.9)
HDL cholesterol, mmol/L 1.2 (0.3) 1.5 (0.4)
LDL cholesterol, mmol/L 3.6 (0.9) 3.8 (0.9)
Use of lipid-lowering medication a 315 (14.3) 330 (12.5)
Current smoking 437 (19.8) 522 (19.7)
Diabetes mellitus 315 (14.3) 282 (10.7)
Chronic kidney disease 139 (6.3) 226 (8.5)
History of CVD 414 (18.7) 186 (7.0)
Values are counts (percentages) or means (standard deviations). CVD = cardiovascular disease; HDL = high-density 
lipoprotein; LDL = low-density lipoprotein.
a Statins constituted 96% of all lipid-lowering medications.
Based on the ACC/AHA guideline,9 the ‘treatment recommended’ group included 96.4% (95% 
CI 95.4-97.1%; n = 1825) of men and 65.8% (95% CI 63.8-67.7%; n = 1523) of women while the 
‘treatment considered’ group included 3.3% (95% CI 2.6-4.2%; n = 63) of men and 14.2% (95% 
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Table 12.2 – Treatment recommendations based on different guidelines
Treatment categories Guidelines
ACC/AHA ATP III ESC
Men (n = 1894):
  Treatment recommended 96.4 (95.4-97.1) 52.0 (49.8-54.3) 66.1 (64.0-68.3)
  Treatment considered 3.3 (2.6-4.2) 14.2 (12.6-15.8) 31.6 (29.5-33.7)
  No treatment 0.3 (0.1-0.7) 33.8 (31.7-35.9) 2.3 (1.6-2.9)
Women (n = 2315):
  Treatment recommended 65.8 (63.8-67.7) 35.5 (33.5-37.5) 39.1 (37.1-41.2)
  Treatment considered 14.2 (12.8-15.7) 14.1 (12.7-15.6) 51.4 (49.3-53.4)
  No treatment 20.0 (18.3-21.6) 50.4 (48.4-52.5) 9.5 (8.3-10.8)
Values are percentages (95% CI) of the population in different categories of treatment recommendations.9, 27, 309 
Individuals receiving statin treatment at baseline (n = 315 men and n = 330 women) were excluded. ACC/AHA = 
American College of Cardiology/American Heart Association; ATP III = Adult Treatment Panel III; ESC = European Society 
of Cardiology.
Table 12.3 – Treatment recommendations based on the ACC/AHA guidelines
Treatment categories Men Women
n = 1894 n = 2315
Treatment recommended:
  Clinical CVD a 256 (13.5) 141 (6.1)
  LDL-C > 190 mg/dL (4.9 mmol/L) 125 (6.6) 254 (11.0)
  Diabetes mellitus 206 (10.9) 217 (9.4)
  10-year ASCVD risk > 7.5% 1238 (65.4) 911 (39.3)
Treatment considered:
  10-year ASCVD risk 5-7.5% 63 (3.3) 330 (14.2)
No treatment:
  10-year ASCVD risk < 5% 6 (0.3) 462 (20.0)
Values are counts (percentages) in each recommended treatment category.9 10-year risk for hard ASCVD was based on 
the Pooled Cohorts Equations.6 Individuals receiving statin treatment at baseline (n = 315 men and n = 330 women) 
were excluded. ACC/AHA = American College of Cardiology/American Heart Association; ASCVD = atherosclerotic 
cardiovascular disease; CVD = cardiovascular disease; LDL-C = low-density lipoprotein cholesterol.
a Clinical CVD includes a history of myocardial infarction, arterial revascularization, stroke, focal transient ischemic 
attack, and heart failure.
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CI 12.8-15.7%; n = 330) of women. Only 0.3% of men (95% CI 0.1-0.7%; n = 6) and 20.0% (95% 
CI 18.3-21.6%; n = 462) of women were categorized in the ‘no treatment’ group (Tables 12.2 
and 12.3).
Using the ATP III guideline,27 52.0% (95% CI 49.8-54.3%; n = 985) of men and 35.5% (95% CI 33.5-
37.5%; n = 821) of women were categorized in the ‘treatment recommended’ group, while the 
‘treatment considered’ group included 14.2% (95% CI 12.6-15.8%; n = 269) of men and 14.1% 
(95% CI 12.7-15.6%; n = 326) of women. The ‘no treatment’ category included the remaining 
33.8% (95% CI 31.7-35.9%; n = 640) of men and 50.4% (95% CI 48.4-52.5%; n = 1168) of women 
(Tables 12.2 and 12.4).
Based on the ESC guideline,309 66.1% (95% CI 64.0-68.3%; n = 1253) of men and 39.1% (95% CI 
37.1-41.2%; n = 906) of women were included in the ‘treatment recommended’ category. The 
‘treatment considered’ group comprised 31.6% (95% CI 29.5-33.7%; n = 598) of men and 51.4% 
(95% CI 49.3-53.4%; n = 1189) of women. Only 2.3% (95% CI 1.6-2.9%; n = 43) of men and 9.5% 
(95% CI 8.3-10.8%; n = 220) of women were assigned to the ‘no treatment’ category (Tables 
12.2 and 12.5).
While all men and women with prevalent CVD were categorized in the ‘treatment recommended’ 
group by the ACC/AHA guideline (Table 12.3), 12.9% of men and 4.2% of women with clinical 
CHD and CHD risk equivalents were categorized in the ‘treatment considered’ or ‘no treatment’ 
category based on the ATP III guideline (Table 12.4). Using the ESC guideline, a small group of 
individuals with clinical CVD and its risk equivalents (0.6% of men and 0.4% of women) were 
categorized in the ‘treatment considered’ group (Table 12.5).
The treatment recommendations based on the 3 guidelines for the populations younger than 
65 years and aged 65 years or older are detailed in the online supplement of the original 
publication.119 The data suggest that almost all men older than 55 years and nearly all women 
older than 65 years are recommended for statin treatment based on the new ACC/AHA guideline.
Discrimination and calibration
The online supplement of the original publication provides the detailed description of the 
proportion of the population to whom each risk estimation model was applied.119 Among 1513 
men and 1920 women included for ASCVD risk prediction (ACC/AHA), 192 men and 151 women 
developed hard ASCVD over 10-year follow-up. Among 1431 men and 1976 women included 
for CHD risk prediction (ATP III), hard CHD occurred in 98 men and 62 women over 10-year 
follow-up. Among 1366 men and 1816 women included for CVD mortality risk prediction (ESC), 
50 men and 37 women died of atherosclerotic CVD over 10-year follow-up. For all outcomes 
studied, follow-up time was truncated at 10 years for individuals with a longer follow-up time 
than 10 years.
After calculating the 10-year risk for individuals based on each risk prediction model, we first 
assessed the discriminative ability of each model. The c-statistic for the ACC/AHA model was 
0.67 (95% CI 0.63-0.71) for men and 0.68 (95% CI 0.64-0.73) for women for hard ASCVD. Use of 
the ATP III risk prediction model resulted in a c-statistic of 0.67 (95% CI 0.62-0.72) for men and 
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Figure 12.2 – Observed versus predicted risks by the ACC/AHA, ATP III, and SCORE risk 
prediction modelsFigure 12.2 
 
 
 
 
 
A. Comparison of average observed hard ASCVD risk over 10-year follow-up (i.e. cumulative incidence of hard ASCVD) 
versus average predicted 10-year hard ASCVD risk by the ACC/AHA risk prediction model 6 across categories of risk for 
men (n = 1513) and women (n = 1920). Individuals receiving statin treatment at baseline, with a history of CVD, or with 
low-density lipoprotein cholesterol levels ≥ 190 mg/dL (4.9 mmol/L) were excluded.
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0.69 (95% CI 0.63-0.75) for women for hard CHD. Using the SCORE equation (ESC), the c-statistic 
was 0.76 (95% CI 0.70-0.82) for men and 0.77 (95% CI 0.71-0.83) for women for CVD mortality.
We then assessed the calibration of each risk prediction model. Figure 12.2 displays the 
comparison of the average 10-year risks predicted by the ACC/AHA, ATP III, or SCORE (ESC) 
risk prediction models with the observed 10-year risks (i.e. cumulative incidence of events) 
in each risk category. Calibration was poor for all 3 models; the ACC/AHA (Figure 12.2A), the 
ATP III (Figure 12.2B), and the SCORE equation (Figure 12.2C) overestimated the 10-year risk 
among men and women across all risk categories. Details regarding the percentages of the 
study population at different categories of risk using each risk prediction model are available in 
online supplement of the original publication.119 The average predicted risks versus observed 
cumulative incidence of hard ASCVD events were 21.5% (95% CI 20.9-22.1%) versus 12.7% 
(95% CI 11.1-14.5%) for men and 11.6% (95% CI 11.2-12.0%) versus 7.9% (95% CI 6.7-9.2%) 
for women using the ACC/AHA risk model. The average predicted versus observed cumulative 
incidences of hard CHD events were 16.1% (95% CI 15.8-16.5%) versus 6.8% (95% CI 5.6-8.3%) 
for men and 5.4% (95% CI 5.2-5.5%) versus 3.1% (95% CI 2.4-4.0%) for women based on the ATP 
III. Using the SCORE equation, the average predicted versus observed cumulative incidences of 
CVD mortality were 6.8% (95% CI 6.5-7.1%) versus 3.7% (95% CI 2.7-4.8%) for men and 3.8% 
(95% CI 3.7-4.0%) versus 2.0% (95% CI 1.4-2.8%) for women. Calibration plots for the ACC/AHA, 
the ATP III, and the ESC risk prediction models are presented in the online supplement of the 
original publication.119
Discussion
In this European population-based prospective cohort study of healthy men and women without 
previous CVD (i.e. primary prevention population) aged 55 years or older, we found that nearly 
all men and more than 65% of women were recommended for drug treatment based on the 
recent ACC/AHA guideline.9
Regarding secondary prevention of CVD, the ACC/AHA guidelines clearly recommend drug 
treatment for all persons with clinical CVD and its risk equivalents.9 Based on the ATP III and ESC 
guidelines, however, it is possible that some individuals with clinical CVD are categorized into 2 
groups of ‘treatment considered’ or ‘no treatment’ based on their LDL cholesterol levels.27, 309
For primary CVD prevention, based on the evidence from clinical trials of statins,320 the new ACC/
AHA guidelines modified clinical decision making and proposed to recommend statin treatment 
B. Comparison of average observed hard CHD risk over 10-year follow-up (i.e. cumulative incidence of hard CHD) versus 
average predicted 10-year hard CHD risk by the ATP III risk prediction model across categories of risk for men (n = 1431) 
and women (n = 1976). Individuals receiving statin treatment at baseline and those with a history of CVD or diabetes 
mellitus were excluded.
C. Comparison of average observed CVD mortality risk over 10-year follow-up (i.e. cumulative incidence of CVD 
mortality) versus average predicted 10-year CVD mortality risk by the SCORE equation 5 across categories of risk for 
men (n = 1366) and women (n = 1816). Individuals receiving statin treatment at baseline and those with history of CVD, 
diabetes mellitus, or chronic kidney disease were excluded.
ACC/AHA = American College of Cardiology/American Heart Association; ASCVD = atherosclerotic cardiovascular 
disease; ATP III = Adult Treatment Panel III; CHD = coronary heart disease; CVD = cardiovascular disease; ESC = European 
Society of Cardiology; SCORE = Systematic Coronary Risk Evaluation.
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solely based on a 10-year ASCVD risk > 7.5%.9 This departure from previous guidelines in the U.S. 
and from the current ESC guideline represents a fairly straightforward approach that deviates 
from risk functions of 10-year hard CHD or CVD mortality combined with blood concentrations 
of LDL cholesterol.27, 309
The new ACA/AHA guideline recommendations 9 resulted in a larger ‘treatment recommended’ 
group in our population in contrast to the larger ‘treatment considered’ group based on the ESC 
guidelines.309 This raises questions about the use of a risk assessment calculator for treatment 
decisions when so large a proportion of the older population is among the ‘treatment 
recommended’ group. A decade ago, Wald and Law described a strategy to prevent CVD by 
prescribing a daily polypill to everyone aged 55 years or older without requiring risk factors 
to be measured.321 Our results suggest that by inclusion of stroke as an outcome and applying 
the lowered evidence-based risk threshold of 7.5% for treatment,320, 322 the new ACC/AHA 
guidelines have approached this age-based strategy. In our population, almost all men older 
than 55 years and almost all women older than 65 years qualified for statin treatment based on 
the ACC/AHA guidelines.9
The clinical usefulness of a risk prediction tool is determined by a combination of its discrimination 
and calibration. In our study, the c-statistic for the 3 risk prediction models ranged between 0.67 
and 0.77, indicating moderate to good discrimination, with the SCORE equation providing the 
highest c-statistic among the 3 models. Theoretically, if a model has near perfect discrimination 
(i.e. the c-statistic exceeds 0.98) and calibration, the cut-off threshold for treatment can be set 
at any level. However, the modest discrimination ability of the risk prediction models in our 
study indicates that there is a substantial overlap in the risk distributions of the individuals 
with and without the events. Therefore, given the current performance of the ACC/AHA risk 
prediction model, the place of the cut-off threshold for treatment is essential.
When an individual’s absolute risk prediction is used for clinical decision making regarding 
initiation of treatment, accurate calibration is very important. As also evident from our 
analyses, concerns regarding model calibration are pertinent to all 3 of the risk prediction 
models; to the Framingham risk score that formed the basis for the ATP III,229, 230, 323, 324 to the 
SCORE equation,325 and recently to the new ACC/AHA risk calculator.264 Miscalibration of the risk 
prediction models, once applied in other populations rather than derivation sets, is expected.326 
Imperfect calibration could partly be explained by differences in the characteristics of the new 
populations, i.e. different levels of baseline risk, for which the risk prediction model is applied. 
Furthermore, if the application cohorts are more contemporary to the cohorts used in the 
derivation sets, temporal improvements in overall health could partly be responsible for poor 
calibration. The risk prediction models underlying all 3 guidelines overestimated the risk among 
men and women in our study. About 17% of men and 16% of women included in the ASCVD risk 
assessment in our study were eventually prescribed statins over the course of follow-up. Based 
on the premise that healthy lifestyle and therapeutic measures would reduce the CVD burden, 
statin prescription together with improvement of high blood pressure treatment, higher and 
other lifestyle modifications over the follow-up period might have contributed to the observed 
overestimations to some extent.
Related closely to the calibration issue is the threshold for making clinical decisions. The new 
ACC/AHA guidelines substantially lowered the cut-off for treatment to an evidence-based 
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threshold of 7.5%.320, 322 If the new ACC/AHA risk prediction model led to overestimation 
among individuals at high levels of actual CVD risk (e.g. > 20% estimated 10-year risk), it would 
not necessarily affect the eventual proportion of people recommended for consideration of 
statin use. However, among individuals with lower actual CVD risks, overestimation by the 
risk prediction models is of much greater concern. Inaccuracy of the prediction models at the 
lower levels of risk could indeed result in many more individuals recommended for statins than 
were intended. While not explicitly stated in the new ACC/AHA guideline, setting of thresholds 
typically involves both an awareness of clinical benefit of the treatment in the target population 
combined with a judgment about cost-effectiveness. Different countries and settings may decide 
on very different thresholds based on cost-effectiveness or resource considerations, which is 
another reason to look critically at the clinical implications of the risk estimation tool and the 
risk threshold in other non-U.S. settings. Beyond the need for improving the risk predictions and 
setting appropriate population-wide thresholds to facilitate better clinical decision making, the 
large proportion of the population recommended for statin treatment based on new guidelines 
should be a concerning signal. These large numbers point out the need for (a) preventing risk 
factor aggregation and (b) conveying information to individuals in ways that effectively lower 
their risk, in an era when cardiovascular disease remains a worldwide public health challenge.
Limitations
An important limitation is that our cohort includes predominantly white individuals aged 
55 years or older. Therefore, the generalizability of our findings to younger and nonwhite 
populations remains uncertain. Furthermore, this study had relatively small numbers of events 
for some outcomes.
Conclusions
With application of the recent ACC/AHA guidelines in a healthy European population-based 
cohort, nearly all men and the majority of women aged 55 years or older were candidates 
for drug treatment. Application of the ACC/AHA, ATP III, and ESC risk prediction models led to 
overestimation of the risk. Given the modest discrimination and poor calibration of the ACC/
AHA risk prediction model, the choice of treatment threshold becomes central.

C HAPTER 13
Evaluati on of Newer Risk Markers for Coronary Heart Disease
Evaluati e van Nieuwe Risicomarkers voor Coronaire Hartziekte
154
Chapter 13
Objective
To evaluate the value of a number of the newer risk markers used to improve the risk 
classification for coronary heart disease (CHD) in asymptomatic persons.
Design
Prospective cohort study in the general population of Rotterdam, the Netherlands (The 
Rotterdam Study).
Methods
Data on measurements taken between 1997 and 2001 in 5933 persons free of CHD (40.6% 
men; mean age 69.1 years) were collected. We studied the predictive ability of 12 newer 
risk markers (N-terminal pro-brain natriuretic peptide [NT-proBNP] levels, von Willebrand 
factor antigen levels, fibrinogen levels, chronic kidney disease, leukocyte count, C-reactive 
protein levels, homocysteine levels, uric acid levels, coronary artery calcification [CAC] scores 
obtained by means of CT, carotid intima-media thickness, peripheral arterial disease, and 
aortic pulse wave velocity). The predictive value was determined by adding a newer marker 
to a prediction model that was based on traditional cardiovascular risk factors.
Results
Risk discrimination improved the most with the addition of CAC scores. A net 23.5% of the 
individuals who developed CHD were reclassified to a higher risk category, but also 4.2% 
of those who did not develop CHD. This resulted in a net reclassification improvement 
(NRI) of 0.193. The CAC score was followed by NT-proBNP (NRI 0.076) in terms of the most 
improvement to risk classification. Improvements in risk predictions with the other newer 
markers were marginal.
Conclusions
Classification of CHD risk predictions improved most with the addition of the CAC scores to the 
risk model. Further research is needed to assess whether refinements in risk prediction will 
actually lead to more effective prevention of cardiovascular disease together with justifiable 
costs and efforts.
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Doel
Het evalueren van de waarde van een aantal nieuwe risicomarkers voor de verbetering van 
de risicoclassificatie van coronaire hartziekte bij asymptomatische personen.
Opzet
Prospectief cohortonderzoek van de algemene bevolking in Rotterdam (het Erasmus 
Rotterdam Gezondheid Onderzoek).
Methode
Gegevens werden verzameld van metingen verricht in de periode 1997 tot 2001 bij 5933 
personen die vrij waren van coronaire hartziekte (40,6% man; gemiddelde leeftijd: 69,1 jaar). 
Wij onderzochten de voorspellende waarde van de volgende 12 nieuwe risicomarkers voor het 
optreden van coronaire hartziekte: N-terminaal pro-breinnatriuretisch peptide (NT-proBNP), 
antigeen tegen von Willebrand-factor, fibrinogeen, chronische nierziekte, leukocytenaantal, 
C-reactieve proteine, homocysteïne, urinezuur, coronaire calcium (CAC)-score middels CT, 
intima-mediadikte van de A. carotis, perifeer vaatlijden en aortale polsgolfsnelheid. De 
voorspellende waarde werd vastgesteld door een nieuwe marker toe te voegen aan een 
predictiemodel dat was gebaseerd op klassieke cardiovasculaire risicofactoren.
Resultaten
Het onderscheidend vermogen nam het sterkste toe door toevoeging van de CAC-score. 
Hierdoor werd netto 23,5% van de personen die coronaire hartziekte ontwikkelde naar een 
hogere risicocategorie gereclassificeerd, maar ook 4,2% van de personen die geen coronaire 
hartziekte ontwikkelde. Dit resulteerde in een ‘net reclassification improvement’ (NRI) van 
0,193. Na de CAC-score gaf NT-proBNP de sterkste verbetering van de risicoclassificatie (NRI 
0,076). De overige nieuwe markers gaven minimale verbeteringen in de risicovoorspellingen.
Conclusies
De classificatie van het risico op coronaire hartziekte verbeterde het meest na toevoeging 
van de CAC-score aan het predictiemodel. Vervolgonderzoek is noodzakelijk om te bepalen 
of de verbeterde risicovoorspellingen daadwerkelijk resulteren in effectievere preventie van 
cardiovasculaire ziekte tegen verantwoorde kosten en inspanningen.
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Het identificeren van personen met een verhoogd risico op hart- en vaatziekten faciliteert 
gerichte leefstijladviezen en preventieve behandeling. Daarmee vormt het de basis voor de 
preventie van coronaire hartziekte. Nationale en internationale richtlijnen propageren daarom 
het gebruik van zogenoemde risicotabellen op basis van bekende klassieke cardiovasculaire 
risicofactoren.8, 27, 327 Bij een hoog voorspeld risico kan laagdrempeliger gestart worden met 
intensieve bloeddruk- en cholesterolverlagende behandeling. Hoe beter het voorspellend 
vermogen van een risicotabel, hoe gerichter de preventieve behandeling kan worden gegeven 
aan degenen die hier het meeste baat bij hebben.
De afgelopen decennia is een overvloed aan nieuwe risicomarkers aangedragen om risicotabellen 
te kunnen verbeteren. In de studies die deze markers hebben aandragen zijn echter niet altijd 
de optimale methoden gebruikt en de resultaten zijn daarom soms misleidend.197 Een klinisch 
relevant criterium is dat toevoeging van een nieuwe marker voor een substantieel deel van 
de populatie betekent dat zij een ander advies krijgen over het al dan niet starten van een 
preventieve behandeling.114 De behandeladviezen gaan in richtlijnen samen met bepaalde 
afkapwaarden van het voorspelde risico;8, 27, 327 daardoor kan een verandering in voorspeld 
risico voor een individu direct gevolgen hebben voor het behandeladvies (Figuur 13.1). Om deze 
veranderingen te kwantificeren zijn de afgelopen jaren maten voor reclassificatie ontwikkeld 
die snel aan populariteit hebben gewonnen.16, 137, 328
In dit hoofdstuk evalueren wij middels een groot prospectief onderzoek onder de Rotterdamse 
algemene bevolking de toegevoegde waarde van 12 nieuwe markers voor het classificeren 
Figuur 13.1 – Het principe van reclassificatie van personen in klinische risicocategorieën door 
2 achtereenvolgende voorspellingen van het risico op coronaire hartziekte
Figuur 13.1 
 
 
De meerderheid van de algemene bevolking, afgebeeld als de oppervlakte onder de curve, heeft op basis van klassieke 
cardiovasculaire risicofactoren een laag voorspeld risico op coronaire hartziekte (lichtgrijs). Een kleiner aantal personen 
heeft een intermediair risico (grijs) of hoog risico (donkergrijs) op coronaire hartziekte. Toevoeging van een nieuwe 
risicomarker aan het predictiemodel kan resulteren in veranderingen in voorspeld risico (pijlen). Hierdoor verandert 
voor een aantal personen de risicoclassificatie; zij worden gereclassificeerd.
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van het risico op coronaire hartziekte. De gekozen markers representeren de verschillende 
processen die bijdragen aan het ontstaan van atherosclerose en atherotrombose of reflecteren 
de ernst van reeds opgetreden subklinische cardiovasculaire schade.
Methode
Onderzoekspopulatie
De studie is onderdeel van het Erasmus Rotterdam Gezondheid Onderzoek (ERGO, ‘the 
Rotterdam Study’), een prospectief cohort gevormd door inwoners van 45 jaar of ouder van de 
wijk Ommoord te Rotterdam.32-37, 329 De werving van het initiële cohort vond plaats in de periode 
1990 tot 1993 (RS-I). In 2000 werd dit cohort uitgebreid met personen die naar Ommoord waren 
verhuisd na 1990 of inwoners die de leeftijd van 55 hadden bereikt (RS-II) (Figuur 1.1). Van 
deze twee subcohorten samen participeerde 75% (10.994 van 14.687) van de aangeschreven 
inwoners. De gegevens die gepresenteerd worden in dit hoofdstuk zijn verzameld bij 6498 
deelnemers van 55 jaar of ouder tijdens de derde ronde van het initiële cohort (RS-I-3; 1997 tot 
1999) en de eerste ronde van de uitbreiding van het cohort (RS-II-1; 2000 tot 2001) (Figuur 1.1). 
In totaal werden 565 deelnemers, die al bekend waren met coronaire hartziekte (gedefinieerd 
als een myocardinfarct of coronaire revascularisatie), geëxcludeerd voor deze analyse.105 Dit 
resulteerde in een studiepopulatie van 5933 deelnemers.
Risicofactoren en markers
We verzamelden informatie over de volgende klassieke cardiovasculaire risicofactoren: leeftijd, 
geslacht, roken, BMI, bloeddruk, lipidenspectrum, diabetes mellitus en medicatiegebruik.
Daarnaast werden nieuwe risicomarkers bepaald in het bloed: N-terminaal pro-breinnatriuretisch 
peptide (NT-proBNP), antigeen tegen von Willebrand-factor, fibrinogeen, chronische nierziekte 
(gedefinieerd als een geschatte glomerulaire filtratiesnelheid van < 60 mL/min per 1,73 m2), 
leukocytenaantal, hoog-sensitieve test op C-reactieve proteïne (CRP), homocysteïne en 
urinezuur. Ook werden de volgende maten van subklinische atherosclerose gemeten: coronaire 
calcium (CAC)-score (zie Figuur 13.3 330), intima-mediadikte van de A. carotis (cIMT) en perifeer 
vaatlijden (gedefinieerd als enkel-arm-index ≤ 0,9). Als maat voor de aortastijfheid werd de 
polsgolfsnelheid in de aorta gemeten tussen de A. carotis en A. femoralis. Metingen van de CRP-
concentratie (n = 3029) en CT-scans met CAC-score (n = 3678) waren beschikbaar bij kleinere 
aantallen deelnemers; zij verschilden niet in kenmerken van de gehele studiepopulatie.
Details ten aanzien van de gebruikte methoden, assays en apparatuur voor zowel klassieke 
risicofactoren als nieuwe markers zijn na te lezen in een eerdere publicatie.165
Klinische uitkomstmaten
Informatie over de uitkomstmaten werd verkregen via de huisartsen en uit ontslagbrieven van 
ziekenhuisopnames en werd vervolgens gecodeerd door arts-onderzoekers en superviserende 
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medisch specialisten.105 Incidente coronaire hartziekte was gedefinieerd als het optreden van 
de volgende harde coronaire uitkomstmaten: zeker fataal of niet-fataal myocardinfarct of 
overlijden door coronaire hartziekte.105 Alleen de eerst opgetreden coronaire uitkomst van 
iedere deelnemer werd geanalyseerd; van 20 deelnemers was de follow-up incompleet.
Data-analyse
We evalueerden de onafhankelijke associatie van iedere marker met coronaire hartziekte met 
behulp van Coxregressieanalyse. Multivariabele gecorrigeerde hazardratio’s (HRs) voor continue 
markers werden berekend voor de vergelijkingen van het hoogste versus het laagste kwartiel; 
het laagste kwartiel diende als referentie.
Vervolgens modelleerden we een Weibull-regressiemodel op basis van de variabelen uit de 
Framingham-risicoscore (leeftijd, geslacht, systolische bloeddruk, bloeddruk verlagende 
behandeling, totaal cholesterol, HDL cholesterol, diabetes mellitus en roken).331 We refereren 
naar dit model als het ‘basismodel’. We vergeleken het basismodel met de 12 nieuwe-marker-
modellen aan de hand van de toename in onderscheidend vermogen.28, 233, 328 Een verbetering 
van het onderscheidend vermogen is af te lezen aan een toename in c-statistiek. De c-statistiek 
is een variant van de ‘area under the receiver operating characteristic curve’ (AUC) voor 
prospectieve data. De AUC is de kans op correcte voorspelling van een ziekte of uitkomst bij 
een willekeurig paar personen, van wie 1 met en 1 zonder de ziekte of uitkomst die voorspeld 
moet worden. Meestal neemt de AUC maar weinig toe door een marker toe te voegen aan 
een predictiemodel. Wil toevoeging van een marker de risicoclassificatie van een individu—en 
daarmee de adviezen voor behandeling—veranderen, dan moet die extra marker zorgen dat het 
voorspelde risico op coronaire hartziekte voor dit individu over de afkapwaarde heen gaat, naar 
boven of naar beneden (Figuur 13.1). Om die reden is de toename in c-statistiek van beperkte 
waarde voor de beoordeling of een nieuwe marker het klinisch handelen zal veranderen.
Daarom evalueerden we ook de risico-reclassificatie zoals uitgedrukt in de ‘net reclassification 
improvement’ (NRI).16, 137, 328 De NRI is de netto verbetering van het aantal correct geclassificeerde 
personen in risicocategorieën door toevoeging van een marker aan een model. De NRI vereist 
1 of meer afkappunten voor classificatie (in dit hoofdstuk: laag, intermediair en hoog risico 
op coronaire hartziekte) (Figuur 13.1). De NRI wordt uitgedrukt als een statistiek zonder 
eenheid, omdat het de optelsom is van 2 percentages met verschillende delers: (a) het netto 
beter geclassificeerde percentage personen bij wie de uitkomstmaat is opgetreden; en (b) het 
netto beter geclassificeerde percentage personen zónder die uitkomst. Daarom heeft de NRI 
een theoretisch bereik van -2 tot 2. De NRI kwantificeert de verbetering in risicoclassificatie 
door toevoeging van een variabele (in dit hoofdstuk de 12 nieuwe risicomarkers) aan een 
voorspellend model. De berekening van de NRI was gebaseerd op klinisch relevante categorieën 
van het 10-jaarsrisico op coronaire hartziekte volgens Amerikaanse richtlijnen voor preventie 
van coronaire hartziekte: laag risico (< 10%), intermediair risico (10 tot 20%) en hoog risico (> 
20%).27
Voor een gedetailleerdere bespreking van de data-analyse en resultaten verwijzen we naar de 
oorspronkelijke publicatie.165
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Resultaten
De kenmerken van de studiepopulatie voor zowel de klassieke risicofactoren als de nieuwe 
markers staan in Tabel 13.1. Gedurende een mediane follow-upduur van 6,8 jaar (25e en 75e 
percentiel: 5,8 en 8,1 jaar) deden zich 347 eerste manifestaties van coronaire hartziekte voor; 
bij 190 deelnemers ging het om een niet-fataal myocardinfarct en 157 deelnemers overleden 
door de coronaire hartziekte. Dit correspondeert met een incidentiecijfer van 8,77 per 1000 
persoonsjaren.
De HRs voor de nieuwe risicomarkers, gecorrigeerd voor klassieke risicofactoren, zijn 
weergegeven in Figuur 13.2. De meeste markers waren statistisch significant geassocieerd met 
het optreden van coronaire hartziekte. De sterkste associaties werden gevonden voor de CAC-
score (HR 6,2; 95% BI 3,4-11,5), NT-proBNP (HR 2,5; 95% BI 1,7-3,6), leukocytenaantal (HR 1,8; 
95% BI 1,3-2,5), CRP (HR 1,6; 95% BI 1,0-2,5) en cIMT (HR 1,6; 95% BI 1,1-2,3).
Figuur 13.2 – Multivariabele gecorrigeerde hazardratio’s van nieuwe risicomarkers voor het 
optreden van coronaire hartziekte
Figuur 13.2 
 
 
De hazard ratio’s zijn gecorrigeerd voor leeftijd, geslacht, systolische bloeddruk, antihypertensieve behandeling, totaal 
cholesterol, HDL cholesterol, diabetes mellitus en roken. Vergelijkingen van continue markers worden gepresenteerd 
als het hoogste versus het laagste kwartiel (als referentie). CAC = coronaire calcium; cIMT = intima-mediadikte van 
de A. carotis; CRP = C-reactieve proteïne; NTproBNP = N-terminaal pro-breinnatriuretisch peptide; PWV = aortale 
polsgolfsnelheid; vWF = von Willebrand-factor.
Het onderscheidend vermogen van het basismodel zonder toevoeging van nieuwe risicomarkers 
was redelijk, met een c-statistiek van 0,73 (95% BI 0,71-0,75). Door toevoeging van de nieuwe 
markers aan het predictiemodel werden maximale toenames in c-statistiek gezien voor de CAC-
score (0,05; 95% BI 0,02-0,06) en voor NT-proBNP (0,02; 95% BI 0,01-0,04) (Tabel 13.2).
De verbetering in classificatie van personen in risicocategorieën was ook het grootst na 
toevoeging van de CAC-score (Tabel 13.2). De NRI voor de CAC-score wordt berekend door 
de som van het netto percentage beter geclassificeerde personen met coronaire hartziekte 
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Tabel 13.1 – Kenmerken van de studiepopulatie
Meting Waarde
Klassieke cardiovasculaire risicofactoren:
  Man 40,6%
  Leeftijd, jaren 69,1 (8,5)
  Systolische bloeddruk, mmHg 143 (21)
  Diastolische bloeddruk, mmHg 77 (11)
  Bloeddrukverlagende behandeling 23,5%
  Quetelet-index, kg/m2 27,0 (4,0)
  Totaal cholesterol, mmol/L 5,8 (1,0)
  HDL cholesterol, mmol/L 1,4 (0,4)
  Triglycerides, mmol/L 1,5 (0,8)
  Cholesterolverlagende behandeling 10,2%
  Glucose, mmol/L 5,9 (1,5)
  Diabetes mellitus 12,9%
  Roker 17,5%
Nieuwe cardiovasculaire risicomarkers:
  NT-proBNP, pmol/L a 9,5 (5,1-18,1)
  vWF antigeen, IU/mL a 1,2 (0,9-1,6)
  Fibrinogeen, μmol/L a 11,2 (9,7-12,9)
  eGFR, mL/min/1,73 m2 a 76 (67-87)
  Chronische nierziekte 12,2%
  Leukocytenaantal, per L 6,8 x 109 (1,9 x 109)
  CRP, mg/L a,b 2,3 (1,2-4,4)
  Homocysteïne, μmol/L a 13,5 (11,4-16,6)
  Urinezuur, μmol/L a 300 (260-360)
  CAC score a,c 66 (4-323)
  cIMT, mm a 1,0 (0,9-1,1)
  Enkel-arm-index 1,1 (0,2)
  Perifeer vaatlijden 14,0%
  PWV, m/s a 12,6 (10,9-14,8)
Waardes zijn percentages of gemiddelden (standaard deviaties). CAC = coronaire calcium; cIMT = intima-mediadikte 
van de A. carotis; CRP = C-reactieve proteïne; eGFR = geschatte glomerulaire filtratiesnelheid; NT-proBNP = N-terminaal 
pro-breinnatriuretisch peptide; PWV = aortale polsgolfsnelheid; vWF = von Willebrand-factor.
a Mediaan (interkwartielafstand) vanwege een scheve verdeling.
b Metingen beschikbaar van 3029 deelnemers.
c Metingen beschikbaar van 3678 deelnemers.
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(23,5%) en zonder coronaire hartziekte (-4,2%). De toevoeging van CAC-score gaat dus 
gepaard met een NRI van 0,193 (95% BI 0,125-0,262). Na de CAC-score is NT-proBNP de meest 
opvallende marker: na toevoeging van NT-proBNP aan het basismodel werd netto 5,3% van de 
personen met coronaire hartziekte en 2,3% van de personen zonder coronaire hartziekte beter 
geclassificeerd (NRI 0,076; 95% BI 0,028-0,125). Tabellen 13.3 en 13.4 zijn de volledige risico-
reclassificatietabellen voor het toevoegen van respectievelijk de CAC-score en NT-proBNP aan 
het basismodel. Het reclassificerend vermogen van de overige markers was minimaal.
De associaties en het onderscheidend vermogen waren iets sterker bij mannen dan bij 
vrouwen voor de meeste nieuwe risicomarkers. Voor gedetailleerdere resultaten van de 
geslachtsspecifieke analyse verwijzen we naar de oorspronkelijke publicatie.165
Tabel 13.2 – Onderscheidend en reclassificerend vermogen van nieuwe risicomarkers voor 
het optreden van coronaire hartziekte
Risicomarker Toename in
c-statistiek
Netto percentage personen 
beter geclassificeerd
NRI
(95% BI) a Met CHZ Zonder CHZ (95% BI) b
NT-proBNP 0,02 (0,01-0,04)    5,3%  2,3%  0,076 (0,028-0,125)
vWF antigeen 0,00 (0,00-0,00)    0,6% -0,2%  0,004 (-0,017-0,025)
Fibrinogeen 0,00 (0,00-0,01)    3,1% -0,2%  0,029 (-0,002-0,060)
Chronische nierziekte 0,00 (0,00-0,00)    2,2%  0,5%  0,027 (-0,002-0,057)
Leukocytenaantal 0,01 (0,00-0,02)    1,9% -0,4%  0,015 (-0,015-0,046)
CRP c 0,00 (-0,01-0,00)    2,1% -0,1%  0,020 (-0,023-0,064)
Homocysteïne 0,00 (0,00-0,00) -  0,4%  0,1% -0,003 (-0,030-0,023)
Urinezuur 0,00 (0,00-0,00)    0,6%  0,2%  0,008 (-0,005-0,021)
CAC score d 0,05 (0,02-0,06)  23,5% -4,2%  0,193 (0,125-0,262)
cIMT 0,00 (0,00-0,00)    0,2% -0,4%  0,016 (-0,011-0,044)
Perifeer vaatlijden 0,00 (0,00-0,00)    0,6%  0,0%  0,006 (-0,018-0,029)
PWV 0,00 (0,00-0,00)    0,3% -0,3%  0,000 (-0,021-0,021)
CAC = coronaire calcium; CHZ = coronaire hartziekte; cIMT = intima-mediadikte van de A. carotis; CRP = C-reactieve 
proteine; NRI = ‘net reclassification improvement’; NT-proBNP = N-terminaal pro-breinnatriuretisch peptide; PWV = 
aortale polsgolfsnelheid; vWF = von Willebrand-factor.
a Toename in c-statistiek in het uitgebreide model (met klassieke risicofactoren en de nieuwe risicomarker) versus het 
basismodel (met alleen klassieke risicofactoren).
b De NRI voor het uitgebreide model (met klassieke risicofactoren en de nieuwe risicomarker) versus het basismodel 
(met alleen klassieke risicofactoren) met 10-jaarsrisico-categorieen van < 10%, 10 tot 20% en > 20%.
c Metingen beschikbaar van 3029 deelnemers.
d Metingen beschikbaar van 3678 deelnemers.
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Beschouwing
Van 12 nieuwe risicomarkers voor coronaire hartziekte gaf de mate van coronaire verkalking 
op een CT-scan de sterkste verbetering in de voorspelling van het risico op coronaire hartziekte 
als een marker werd toegevoegd aan een model met klassieke cardiovasculaire risicofactoren. 
Netto zou een kwart van de personen die coronaire hartziekte ontwikkelden met behulp van 
de CAC-score in een hogere risicoklasse zijn ingedeeld. Op grond daarvan zouden zij voor 
intensievere preventieve behandeling in aanmerking gekomen zijn.
Andere vasculaire risicomarkers, zoals cIMT, enkel-arm-index en aortale polsgolfsnelheid, 
waren in verscheidene populaties sterke voorspellers van coronaire hartziekte,332-334 maar deze 
waren van beperkte toegevoegde waarde in ons onderzoek. Hierbij moet worden aangetekend 
dat directe vergelijkingen met deze studies bemoeilijkt worden door de variatie in het aantal 
risicocategorieën, de afkappunten van deze categorieën en de selectie van uitkomstmaten.211 
De CAC-score is een directe en zeer nauwkeurige afspiegeling van de ernst van atherosclerose in 
het coronaire vaatbed (Figuur 13.3 330). Dit kan de zeer goede prestaties verklaren van de CAC-
score vergeleken met de vasculaire maten elders in de vaatboom, zoals cIMT, enkel-arm-index 
en aortale polsgolfsnelheid. In ons onderzoek was de NT-proBNP-concentratie de bloedwaarde 
die het sterkste verband vertoonde met coronaire hartziekte en het grootste reclassificerende 
vermogen had. Al eerder was aangetoond dat verhoogde concentraties van dit peptide in het 
bloed een sterke voorspeller zijn voor cardiovasculaire uitkomsten en overlijden.178, 203 NT-
proBNP wordt aangemaakt door cardiomyocyten onder invloed van mechanische rek. Stijgingen 
in concentraties van NT-proBNP zijn dan ook sterk gecorreleerd met subklinische en manifeste 
hartziekte. Ook neemt de voorspellende waarde van NT-proBNP toe met het vorderen van 
de leeftijd.335 Daarom is deze marker waarschijnlijk het bruikbaarst voor het voorspellen van 
coronaire hartziekte bij ouderen. Onze studie maakt het verschil tussen statistische significantie 
en klinische relevantie duidelijk voor een aantal andere bloedwaarden, zoals fibrinogeen, 
homocysteïne en CRP. In termen van risico-reclassificatie was de meerwaarde van deze markers 
minimaal wanneer ze werden toegevoegd aan het basismodel met klassieke risicofactoren.
Beperkingen
Het deel van het ERGO-cohort dat in dit hoofdstuk wordt beschreven, bestaat vrijwel volledig 
uit blanke deelnemers die allen 55 jaar of ouder zijn. Hierdoor zijn de resultaten van dit 
onderzoek niet te generaliseren naar jongere en niet-blanke bevolkingsgroepen. Ook is niet 
duidelijk of onze resultaten te extrapoleren zijn naar het model dat door het CBO en de NHG 
wordt geadviseerd;327 dat model voorspelt onder andere ook cerebrovasculaire uitkomsten en 
hartfalen.225, 257, 337
Voor de klinische praktijk zouden ook een aantal alternatieve algoritmen met CAC-score 
overwogen kunnen worden, zoals het in eerste instantie inschatten van het cardiovasculaire 
risico met de CAC-score en in een tweede stap de risicostratificatie te verfijnen met behulp van 
klassieke risicofactoren. Ook zou de afwezigheid van coronaire verkalkingen (CAC-score = 0; 
14,2% van de studiepopulatie) bij screening van asymptomatische personen gebruikt kunnen 
worden om het 10-jaarsrisico op coronaire hartziekte vrijwel uit te sluiten.338 Deze alternatieven 
hebben wij buiten beschouwing gelaten in dit hoofdstuk.
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Implementatie in de praktijk?
Ons onderzoek is een eerste stap in het identificeren van relevante nieuwe markers voor 
het voorspellen van coronaire hartziekte in de klinische praktijk. Op dit moment is er nog 
niet voldoende wetenschappelijke onderbouwing voor het invoeren van CAC-scores in 
risicovoorspellingen van coronaire hartziekte.339, 340 Het opstellen van een cardiovasculair 
risicoprofiel met daarin CAC-scores zal duurder zijn dan de huidige strategieën. Ook moet de 
Figuur 13.3 – Coronaire calciumscoreFiguur 13.3 
A   
 
B   
 
C   
 
 
CT-scans zonder contrast van verschillende deelnemers met uiteenlopende mate van coronaire verkalking: (A) geen tot 
lichte verkalking, (B) matige verkalking en (C) uitgebreide coronaire verkalking. Met behulp van dit soort scans wordt de 
coronaire calciumscore als volgt vastgesteld: 2 of meer aangrenzende pixels in het epicardiale coronaire vaatbed met 
een signaalintensiteit > 130 Hounsfield-units worden geïdentificeerd als verkalking; daarna wordt volgens de methode 
van Agatston 336 het product berekend van de verkalkte oppervlakte (in mm2) en de attenuatiefactor (1 tot 4), afhankelijk 
van de densiteit van de verkalking. De totale coronaire calciumscore, die kan variëren van 0 tot ver boven 1000, wordt 
verkregen door het optellen van de scores van alle coupes. Gemodificeerd overgenomen uit een eerdere publicatie.330
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stralingsbelasting van een CT-scan bij gezonde personen afgewogen worden tegen de verbeterde 
classificatie,341 en moeten bovenal de effectiviteit en kosteneffectiviteit nog vast komen te 
staan. De onderbouwing voor een gunstige kosteneffectiviteit van de CAC-score bestaat op 
dit moment alleen uit de resultaten van een Amerikaans gerandomiseerd onderzoek. Daarin 
concludeerde men dat CAC-screening een bijdrage kan leveren aan de primaire preventie van 
harten vaatziekten: 4 jaar na randomisatie tussen wel of niet een CT-scan ondergaan hadden 
de deelnemers van wie de CAC-score was bepaald een beter cardiovasculair risicoprofiel dan de 
controlegroep, tegen vergelijkbare kosten.342
Conclusies
In dit prospectieve onderzoek onder de algemene Nederlandse bevolking waren verbeteringen 
in classificatie van het risico op coronaire hartziekte het meest statistisch significant en 
klinisch relevant na toevoeging van de CAC-score aan het predictiemodel. Gerandomiseerd 
vervolgonderzoek is noodzakelijk om te bepalen of de verbetering in risicovoorspellingen 
aan de hand van coronaire verkalkingen—gemeten met CT—ook daadwerkelijk resulteert in 
minder hart- en vaatziekten tegen maatschappelijk verantwoorde kosten, inspanningen en 
stralingsbelasting bij asymptomatische ouderen.114, 339, 340
167
13
Newer risk markers for CHD prediction

C HAPTER 14
Coronary Calcifi cati on and the Risk of Heart Failure
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Objectives
The purpose of this study was to determine the association of coronary artery calcification 
(CAC) with incident heart failure in the elderly and examine its independence of overt 
coronary heart disease (CHD).
Background
Heart failure is often observed as a first manifestation of coronary atherosclerosis rather than 
a sequela of overt CHD. Although numerous studies have shown that CAC, an established 
measure of coronary atherosclerosis, is a strong predictor of CHD, the association between 
CAC and future heart failure has not been studied prospectively.
Methods
In the Rotterdam Study, a population-based cohort, 1897 asymptomatic participants (mean 
age, 69.9 years; 58% women) underwent CAC scoring and were followed for the occurrence 
of heart failure and CHD.
Results
During a median follow-up of 6.8 years, there were 78 cases of heart failure and 76 cases of 
nonfatal CHD. After adjustment for cardiovascular risk factors, increasing CAC scores were 
associated with heart failure (P for trend = 0.001), with a HR of 4.1 (95% CI 1.7-10.1) for CAC 
scores > 400 compared with CAC scores of 0 to 10. After censoring participants for incident 
nonfatal CHD, increasing extent of CAC remained associated with heart failure (P for trend 
= 0.046), with a HR of 2.9 (95% CI 1.1-7.4) for CAC scores > 400. Moreover, adding CAC to 
cardiovascular risk factors resulted in an optimism-corrected increase in the c-statistic by 
0.030 (95% CI 0.001-0.050) to 0.734 (95% CI 0.698-0.770) and continuous net reclassification 
improvement of 0.340(95% CI 0.114-0.567).
Conclusions
CAC has a clear association with the risk of heart failure, independent of overt CHD. Because 
heart failure is highly prevalent in the elderly, it might be worthwhile to include heart failure 
as an outcome in future risk assessment programs incorporating CAC.
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Coronary artery calcification (CAC), an established measure of subclinical coronary 
atherosclerosis, is a strong and independent predictor of future coronary heart disease (CHD).70, 
257, 343, 344 Furthermore, calcium scoring appears to improve CHD risk prediction beyond risk 
scoring algorithms such as the Framingham risk score and is considered useful in persons at 
intermediate risk of CHD (i.e. a 10-year absolute risk of 10 to 20%).165, 188, 343, 345, 346
It is well known that heart failure is a highly prevalent disease in the elderly, associated with 
reduced life expectancy and ever increasing costs.31, 78, 347 Especially in the elderly, coronary 
atherosclerosis is the current leading cause of heart failure and heart failure is often observed 
as a first manifestation of coronary atherosclerosis rather than a sequela of overt coronary 
insufficiency or myocardial infarction (MI).22, 348
In this light, heart failure could be considered an additional outcome in cardiovascular risk 
assessment programs using CAC. As a prerequisite, it is important to examine the strength of the 
association between CAC and incident heart failure, independent of cardiovascular risk factors 
and overt CHD. In the Rotterdam Study, a prospective population-based cohort study among 
elderly individuals, we investigated the association between CAC, as detected by electron-beam 
computed tomography (CT) and the risk of heart failure and examined whether this association 
is independent of incident overt CHD during follow-up.
Methods
Study design, setting, and population
This study is embedded in the Rotterdam Study, a prospective population-based cohort study 
among persons older than 55 years of age that started in 1990. Starting in 2000, the original 
cohort (RS-I) was extended with a second cohort (RS-II) of persons who reached the age of 55 
years and persons who had moved to the research area (Figure 1.1). The rationale and design 
of the Rotterdam Study were described elsewhere.32-37
For both cohorts, identical examinations took place from 1997 to 2001 (Figure 1.1), and 
participants through 85 years of age were invited to undergo a CT scan in a separate visit. Scans 
were obtained in 2349 participants (61% response rate). Clinical characteristics of responders 
and non-responders were highly comparable.349 Due to several causes, image acquisition data 
could not be analyzed in 57 participants. Therefore, data were available for 2292 participants. 
For the present study, we excluded 79 participants with known heart failure and 10 participants 
with incomplete data concerning heart failure status at the time of CT scanning. Furthermore, 
we excluded the subset of the study population with a documented history of CHD (n = 306), 
defined as a recognized or unrecognized MI, percutaneous coronary intervention (PCI), or 
coronary artery bypass grafting (CABG). This left a total of 1897 coronary asymptomatic 
individuals eligible for the present study. The median duration between the examination at the 
Rotterdam Study research center and CT scanning was 44 days.
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We assessed CAC in the epicardial coronary arteries detected on electron-beam CT scans, as 
described in detail previously.70 Briefly, imaging was performed with a C-150 Imatron scanner 
(GE Imatron Inc., South San Francisco, CA, U.S.). From the level of the root of the aorta through 
the heart, 38 images were obtained with a 100-ms scan time and 3-mm slice thickness. A 
calcification was defined as a minimum of 2 adjacent pixels (0.65 mm2 area) with a density > 
130 Hounsfield units. CAC scores were calculated according to Agatston’s method.336 See Figure 
13.3 for examples of CAC imaging.221, 330 Conforming to the study protocol, approved by the 
medical ethics committee, participants were not informed about their CAC score, nor were 
their treating physicians.
Assessment of covariables
In the Rotterdam Study, assessment of anthropometrics, cardiovascular risk factors, and use 
of medication was described previously.350 We defined diabetes mellitus as a fasting serum 
glucose level of ≥ 7.0 mmol/L, a nonfasting serum glucose level of ≥ 11.1 mmol/L (only if fasting 
serum was unavailable), or the use of oral blood glucose-lowering medication or insulin.
Assessment of outcomes
Follow-up started at the date of CT scanning. Cases of prevalent and incident heart failure and 
CHD were obtained by continuously monitoring participants of the Rotterdam Study during 
follow-up as described previously.105 CHD events were defined as MI, PCI, CABG, or CHD 
mortality. Assessment of heart failure and CHD events was described in detail previously.105 Two 
research physicians independently classified all potential events. Heart failure was classified 
as definite, probable, possible, or unlikely. In case of disagreement, consensus was reached 
in a separate session. Afterward, a cardiologist reviewed all events. Definite heart failure was 
defined as a combination of the presence of at least 1 of the typical symptoms or signs, such 
as breathlessness, ankle edema, and pulmonary crepitations, and confirmation by objective 
evidence of cardiac dysfunction. Also, for definite heart failure, the diagnosis had to have 
been made by a cardiologist or an internist. Heart failure was classified as probable when at 
least 2 typical symptoms are present, and at least 1 of the following: history of cardiovascular 
disease (e.g. MI, valvular heart disease, hypertension), positive response to initiated treatment 
for heart failure, or objective evidence of cardiac dysfunction. In accordance with the criteria 
of the European Society of Cardiology, only definite and probable cases were included in the 
analysis.76
Statistical analysis
CAC scores were divided into 4 categories: 0 to 10, 11 to 100, 101 to 400, and > 400, 
adapted from the categorization as proposed by Rumberger and colleagues.351 We used Cox 
proportional hazards models to construct age- and sex-adjusted heart failure-free survival 
curves and to calculate hazard ratios (HRs) for the risk of heart failure for the natural logarithm 
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of the continuous CAC scores [log(CAC + 1)] and the different CAC score categories.107 Before 
logarithmic transformation, we added 1 to all CAC scores to deal with participants who had a 
CAC score of 0. In model 1, we adjusted for age and sex. In model 2, we additionally adjusted for 
the following traditional cardiovascular risk factors: systolic blood pressure, current smoking, 
diabetes mellitus, total cholesterol to high-density lipoprotein cholesterol ratio, and body mass 
index. Participants with a CAC score of 0 to 10 served as the reference category. The P value 
for trend was obtained by entering CAC score categories into the Cox models as a continuous 
variable. Participants were censored at the date of death, loss to follow-up, or the end of the 
study period, defined as the last date of follow-up. In addition, we repeated the analyses after 
censoring participants when incident clinical nonfatal CHD occurred during follow-up (model 3 
and additionally adjusted for cardiovascular risk factors in model 4). This was done to examine 
the association between CAC and risk of future heart failure, independent of incident CHD. We 
assessed the interaction terms between sex and the natural logarithm of the continuous CAC 
scores in all 4 models, which were all not significant (all P values > 0.30).
Next, we examined the added discriminative ability of log(CAC + 1) when added to the 
aforementioned cardiovascular risk factors. This was done by calculating optimism-corrected 
c-statistics as well as the optimism-corrected difference in c-statistic of a model including the 
cardiovascular risk factors and log(CAC + 1) compared with a model including the cardiovascular 
risk factors only.352 These analyses were performed using 100 bootstrap repetitions.28, 233 To 
further quantify the discriminative ability of CAC, we estimated the integrated discrimination 
improvement as a measure of the improvement in sensitivity with the addition of log(CAC 
+ 1), corrected for the decrease in specificity (i.e. the difference in discrimination slopes).16 
Finally, we computed the true improvement in risk classification by addition of log(CAC + 1), by 
calculating the continuous net reclassification improvement.137, 194
In 83 (4.4%) of the participants, 1 or more cardiovascular covariables were missing. These missing 
values were handled by single imputation using an expectation-maximization algorithm.109 With 
the exception of the baseline characteristics (Table 14.1), results are reported for imputed data. 
All measures of association are presented with 95% confidence intervals (CIs). We used the 
level of significance of P < 0.05. Data were analyzed using the PASW Statistics package, version 
17.0.2 (SPSS Inc., Chicago, Ill, U.S.).The measures of discrimination and reclassification were 
computed using R version 2.10.1.110
Results
The baseline characteristics of the study population by category of CAC are shown in Table 14.1. 
For the total population, the median CAC score was 78 (interquartile range: 7 to 351). During a 
median follow-up time of 6.8 years (interquartile range: 6.3 to 7.5 years), there were 78 cases 
of incident heart failure, 76 cases of nonfatal incident CHD (46 MIs, 19 PCIs, and 11 CABG 
procedures), and 29 cases of fatal CHD. These 183 events occurred in 160 participants. Nonfatal 
incident CHD preceded heart failure in 14 of 78 participants (18%). Heart failure represented 
64 of 160 (40%) of the first cardiac events observed. In all but 1 participant, in whom heart 
failure developed during follow-up, coronary calcifications were detected (98.7%). Figure 14.1 
shows the association between CAC score categories and incident heart failure, adjusted for 
age and sex. The event-free survival decreased with increasing CAC scores, with an age- and 
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sex-adjusted cumulative incidence at 6 years of 1.4%, 3.3%, 3.5%, and 5.7% for CAC scores of 0 
to 10, 11 to 100, 101 to 400, and > 400, respectively.
Increasing CAC score categories, adjusted for age and sex, were all significantly associated with 
heart failure (P for trend < 0.001), with an HR of 4.6 (95% CI 1.9-11.2) for CAC scores > 400 
(model 1) (Table 14.2). Additional adjustment for cardiovascular risk factors lowered these 
estimates slightly but remained significant (P for trend = 0.001), with an HR of 4.1 (95% CI 1.7-
10.1) in the CAC score category of > 400 (model 2). Further adjustment for measures of long-
standing hypertension (i.e. use of antihypertensive medication and electrocardiographic left 
ventricular hypertrophy) resulted in minor attenuation of the associations, with an HR of 1.25 
(95% CI 1.10-1.41) for continuous CAC scores.
Table 14.1 – Characteristics of the study population
Total
population
CAC score categories
0-10 11-100 101-400 > 400
n = 1897 n = 528 n = 498 n = 435 n = 436
Age, y 69.9 (6.5) 67.3 (6.0) 69.8 (6.3) 70.9 (6.2) 72.3 (6.2)
Men 41.9% 24.1% 39.4% 47.6% 60.6%
Systolic blood pressure, 
mmHg
143 (21) 138 (21) 144 (21) 144 (22) 147 (21)
Diastolic blood pressure, 
mmHg
76 (11) 75 (10) 77 (11) 76 (11) 77 (11)
Use of blood pressure-
lowering medication
32.4% 24.4% 29.7% 34.5% 43.3%
Electrocardiographic LVH 4.7% 3.6% 4.6% 5.6% 5.2%
Smoking:
  Current 16.9% 12.0% 15.9% 20.3% 20.6%
  Former 51.4% 45.8% 50.8% 51.6% 58.8%
  Never 31.7% 42.4% 33.3% 28.1% 20.6%
Total cholesterol, mmol/L 5.9 (0.9) 5.9 (1.0) 5.9 (0.9) 5.9 (1.0) 5.8 (0.9)
HDL cholesterol, mmol/L 1.4 (0.4) 1.5 (0.4) 1.4 (0.4) 1.4 (0.3) 1.4 (0.4)
Diabetes mellitus 11.5% 6.5% 9.8% 14.4% 16.6%
Body mass index, kg/m2 27.1 (4.0) 26.5 (3.6) 27.6 (4.2) 26.9 (4.1) 27.1 (3.9)
CAC score a 78 (7-351) 1 (0-4) 38 (20-66) 197 (145-264) 820 (578-1422)
CAC score > 0 89.4% 61.7% 100% 100% 100%
Values are percentages or means (standard deviations); unimputed data. CAC = coronary artery calcification; HDL = 
high-density lipoprotein; LVH = left ventricular hypertrophy.
a Median (interquartile range) because of its skewed distribution.
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When repeati ng these analyses with additi onal censoring of parti cipants with the occurrence 
of an MI or coronary revascularizati on procedure during follow-up, esti mates of the HRs for 
increasing CAC score categories decreased but remained associated (P for trend = 0.027) and 
signifi cant in the upper CAC score category (model 3). Even aft er adjustment for cardiovascular 
risk factors (model 4), every 1-unit increase in log(CAC + 1) corresponded to an HR of 1.17 (95% 
CI 1.02-1.33). Furthermore, increasing CAC score categories remained associated with the risk 
of heart failure (P for trend = 0.046) and a CAC score > 400 remained signifi cantly elevated, with 
an HR of 2.9 (95% CI 1.1-7.4).
In our populati on free of heart failure and CHD at baseline, the predicti on model based on the 
cardiovascular risk factors performed sati sfactorily with a c-stati sti c of 0.705 (95% CI 0.666-
0.754). CAC scores, when added to the model, increased the c-stati sti c by 0.030 (95% CI 0.001-
0.050) and resulted in a c-stati sti c of 0.734 (95% CI 0.698-0.770). The integrated discriminati on 
improvement was 0.011 (95% CI 0.001-0.020). Additi on of the conti nuous CAC scores to the 
model containing cardiovascular risk factors led to a conti nuous net reclassifi cati on improvement 
of 0.340 (95% CI 0.114-0.567).
Figure 14.1 – Heart failure-free survival, by coronary artery calcifi cati on score category
Figure 14.1 
 
 
As the extend of coronary calcifi cati on increases, heart failure-free survival adjusted for age and sex decreases over 
ti me (P for trend < 0.001).
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Discussion
Our results indicate a clear and graded association between the extent of CAC and the risk 
of heart failure in a population of Dutch elderly. All but a single participant in our study in 
whom heart failure developed had CAC detected, and participants in the highest CAC score 
category (> 400) were more than 4 times more likely to develop heart failure compared with 
participants with a 0 or very low CAC score, independent of cardiovascular risk factors. After 
censoring participants with the occurrence of incident nonfatal CHD, a 3-fold increased risk of 
heart failure persisted for this CAC score category, indicating a clear association between CAC 
and risk of heart failure apart from overt CHD. Moreover, adding continuous CAC scores to 
the cardiovascular risk factors increased the discriminative ability of the prediction model and 
improved the classification of the risk estimation.
Thus far, numerous large population-based studies investigating CAC and future cardiovascular 
disease only examined the risk of MI, coronary revascularization, stroke, death, or a combination 
of these outcomes.70, 188, 257, 343-346 Recently, increasing CAC scores have been cross-sectionally 
associated with self-reported history of heart failure, with odds ratios adjusted for age and sex 
of 1.3 (95% CI 0.7-2.2) for CAC scores of 10 to 99, 1.9 (95% CI 1.1-3.3) for CAC scores of 100 
to 399, and 2.2 (95% CI 1.2-4.1) for CAC scores > 399.353 The strength of the associations of 
CAC with heart failure is substantially lower compared with the associations with CHD events 
in the elderly that we reported previously.70, 165, 257, 345 For instance, we showed that log(CAC 
+ 1) yielded a multivariable adjusted HR of 1.33 (95% CI 1.21-1.47) with hard CHD compared 
with 1.26 (95% CI 1.11-1.42) for heart failure (Table 14.2).345 This is most likely explained by 
the heterogeneous etiology of heart failure in the general population. Nonetheless, we show 
that CAC measurements are of added value in predicting future heart failure in the elderly, 
regardless of the underlying etiology.
In our study, heart failure represented 40% (64 of 160) of the first cardiac events observed. This 
is in agreement with numbers from a recent report of the Framingham Heart Study showing in 
an elderly subpopulation that 48% of the participants with a cardiac event had heart failure as 
their initial presentation.334 This reinforces heart failure as an additional outcome measure in 
studies on cardiovascular risk prediction in the elderly, in addition to hard coronary outcomes. 
Although abundant research indicates that CAC screening in the elderly has additive value for 
CHD risk prediction over traditional risk factors, its effect on clinical outcomes and its cost-
effectiveness in large-scale randomized trials are much awaited.339, 354-357 Given our study results, 
heart failure should be considered an additional outcome measure in possible future cardiac 
risk assessment programs using CAC screening.
Strengths and limitations
The strengths of our study include the standardized measurements of cardiovascular risk factors 
in a population-based setting with long and virtually complete follow-up. Furthermore, due to 
the fact that both participants of our study and their treating physicians were not informed 
about the CAC scores, our cohort is one of few in the world in which an unbiased association 
between CAC and future heart failure can be investigated. Awareness of a high CAC score may 
motivate patients to make beneficial lifestyle changes and results in superior risk factor control 
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with increased downstream medical testing in patients with CAC scores > 400.342, 358
Our study also has some limitations that need to be addressed. First, heart failure diagnosis was 
based on the occurrence of symptoms and response to heart failure therapy, usually supported 
by concurrent echocardiography or chest X-ray. Unfortunately, additional information on the 
presence of objective cardiac dysfunction was not present in all cases, especially not for nursing 
home residents. This might have led to some misclassification and thereby underestimation of 
the associations. Second, our results were derived from an elderly population. In this age group, 
CHD is the most important risk factor for heart failure among many others, such as long-standing 
hypertension, atrial fibrillation, valvular heart disease, and various cardiomyopathies.359 This 
may not hold true for younger individuals. The strength of associations of traditional coronary 
risk factors (e.g. cholesterol and hypertension) diminishes with increasing age, whereas 
increasing extent of CAC can be seen as a cumulative measurement of a lifetime exposure to 
cardiovascular risk factors.29, 30 Therefore, our results cannot be generalized to middle-aged 
individuals. Furthermore, as in all prognostic studies in aging populations, competing causes of 
death (e.g. death due to other cardiovascular diseases or cancer) may have interfered with our 
estimation of the event-free survival. Last, because of the limited number of heart failure cases, 
we could not assess differences in prognosis of CAC in subgroups, such as women and those 
with diabetes or hypertension.
Conclusions
The extent of CAC has a clear association with the risk of the development of heart failure, 
independent of overt CHD. Because heart failure is highly prevalent in the elderly, it might 
be worthwhile to include heart failure as an outcome if future risk assessment programs 
incorporate CAC screening.
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Background
Risk scores for prediction of coronary heart disease (CHD) in older adults are needed.
Objective
To develop a sex-specific CHD risk prediction model for older adults that accounts for 
competing risks for non-coronary death.
Design
2 observational cohort studies, using data from 4946 participants aged 65 years or older who 
were free of cardiovascular disease from the Cardiovascular Health Study (CHS) and 4303 
participants in the Rotterdam Study (RS).
Main outcomes
A composite of nonfatal myocardial infarction and coronary death.
Results
During a median follow-up of 16.5 and 14.9 years, 1166 CHS and 698 RS participants had 
CHD events, respectively. Deaths from non-coronary causes largely exceeded the number 
of CHD events, complicating accurate CHD risk predictions. The prediction model had 
moderate ability to discriminate between events and nonevents (c-statistic, 0.63 in both U.S. 
and European men and 0.67 and 0.68 in U.S. and European women). The model was well 
calibrated; predicted risks were in good agreement with observed risks. Compared with the 
Framingham point score, the prediction model classified elderly U.S. persons into higher risk 
categories but elderly European persons into lower risk categories. Differences in classification 
accuracy were not consistent and depended on cohort and sex. Adding newer cardiovascular 
risk markers to the model did not substantially improve performance.
Conclusions
A CHD risk prediction model that accounts for deaths from non-coronary causes among older 
adults provided well-calibrated risk estimates but was not substantially more accurate than 
Framingham point score. Moreover, adding newer risk markers did not improve accuracy. 
These findings emphasize the difficulties of predicting CHD risk in elderly persons and the 
need to improve these predictions.
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Specialist societies recommend initiating preventive treatment of cardiovascular disease on the 
basis of a person’s 10-year risk for coronary heart disease (CHD).216, 247, 360 Well-known prognostic 
models to estimate this risk originate from the Framingham Heart Study,331, 361-363 the Women’s 
Health Study,364 the Prospective Cardiovascular Münster (PROCAM) study,365 and the Systematic 
Coronary Risk Evaluation (SCORE) project.5
Demographic changes have increasingly led to an extension of primary prevention strategies 
for CHD to elderly persons.25, 366 However, these persons are underrepresented or neglected in 
well-known CHD prediction models. Several studies show that existing CHD prediction models 
may extrapolate poorly to persons older than 70 years 367 and that the predictive associations 
of risk factors for CHD may diminish with increasing age.28-30, 216, 323 A CHD prediction model for 
elderly persons should also take into account that with growing age and frailty, CHD events may 
be increasingly precluded by death from competing non-coronary causes. A valid risk prediction 
approach in this situation must account for competing causes of death to prevent inflated 
predictions of limited practical use.294, 368-371
The purpose of this study was to develop and evaluate a population-based algorithm to predict 
coronary risk in elderly persons on the basis of traditional risk factors. We also examined 
model performance after the addition of newer risk markers for cardiovascular disease. Our 
study is the result of a collaboration between 2 large and similarly designed cohort studies on 
cardiovascular disease in elderly persons, the Cardiovascular Health Study (CHS) in the U.S. 72 
and Rotterdam Study (RS) in the Netherlands.32-35
Methods
Study design, setting, and population
The CHS is a prospective population-based study in adults aged 65 years or older with the main 
objective of identifying risk factors related to the onset and course of CHD and stroke. Eligible 
participants were sampled from Medicare eligibility lists in 4 U.S. communities. The rationale 
and design of the CHS have been described elsewhere.72 The RS is a prospective population-
based cohort study of persons aged 55 years or older living in a suburb of Rotterdam, the 
Netherlands. This study aims to assess the determinants of cardiovascular and other diseases 
in elderly persons.32-37
We selected all participants aged 65 years or older who were free of definite CHD and 
cerebrovascular disease at enrollment. After participants with a history of myocardial infarction 
(MI); electrocardiography results consistent with past MI; or a history of percutaneous or 
surgical coronary revascularization procedures, stroke, or carotid endarterectomy were 
excluded, 4946 CHS and 4303 RS participants remained in the analyses. Previous publications 
detail the procedures for assessing medical history at baseline.72, 105, 372
Measurement of coronary risk factors
Participants were categorized in groups of current, former, or never smokers. Former smoking 
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was defined as having abstained from smoking for at least 2 years. Blood pressure was 
measured by using a random-zero sphygmomanometer at the right brachial artery in sitting 
position after a 5-minute rest. The average of 2 consecutive blood pressure measurements 
was used. In the CHS, participants were asked to fast for 12 h before coming to their clinical 
appointments and fasting plasma lipid levels were measured by an Olympus Demand system 
(Olympus, Lake Success, NY, U.S.). In the RS, serum total cholesterol level was determined by 
an automated enzymatic procedure by using the CHOD-PAP reagent agent (Roche Diagnostics, 
Basel, Switzerland) and serum HDL cholesterol level was measured with the HDL cholesterol 
assay (Roche Diagnostics, Basel, Switzerland) by using polyethylene glycol-modified enzymes 
and dextran sulfate. Diabetes mellitus was defined as current use of blood glucose-lowering 
medication or a random or postload serum glucose level of ≥ 11.1 mmol/L.
A 12-lead resting electrocardiogram (ECG) was obtained and stored electronically in both 
cohorts. In the CHS, the ECG reading center used the Novacode ECG measurement and 
classification system 72, 373 to analyze ECG data. In the RS, ECG data were computer-analyzed 
by the MEANS program.54, 105 The presence of ECG-LVH was defined according to the Sokolow-
Lyon voltage criteria.374 In the CHS, fasting serum chemistry analyses were done with the Kodak 
Ektachem 700 Analyzer (Eastman Kodak, Rochester, NY, U.S.). In the RS, CRP was measured 
by Rate Near Infrared Particle Immunoassay (Immage Immunochemistry System; Beckman 
Coulter, Brea, CA, U.S.).375 The ABI was calculated as the ratio of the systolic blood pressure 
of the posterior tibial artery, as assessed by an 8-MHz continuous wave Doppler probe and a 
random-zero sphygmomanometer, to the systolic blood pressure at the right arm. The lowest 
ABI of the left- and right-side readings was used for analysis.376 Duplex ultrasonography of 
both carotid arteries was performed with a 5.0 MHz transducer (SSA-270A; Toshiba America 
Medical Systems, Tustin, CA, U.S.) in the CHS and a 7.5-MHz transducer (UltraMark IV; Advanced 
Technology Laboratories, Bothell, WA, U.S.) in the RS. Common cIMT was determined as 
described elsewhere.41 The maximum common cIMT was determined as the average of the 
maximum cIMT of near- and far-wall measurements over a length of 1 cm, and the average of 
left and right maximum common cIMT was computed and used for analysis.
End points
The outcome for this study was time to first CHD event, a composite of nonfatal MI and fatal 
CHD. Appendix Table 15.1 compares the very similar standardized definitions of CHD events for 
the 2 cohorts and Appendix Table 15.2 provides the incidence of CHD end points (nonfatal MI 
and coronary death).
In the CHS, events were ascertained through regular surveys (surveillance calls, annual visits, 
newspaper obituaries, and reviews of medical records and Medicare data) from the field centers 
or by participants contacting the sites. Potential events were classified by a study-wide review 
committee on the basis of death certificates; autopsy and coroner forms; hospital records; and 
interviews with attending physicians, next of kin, and witnesses.72, 94 In the RS, information 
on end points was obtained from general practitioners and discharge reports from medical 
specialists. All events were classified independently by 2 research physicians. If the physicians 
disagreed, a consensus was reached in a special session. Finally, all events were verified by a 
medical specialist affiliated with the study.105
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For the CHS, the first examination cycle began in 1989, with annual examinations through 1999. 
A second cohort was enrolled in 1992 with the additional recruitment of African Americans. 
In the RS, baseline examinations were conducted from 1990 to 1993 (RS-I-1; Figure 1.1). The 
censoring date was 30 June 2006 in the CHS and 1 January 2007 in the RS. For our analysis, only 
1 CHS participant and 6 RS participants were lost to follow-up after 10 years.
Statistical analysis
We developed prespecified and sex-specific CHD prediction models using age; systolic blood 
pressure, with separate effects for treated and untreated participants; presence of diabetes 
mellitus; levels of total and high-density lipoprotein (HDL) cholesterol; and smoking status as 
covariables. We used a competing risk method based on the Fine and Gray model, using the 
approach by Ruan and Gray.296, 377, 378
We pooled data from both cohorts into 2 sex-specific data sets. Regression models included 
cohort-stratified baseline hazard functions; that is, we assumed that baseline risk for CHD 
may differ but that risk factors act equally on U.S. and European persons 5 and assessed this 
assumption by testing for cohort-risk factor interactions. Appendix Table 15.3 provides details 
about the development steps of the model and the testing of the assumptions.
We assessed prognostic accuracy by evaluating the pooled model on each cohort individually 
and by cross-validation, in which models were fit to one cohort and evaluated in the other. 
We quantified the discriminative ability up to 10 years of follow-up with an adaptation of the 
Harrell’s c-statistic 28 to the competing risks setting.370 Calibration was assessed by plotting 10-
year predicted risk against observed risk.370
Next, we computed 10-year risk predictions based on the original Adult Treatment Panel III 
(ATP III) Framingham point score (FPS),27 which predicts the same composite CHD end point, 
and compared the accuracy of FPS predictions with predictions from our model by using the 
c-statistic 370 and risk classification methods with recommended cut-off values.27 Because head-
to-head comparisons of different non-nested prediction models, particularly those that have not 
been fitted on the same population, are hard to interpret with single measures (such as the net 
reclassification improvement [NRI]16), we used summary metrics based on the margins of the 
reclassification table proposed by Janes and Pepe.160, 209, 212 We focused on differences between 
the 2 models in proportions of events and nonevents classified into the high-risk (> 20%) or 
low-risk (< 10%) categories. In these categories, decisions to test or treat are more established 
than in the intermediate-risk category, in which appropriate clinical actions are sometimes less 
certain. The comparisons are summarized as changes in the true- and false-positive and true- 
and false-negative rates. Because the FPS is intended for non-diabetic persons, we also refit and 
reexamined our model in non-diabetic participants.
In a further step, we examined the incremental value of extending the competing risks model 
based on traditional risk factors with the single addition of body mass index, C-reactive protein 
(CRP) levels, carotid intima-media thickness (cIMT), ankle-brachial index (ABI), or the presence 
of left ventricular hypertrophy on electrocardiography (ECG-LVH).16 We evaluated the added 
value of these markers on the basis of statistically significant overall model improvement and the 
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increase in the c-statistic.28 Because we compared nested models, we used the NRI to present 
reclassification accuracy. We computed the NRIs by adapting the suggestion of Steyerberg and 
Pencina for survival data 16, 194 to the competing risks setting. Appendix Table 15.3 provides 
details of the evaluation of extended models.
In a sensitivity analysis, we excluded participants aged 80 years or older because the FPS are 
developed for adults up to age 79 years; there were few meaningful changes in our results so 
we do not report them.
We report estimates of hazard ratios and c-statistics with 95% CIs. All hypothesis tests are 
2-sided, and the significance level was set to 5%. Data were analyzed using R version 2.14.2 .110 
The Appendix to this chapter provides more detailed descriptions of our statistical analysis and 
methods.
Results
Baseline characteristics are presented in Table 15.1. In the CHS cohort, 15.5% of men and 11.5% 
of women were aged 80 years or older. In the RS cohort, the corresponding proportions were 
19.7% and 33.3%. The median duration of follow-up was 16.5 years (interquartile range, 13.5 
to 16.7 years) in the CHS and 14.9 years (interquartile range, 14.1 to 15.7 years) in the RS. We 
observed 563 CHD events in men and 603 in women in the CHS; in the RS, we observed 283 
events in men and 415 in women. This corresponded with 10-year cumulative incidences of 
19.9% and 15.8% in men in the CHS and the RS, respectively, and similar incidences in women 
(11.5% and 10.4%, respectively). In both cohorts, the number of competing non-coronary 
deaths exceeded the number of CHD events over the entire age range; we observed 2000 and 
2244 non-coronary deaths in the CHS and the RS, respectively (Appendix Tables 15.1 and 15.2). 
The incidence of competing non-coronary death increased more rapidly with age than did the 
incidence of CHD (Figure 15.1).
Coronary heart disease prediction
Coronary risk factors were associated with CHD about equally in men and women (Table 15.2). 
However, total cholesterol level was predictive of CHD in European but not in U.S. women, so 
we accounted for cholesterol– cohort interaction in our final prediction model. We also note 
that systolic blood pressure in men treated for hypertension was not statistically significant 
and smoking was borderline statistically significant in the multivariable model (Table 15.2). In 
women, the positive association of age with CHD was nonlinear and decreased with increasing 
age. We refer to our model based on established risk factors as the coronary risk in the elderly 
(CORE) model for the remainder of the text.
The discriminatory performance of the CORE model was moderate and lower in men than in 
women (c-statistic, 0.63 in both U.S. and European men and 0.68 and 0.67 in U.S. and European 
women, respectively) (Table 15.3). Cross-validation led to loss of discrimination compared with 
the pooled model (Table 15.3). Predicted 10-year risks were in good agreement with observed 
risks in each cohort, indicating good calibration (Figure 15.2). The Appendix to this chapter 
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includes an example that explains how the CORE model can be applied to derive predicted 
risks by using the coefficients and subdistribution hazards from Appendix Tables 15.4 and 15.5, 
respectively. A risk calculator developed from our model for the prediction horizons of 3, 5, 7, 
and 10 years is available online at www.ceb-institute.org/evibox/chd/.
Comparison with the Framingham point score
We compared the CORE model with the FPS. The c-statistic of the FPS was 0.02 to 0.03 units 
lower than that of the CORE model in both cohorts Table 15.3.
In U.S. men, the CORE model classified many more persons into the high-risk group than did 
Table 15.1 – Characteristics of study populations
Cardiovascular Health Study Rotterdam Study
Men Women Men Women
n = 1917 n = 3029 n = 1454 n = 2849
Age, y 72 (69-77) 71 (68-76) 73 (69-78) 76 (70-83)
White ethnicity 1628 (85) 2505 (83) 1301 (99) 2444 (99)
Use of blood pressure-
lowering medication
750 (39) 1353 (45) 394 (31) 1095 (45)
Systolic blood pressure, mmHg:
  Treated 137 (123-153) 140 (126-156) 142 (128-158) 147 (132-163)
  Untreated 132 (119-146) 130 (118-145) 138 (126-154) 142 (128-156)
Smoking:
  Current 221 (12) 377 (12) 414 (30) 342 (13)
  Former 1065 (56) 895 (30) 876 (63) 636 (24)
  Never 628 (33) 1754 (58) 106 (8) 1639 (63)
Total cholesterol, mmol/L 5.1 (4.5-5.7) 5.6 (5.0-6.3) 6.1 (5.3-6.8) 6.7 (5.9-7.5)
HDL cholesterol, mmol/L 1.2 (1.0-1.4) 1.5 (1.2-1.8) 1.2 (1.0-1.4) 1.4 (1.2-1.6)
Diabetes mellitus 318 (17) 391 (13) 143 (10) 336 (12)
ECG-LVH 77 (4) 123 (4) 72 (5) 126 (6)
Body mass index, kg/m2 26 (24-29) 26 (23-30) 26 (24-27) 27 (24-29)
C-reactive protein, nmol/L 0.23 (0.12-0.42) 0.14 (0.27-0.48) 0.22 (0.10-0.44) 0.21 (0.10-0.38)
Ankle-brachial index 1.2 (1.1-1.2) 1.1 (1.0-1.2) 1.2 (1.0-1.3) 1.2 (1.0-1.2)
cIMT, mm 1.1 (1.0-1.2) 1.0 (0.9-1.2) 1.1 (0.9-1.2) 1.0 (0.9-1.1)
Values are counts (percentages) or medians (interquartile range); unimputed data. cIMT = carotid intima-media 
thickness; ECG-LVH = electrocardiographic left ventricular hypertrophy; HDL = high-density lipoprotein.
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the FPS (47.7% versus 22.5%) (Table 15.4). More specifically, compared with the FPS, the CORE 
model increased classification of events and nonevents as high-risk by 30.6 and 23.8 percentage 
points, respectively. Similar results were seen for non-diabetic U.S. men (increases in true- and 
false-positive rates of 24.0 and 16.6 percentage points, respectively). Of note, observed risks in 
high-risk non-diabetic men were almost identical in the 2 models (24.6% in the CORE model and 
24.8% for the FPS), whereas the number of events classified as high-risk in the CORE model was 
nearly double that of the FPS (51.4% versus 27.4%). Therefore, the increase in the true-positive 
rate can be ascribed at least in part to better discriminative properties of the CORE model. 
The reclassification table for the comparison of the CORE model to the FPS in non-diabetics is 
presented in the online supplement of the original publication.104
In U.S. women, the CORE model classified fewer events and nonevents as low-risk than the FPS 
(differences of 20.7 and 19.0 percentage points, respectively) (Table 15.4). In Europeans, the 
CORE model generally classified more persons into lower risk categories than the FPS (Table 
15.5).
In European men, the CORE model classified fewer nonevents as high-risk (a difference of 14.2 
percentage points) but at the expense of a 10.5-percentage point increase in events misclassified 
in lower risk strata (Table 15.5). The general downward movement of persons with the CORE 
model was due to systematic overestimation of risk in RS participants with the FPS. For example, 
observed risks were 11.1% and 19.7% in the intermediate- and high-risk categories using the 
FPS in European women.
Table 15.3 – Discriminatory performance of the CORE model and Framingham point score
Model C-statistic (95% CI)
Men Women
Model derived from pooled CHS and RS data:
  Evaluated in CHS 0.63 (0.60-0.65) 0.68 (0.65-0.70)
  Evaluated in RS 0.63 (0.59-0.66) 0.67 (0.64-0.70)
Cross-validation performance:
  Model derived in RS evaluated in CHS 0.60 (0.57-0.63) 0.67 (0.64-0.69)
  Model derived in CHS evaluated in RS 0.62 (0.58-0.65) 0.65 (0.62-0.68)
Framingham point score predictions:
  Evaluated in CHS 0.60 (0.57-0.63) 0.66 (0.64-0.69)
  Evaluated in RS 0.60 (0.56-0.63) 0.65 (0.62-0.69)
CHS = Cardiovascular Health Study; CORE = coronary risk in the elderly; RS = Rotterdam Study.
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Additional risk markers
Of the additional risk markers we evaluated, only the presence of ECG-LVH and low ABI were 
significantly associated with CHD in both sexes. There was negligible improvement in predictive 
accuracy when we added ECG-LVH and ABI to the CORE model (an increase in the c-statistic of 
only 0.019 with an NRI of 0.039 in U.S. men and an increase of only 0.010 with an NRI of 0.025 
in European men) (Table 15.6). In women, adding cIMT, CRP, ABI, and ECG-LVH led to limited 
improvements in CHD prediction beyond established risk factors. Combining these 4 markers 
into an extended model resulted in small to moderate predictive improvements in both the U.S. 
and European populations (the c-statistic increased to 0.69 in both populations with NRIs of 
0.068 and 0.096, respectively) (Table 15.6). Reclassification tables for the addition of the separate 
markers to the CORE model are presented in the online supplement of the original publication.104
Table 15.6 – Improvements in discrimination and risk classification for extensions of the CORE 
model
Additional risk marker HR (95% CI) Improvement 
in c-statistic
NRI
CHS RS CHS RS
Men:
  ABI (per 0.1-unit) 0.58 (0.41-0.81) 0.013 -0.004 0.033 0.003
  BMI (per 5-kg/m2) 1.01 (0.99-1.03) NA  NA NA NA
  cIMT (per 1-unit on log-transformed scale) 1.22 (0.91-1.66) NA  NA NA NA
  CRP (per 1-unit on log-transformed scale) 1.00 (1.00-1.01) NA  NA NA NA
  ECG-LVH 2.17 (1.71-2.76) 0.009  0.011 0.017 0.021
  ABI and ECG-LVH 0.019  0.010 0.039 0.025
Women:
  ABI (per 0.1-unit) 0.93 (0.90-0.96) 0.001  0.014 0.001 0.036
  BMI (per 5-kg/m2) 1.01 (0.99-1.02) NA  NA NA NA
  cIMT (per 1-unit on log-transformed scale) 2.81 (1.96-4.02) 0.010  0.013 0.022 0.061
  CRP (per 1-unit on log-transformed scale) 1.08 (1.03-1.13) 0.003  0.004 0.024 0.008
  ECG-LVH 1.63 (1.31-2.02) 0.005  0.007 0.041 0.019
  ABI, cIMT, CRP, and ECG-LVH 0.016  0.026 0.068 0.096
ABI = ankle-brachial index; BMI = body mass index; CHS = Cardiovascular Health Study; cIMT = carotid intima-media 
thickness; CORE = coronary risk in the elderly; CRP = C-reactive protein; ECG-LVH = electrocardiographic left ventricular 
hypertrophy; NA = not applicable because of a nonsignificant improval in global model fit; NRI = net reclassification 
improvement; RS = Rotterdam Study.
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Discussion
In this study, we report the performance of a sex-specific CHD prediction model tailored for an 
older population, based on 2 large population-based cohort studies of cardiovascular disease 
in the elderly. The model accounts for the fact that death from other causes often precludes 
CHD occurrence. Predicted risks for the presented model were well calibrated, and risk factors 
generally showed consistent effects across U.S. and European persons. However, our model 
had moderate discrimination, its accuracy was not substantially better than the FPS, and adding 
newer coronary risk markers did not substantially improve risk prediction.
Healthy elderly persons have been promoted as a target for primary prevention of CHD.25, 26 
According to the ATP III guideline, risk models assessing absolute CHD risk should guide primary 
preventive measures.216 However, existing risk stratification approaches have not considered 
important characteristics of elderly persons, especially their considerable risk for dying of 
competing causes rather than CHD. The CORE model addresses this gap, and the 10-year CHD 
risk it predicts can be used in accordance with the ATP III guideline. In contrast to risk scores 
based on models that ignore or censor competing events, our model provides real-life and 
therefore more meaningful estimates of CHD risk for elderly patients and physicians. The 10-year 
risk for CHD did not exceed approximately 20% in men or 15% in women, and the occurrence of 
non-coronary death dominated the occurrence of CHD (Figure 15.1). This observation refutes 
the perception that all elderly men are at high risk for CHD.379
Competing risks
The discriminatory performance of the CORE model was modest compared with those based 
on younger age ranges; c-statistics of ≥ 0.80 have been reported for models based on similar 
established risk factors.364, 365 However, such comparisons must be interpreted with caution, 
because inappropriately neglecting a substantial risk for competing non-coronary death leads 
to apparently high but uninterpretable c-statistics.371 Comparison with the well-known ATP 
III FPS 27 in the competing risks setting of our model showed that the FPS had slightly lower 
accuracy.
Several studies have observed that associations of traditional risk factors with CHD diminish 
with age.28-30, 216, 323 For example, smoking is one of the most influential CHD risk factors but had 
only borderline statistical significance in our cohorts when we used the competing risk method. 
The strong association of smoking with death from other causes (such as cancer or chronic 
obstructive pulmonary disease) competes with the observation and predictability of CHD.380 
Considering competing causes of death naturally leads to impairment of nonspecific risk factors 
(such as age) in predicting CHD,371 in the same way that the benefit of treating a disease may be 
reduced by other causes of death.
Framingham point score
In elderly U.S. persons, improved predictions with the CORE model (such as the 30.6-percentage 
point increase in true-positive classifications for men) were often paired with risk 
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misclassifications (such as the 23.8-percentage point increase in false-positive classifications 
for men) (Table 15.4). In U.S. women, the models primarily differed in classifications of low-
risk, in which decreases in the false-negative rate were paired with similar decreases in the 
true-negative rate. However, the decision to use a risk prediction model depends not only on 
the balance of improved and decreased risk classification but also on the costs and benefits of 
correct and incorrect classifications, and therefore on such factors as the cost of medication and 
side effects of treatment. For example, because of the availability of effective treatment for CHD 
prevention with limited side effects, the increase in the true-positive rate (those who would 
correctly qualify for treatment) in U.S. men with the CORE model may outweigh the increase 
in the false-positive rate (those who would receive unnecessary preventive treatment). At the 
same time, very few U.S. women were classified as high-risk in both models, and therefore only 
a few women with future CHD events would have received preventive treatment. This raises the 
question of whether current risk thresholds for treatment allocation need to be reevaluated for 
elderly women, as has been suggested for younger women.206
Compared with earlier Framingham risk functions,331, 362 the FPS risk prediction tool is more 
appropriate for use in older populations because it includes interaction terms for total 
cholesterol level and smoking with age and has an upper age limit of 79 rather than 74 years.216 
Our U.S. study population included a modest proportion of participants aged 80 years or older 
(15.5% of men and 11.5% of women in the CHS). However, excluding these participants did not 
lead to meaningful changes in our results. This is consistent with the observation that absolute 
risk for CHD stabilizes after age 80 years (Figure 15.1).
In elderly European persons, the interpretation of model differences was dominated 
by substantial risk overestimation with the FPS, corresponding with earlier findings of 
overestimation of Framingham functions in lower-risk European populations.229, 230, 367
Additional risk markers
Measures that integrate risk factor information over time, such as measures of abnormal 
cardiac function, subclinical measures of atherosclerosis, or markers of inflammation, have 
been suggested to be more promising than traditional risk factors for predicting CHD at older 
age.290 Our model yielded statistically significant improvements in risk prediction when we 
added ABI and ECG-LVH for men and ABI, cIMT, CRP, and ECG-LVH for women. However, clinical 
improvement in risk prediction was small in men and moderate in women (NRIs of up to 0.094 
in women in the RS). An improvement of this extent does not outweigh the additional effort 
required to integrate multiple non-traditional markers into clinical practice. Therefore, we did 
not include these additional risk markers in our final model. Other markers, such as coronary 
artery calcification, may perform better in elderly persons, but evaluations in large elderly 
populations are still lacking.
Limitations
Our study has limitations. First, the cohorts differed ethnically, particularly in the number of 
African Americans (who have higher cardiovascular risk). Second, despite the highly similar CHD 
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end point definitions in both cohorts, subtle differences in end point ascertainment may have 
led to unknown differences in CHD incidence (Appendix Table 15.1).94, 105 Third, the CORE model 
was developed and compared in the same population. However, because the model was largely 
prespecified by using 2 large cohorts, and the model derived from pooled data showed similar 
performance in both cohorts, we consider it unlikely that over-optimism has a major effect on 
the comparison of the CORE model with the FPS. Fourth, our approach to reclassification did 
not distinguish between persons with competing events and those without an event (both are 
classified as not having the event of interest). Fifth, the FPS is designed for persons up to age 
79 years but was used for older persons in our study as well. Sixth, we examined only a few 
additional variables in extended models. Finally, we used the recommended cut-off values for 
risk classification,216 but the appropriateness of these cut-offs in elderly persons is uncertain. 
Using different values could have affected the results of our reclassification analyses and 
subsequent clinical implications.
Conclusions
Deaths from non-coronary causes dominate CHD events in elderly persons and therefore pose 
a challenge to CHD prediction. We developed a model for predicting CHD risk in elderly persons 
that provides meaningful real-life estimates of absolute CHD risk. The CORE model showed 
good generalizability in aging U.S. and European populations, but only moderate discrimination 
and no consistent improvements in risk classification compared with the FPS. Moreover, adding 
promising newer cardiovascular markers did not substantially improve CHD risk prediction of 
the model. This emphasizes the need for further work to improve cardiovascular risk prediction 
in an elderly population.
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Appendix
Appendix Table 15.1 – Definitions of coronary heart disease end points used
End point Cardiovascular Health Study Rotterdam Study
Nonfatal MI ECG and/or cardiac enzyme changes. ECG and cardiac enzyme changes.
Fatal MI MI ≤ 28 days before death and no 
known non-atherosclerotic cause of 
death.
MI ≤ 28 days before death and no 
known non-atherosclerotic cause of 
death.
Atherosclerotic 
CHD death
Chest pain ≤ 72 hours before death 
and no known non-atherosclerotic 
cause of death.
Chest pain ≤ 72 hours before death 
and no known non-atherosclerotic 
cause of death.
History of chronic ischemic heart 
disease in the absence of valvular 
heart disease or non-ischemic 
cardiomyopathy and no known non-
atherosclerotic cause of death.
History of chronic ischemic heart 
disease in the absence of valvular 
heart disease or non-ischemic 
cardiomyopathy and no known non-
atherosclerotic cause of death.
Death certificate consistent with 
atherosclerotic CHD death and no 
known non-atherosclerotic cause of 
death.
Mode of death consistent with CHD 
in the absence of significant valvular 
heart disease or non-ischemic 
cardiomyopathy and no known non-
atherosclerotic cause of death.
Coronary death related to CHD 
procedures, such as CABG or PCI.
Coronary death related to CHD 
procedures, such as CABG or PCI.
CABG = coronary artery bypass grafting; CHD = coronary heart disease; ECG = electrocardiography; MI = myocardial 
infarction; PCI = percutaneous coronary intervention. Adapted from Ives and colleagues 94 and Leening and colleagues.105
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Appendix Table 15.2 – Incidence of coronary heart disease and competing non-coronary death
Cardiovascular Health Study Rotterdam Study
Men Women Men Women
n = 1917 n = 3019 n = 1454 n = 2849
Overall CHD 563 (19.9%) 603 (11.5%) 283 (15.8%) 415 (10.4%)
  Nonfatal MI 343 (12.6%) 338 (7.0%) 128 (7.3%) 121 (3.0%)
  Fatal MI 47 (1.5%) 51 (1.0%) 24 (1.4%) 49 (1.3%)
  Atherosclerotic CHD death 173 (5.8%) 214 (3.5%) 131 (7.1%) 245 (6.1%)
Competing non-coronary death 839 (26.6%) 1161 (19.1%) 777 (38.5%) 1467 (35.5%)
Total folow-up, pys 19,664 36,845 12,965 27,876
Median follow-up, y 16.6 16.5 14.8 14.9
Values are number of events (10-year cumulative incidence) unless noted otherwise. CHD = coronary heart disease; MI 
= myocardial infarction.
Additional details about the statistical analysis
Competing risk methods were used throughout, and model development was based on the Fine 
and Gray model 296 as implemented in the kmi package for R.377, 378 The cumulative incidence 
function, which describes the absolute risk for failing from CHD as time progresses,368 is of 
primary prognostic significance in competing risk analyses. In line with this function, we used the 
Fine and Gray model, a multivariable regression model that directly associates covariable effects 
with the cumulative incidence function via the subdistribution hazard. Hence, the regression 
coefficients of the model have a direct prognostic interpretation for CHD events.370, 381, 382
Possible cohort-risk factor interactions were assessed by introducing interaction terms. Total 
cholesterol level showed a stronger association with CHD among women in the RS than those 
in the CHS (P = 0.004); we therefore introduced an interaction term in the final competing risks 
model in women (Table 15.3 and Appendix Tables 15.3 and 15.4). Nonlinearity of predictors was 
assessed by comparing natural cubic splines (with 4 and 5 degrees of freedom) with the linear fit 
by using a likelihood ratio test.28 Because strong evidence indicated a nonlinear effect of age on 
CHD incidence in women, we included a linear and a quadratic age term in the model,331 which 
fitted the model equally well in terms of the Akaike Information Criterion as a more complex 
model using a natural cubic spline function. We tested the proportional subdistribution hazards 
assumption on the basis of scaled Schoenfeld residuals.
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Appendix Table 15.3 – Steps in development, assessment, and extension of the CORE model
Assumption / 
modelling step
Test / comparison / 
predictor
Men Women Decision
Linearity 
assumption 
of continuous 
predictors
Restricted cubic spline 
transformation, 4 to 
5 knots. Likelihood 
ratio test against non-
transformed linear term:
  Age P = 0.60 P < 0.001 Men: accept linearity
Women: reject linearity; 
age + age2 appropriate
  Total cholesterol P = 0.98 P = 0.21 Accept linearity
  HDL cholesterol P = 0.60 P = 0.72 Accept linearity
  Systolic blood pressure P = 0.22 P = 0.25 Accept linearity
Risk factor-
cohort 
interaction
Total cholesterol P > 0.05 P = 0.004 Add total cholesterol-
cohort interaction term 
for women
Remaining predictors P > 0.05 P > 0.05
Proportional 
subdistribution 
hazard 
assumption
Age P < 0.001 Interpret as weighted 
average effect over 
follow-up
Age + age2 P < 0.001 Interpret as weighted 
average effect over 
follow-up
Remaining predictors P > 0.05 P > 0.05
Model extension Ankle-brachial index P = 0.001 a P < 0.001 a Retain term
ECG-LVH P < 0.001 P < 0.001 Retain term
cIMT P > 0.05 P < 0.001 b Men: reject term
Women: retain term
C-reactive protein P > 0.05 P < 0.001 b Men: reject term
Women: retain term
Body mass index P > 0.05 P > 0.05 Reject term
Tables 15.3 and 15.6 and Appendix Tables 15.4 and 15.5 provide more details. cIMT = carotid intima-media thickness; 
CORE = coronary risk in the elderly; ECG-LVH = electrocardiographic left ventricular hypertrophy; HDL = high-density 
lipoprotein; NA = not applicable.
a Best fit as a linear term.
b Best fit as a log-transformed term.
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Fewer than 1% of the values for traditional risk factors were missing in CHS participants and 
up to 4.4% were missing in RS participants who visited the research center at baseline (7153 
participants). For variables used as additional risk markers in our extended model, values were 
missing for up to 11.6% of the variables in the RS, with the exception of cIMT (23.0%). We 
imputed missing covariables separately for men and women and for the CHS and RS cohorts, 
defining imputation models that included the outcomes of CHD and competing non-coronary 
death.383 Multiple imputation of missing data was performed with the contributed mice 
package in R, and analyses were based on 5 imputed data sets.384 All analyses were additionally 
done on complete cases to check for potential differences between results based on imputed 
data and those based on complete cases. With the exception of the baseline characteristics 
(Table 15.1), results are reported for imputed data. When calculating the c-statistic, we used 
multiple imputation of potential censoring times for competing events 377, 378 instead of treating 
competing events as ‘censored at infinity’.370
For graphical display, the actual 10-year risk for the mutually exclusive CHD and competing 
non-coronary death events was estimated on the basis of the Fine and Gray models with 
age (included as a natural cubic spline) as the only covariable. Figure 15.1 displays the actual 
predicted risks.
Statistical assessments of the model showed that in men and women, the proportional hazards 
assumption was violated for age but for none of the remaining covariables. The reported age 
effects should therefore be interpreted as the weighted average effect over the entire follow-
up.381
We used the cumulative incidence function to estimate the number of events and nonevents 
presented in Tables 15.4 and 15.5.
The FPS is designed for persons aged 79 years or younger. Participants aged 80 years or older 
were assigned an age of 79 years for the purpose of calculating their predicted risks using the 
FPS. Because the highest possible risk category of the FPS is denoted as ≥ 30% but not in terms 
of a single value, we used a value of 35% for participants with a predicted risk of ≥ 30%.
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Appendix Table 15.4 – Coefficients in the CORE model
Risk factor Scaling Men Women
Age, y:
  Linear (Age – 75) / 10  0.205  0.463
  Quadratic [(Age – 75) / 10]2 -0.262
Use of blood pressure-lowering medication  0.410  0.288
Systolic blood pressure, mmHg:
  Treated (SBP – 130) / 10 -0.0005  0.080
  Untreated (SBP – 130) / 10  0.107  0.127
Total cholesterol, mmol/L TC – 5  0.112 U.S.: 0.041
European: 0.198
HDL cholesterol, mmol/L HDL-C – 1 -0.372 -0.432
Ever smoking  0.134  0.125
Diabetes mellitus  0.306  0.330
CORE = coronary risk in the elderly; HDL-C = high-density lipoprotein cholesterol; SBP = systolic blood pressure; TC = 
total cholesterol.
Appendix Table 15.5 – Cumulative baseline subdistribution hazard for different time horizons
Population 3 years 5 years 7 years 10 years
U.S. elderly:
  Men 0.049 0.086 0.120 0.174
  Women 0.025 0.046 0.074 0.125
European elderly:
  Men 0.040 0.065 0.074 0.125
  Women 0.019 0.032 0.047 0.064
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Example of coronary heart disease risk computation
We show the computation of the predicted risks for CHD at 3, 5, 7, and 10 years for a U.S. 
or European man or woman aged 65 years or older. Given the advanced age and limited life 
expectancy of this population, the risk prediction horizon can be adapted flexibly (Appendix 
Table 15.5). The baseline cumulative subdistribution hazard refers to a U.S. or European man 
or woman aged 75 years whose systolic blood pressure is 130 mmHg, total cholesterol level is 5 
mmol/L, and HDL cholesterol level is 1 mmol/L and who does not smoke, is not receiving blood 
pressure-lowering medication, and is not diabetic.
The actual probability or predicted risk for an individual to have a CHD event at time t depends 
on the covariable vector (xi1, …, xip) and on the baseline cumulative subdistribution hazard 370: Ii 
(t | xi) = 1 − exp [-exp(
The actual probability or predicted risk for an individual to have a CHD event at time t 
depends on the covariable vector (xi1, . . . , xip) and on the baseline cumulative subdistribution 
hazard 370: Ii (t  i  – ∑     βk * xik) * ∫      
 
 
 (s)ds] where ∫      
 
 
(s)ds refers to 
the cumulative baseline subdistribution hazard (given for different time points in Appendix 
Table 15.5), β refers to the vector of coefficients from the Fine and Gray model 
296 provided in 
Appendix Table 15.4, and exp(β) refers to the hazard ratios given in Table 15.2. 
 
The following example illustrates the computation of the 10-year CHD risk for a U.S. man aged 
72 years who is receiving blood pressure-lowering medication; whose systolic blood pressure 
is 136 mmHg, total cholesterol level is 4.4 mmol/L, and HDL cholesterol level is 1.56 mmol/L; 
who is not diabetic; and who is a current smoker. 
 
Linear Predictor = ∑     βk * xik = [0.205 * (72 – 75) / 10] + [0.410 * 1 (use of blood 
pressure-lowering medication) + [-0.0005 * (136 – 130) / 10] + [0.112 * (4.4 – 5)] + [-0.372 * 
(1.56 – 1)] + [0.306 * 0 (absence of diabetes)] + [0.134 * 1 (current smoking) = 0.2067 
βk * xik) * 
The actual proba ility or p edicted risk for an i dividual to have a CHD ev nt a time t 
dep nds on the covari ble v ctor (xi1, . . , xip) and on the baseline cumulative subdistribution 
haz rd 370: Ii (t | xi) = 1 – exp [-exp(∑     ∫      
 
 
 (s)ds] where ∫      
 
 
(s)ds refers to
the cumulative baseline subdistribution haz rd (given for different time points in Appendix 
Table 15.5), β refers to he v ctor f coefficients from the Fine and Gray model 
296 provide  in
Appendix Table 15.4, and exp(β) refers to he haz rd atios given i Table 15.2. 
 
The foll wing example illustrates the computation of the 10-year CHD risk for a U.S. man aged 
72 years who is rec iving blood pressure-lowering medication; whose systolic blood pressure 
is 136 m Hg, total cholesterol lev l is 4.4 m ol/L, and HDL cholesterol lev l is 1.56 m ol/L; 
who is not diabetic; and who is a current smoker. 
 
Linear P edictor = ∑     βk * xik = [0.205 * (72 – 75) / 10] + [0.410 * 1 (use of blood 
pressure-lowering medication) + [-0.00 5 * (136 – 130) / 10] + [0.112 * (4.4 – 5)] + [-0.372 * 
(1.56 – 1)] + [0.306 * 0 (absence of diabetes)] + [0.134 * 1 (current smoking) = 0.2067 
 
e
   
 e
 
 
he cumulative 
baseline subdistribution hazard (given for different time points in Appendix Table 15.5), β refers 
to the vector of coefficients from the Fine and Gray model 296 provided in Appendix Table 15.4, 
and exp(β) refers to the hazard ratios given in Table 15.2.
The following example illustrates the computation of the 10-year CHD risk for a U.S. man aged 
72 years who is receiving blood pressure-lowering medication; whose systolic blood pressure is 
136 mmHg, total cholesterol level is 4.4 mmol/L, and HDL cholesterol level is 1.56 mmol/L; who 
is not diabetic; and who is a current smoker.
Linear Predictor = 
The actual probability or predicted risk for an individual to have a CHD event at time t 
depends on the covariable vector (xi1, . . . , xip) and on the baseline cumulative subdistribution 
hazard 370: Ii (t | xi) = 1 – exp [-exp(∑     βk * xik) * ∫      
 
 
 (s)ds] where ∫      
 
 
(s)ds refers to 
the cumulative baseline subdistribution hazard (given for different time points in Appendix 
Table 15.5), β refers to the vector of coefficients from the Fine and Gray model 
296 provided in 
Appendix Table 15.4, and exp(β) refers to the hazard ratios given in Table 15.2. 
 
The follo ing exa ple illustrates the co putation of the 10-year CHD risk for a U.S. an aged 
72 years who is receiving blood pressure-lowering medication; whose systolic blood pressure 
is 136 mmHg, total cholesterol level is 4.4 mmol/L, and HDL cholesterol level is 1.56 mmol/L; 
wh  is not diabetic; and who is a current smoker. 
 
Li ear i t r ∑     βk * xik = [0.205 * (72 – 75) / 10] + [0.410 * 1 (use of blood 
pressure-lowering medication) + [-0.0005 * (136 – 130) / 10] + [0.112 * (4.4 – 5)] + [-0.372 * 
(1.56 – 1)] + [0.306 * 0 (absence of diabetes)] + [0.134 * 1 (current smoking) = 0.2067 
βk * xik = [0.205 * (72 − 75) / 10] + [0.410 * 1 (use of blood pressure-
lowering medication) + [−0.0005 * (136 − 130) / 10] + [0.1 2 * (4.4 − 5)] + [−0.372 * (1 56 − 1)] 
+ [0.306 * 0 (absence of diabetes)] + [0.134 * 1 (current smoking) = 0.2067
Predicted 10-year risk for CHD = 1 − exp[-0.174 * exp(0.2067)] = 0.192 = 19.2%.
A risk calculator developed from our model for the prediction horizons of 3, 5, 7, and 10 years 
is available online at www.ceb-institute.org/evibox/chd/.
Old age is associated with disease, but does not cause it.
- Sir Richard Peto and Sir W. Richard S. Doll (1912 – 2005)
There is no such thing as aging
BMJ 1997;315(7115):1030-2
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The marked reduction in coronary heart disease (CHD) mortality has been one of the most 
impressive achievements in the history of modern medicine.20 Notable contributions in invasive 
treatment of patients with CHD were made by René Favaloro introducing coronary artery bypass 
grafting (CABG) in 1967,385 Andreas Grüntzig introducing percutaneous coronary interventions 
(PCI) in 1977,386 and the Thrombolysis In Myocardial Infarction (TIMI) study group, led by 
Eugene Braunwald, championing the ‘open artery’ principle in 1985.387 Long-term reductions in 
CHD mortality also come from the introduction of pharmacological agents to reduce mortality 
after a myocardial infarction, including β blockers,388 aspirin,389, 390, ACE inhibitors,391 and 
statins.392. However, improvements in treatment for patients with manifest CHD is only part of 
the explanation why CHD mortality has plummeted.393 It is estimated that half of the deaths 
prevented can be attributed to primary prevention through risk factor modification.394-396 
Notable achievements include marked reductions in tobacco consumption,397, 398 improved blood 
pressure control,398 and population interventions on caloric and salt intake.398 Nonetheless, the 
sobering data presented in Part III of this thesis indicate there is a lot more work to be done in 
the field of primary prevention of cardiovascular disease (CVD).
To further optimize primary prevention of CVD, 2 tiers of commitment are required. First, we 
need stronger population measures to increase cardiovascular health in the overall population, 
for instance through expanding smoking bans, raising taxes on tobacco and unhealthy foods, 
and encouraging physical activity. Second, at individual patient level we need to better 
understand and identify which patient will benefit most from individualized preventive efforts, 
and, most importantly, act accordingly. The work described in this thesis is focused on improving 
identification of individuals free of CVD – but at an increased risk for CVD – who may benefit 
from preventive treatment.
In this chapter the focus is on some of the methodological considerations pertaining to the work 
described in this thesis, and how the work described in this thesis can be used to potentially 
enhance or nurture entirely different approaches for primary prevention strategies.
Methodological considerations
Specific limitations to the study design and analyses presented in this thesis are discussed in 
the individual chapters. Nonetheless, a number of general points with respect to the Rotterdam 
Study data can be made.
First, internal validity of the findings is likely to be high given that: no exclusion criteria were 
specified at baseline, loss to follow-up was low, and data collection of determinants and 
outcomes was done independently using calibrated devices and protocols. Nonetheless, self-
selection of participants (e.g. by health status, as discussed in Chapter 3) may have introduced 
selection bias and – despite a wide gauntlet of risk factors measured – unmeasured confounding 
might be present. In large data sets, such as the Rotterdam Study and the Cardiovascular Health 
Study, improved external validity is traded-off with respect to the available measurements.
Next, external validity (i.e. generalizability) is mostly limited to older, suburban, white, Western 
European (Rotterdam Study) and U.S. (Cardiovascular Health Study) populations. This is clearly 
illustrated by the lower background incidence of CVD in the Rotterdam Study when compared to 
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U.S. data in Chapters 12 and 15. However, it should be noted that the observed relative effects 
of cardiovascular risk factors were highly similar in the Rotterdam Study and the Cardiovascular 
Health Study (Chapter 15).
Future perspectives and challenges for risk-based treatment allocation in primary prevention 
of cardiovascular disease
The emerging field of ‘Preventive Cardiology’ is vast and holds great promise. As improvements 
in prognosis for clinically manifest CVD with novel treatment get smaller and smaller, more eyes 
turn towards the preclinical stages of CVD, i.e. primary prevention. Rather than briefly touching 
upon a large number of avenues for future research in primary prevention of CVD, I rather 
discuss two important issues in greater detail.
For decades, clinical practice guidelines have emphasized the value of considering the additive 
effect of multiple risk factors on 10-year cardiovascular risk. First, a similar evolution seems 
needed in order to transition to a longitudinal lifetime perspective, by moving away from single 
measurements of risk factors to a broader appreciation for the influence of the entire range 
of risk factor burden on lifetime risk of a broad spectrum of CVD. I aim to describe how this 
transition could be made in more detail below.
Second, a major challenge for contemporary risk-based strategies is the oppressive role of 
age on recommendations for statin allocation in primary prevention of CVD. Using a number 
of examples I will try to set forth dilemmas in clinical practice resulting from age-driven risk 
prediction models. Over the last decade a number of alternative strategies for statin allocation 
have been proposed and I aim to put these into perspective.
Lifetime perspectives on cardiovascular disease risk in primary prevention
The discordance between short-term (10-year) and long-term (30-year to lifetime) cardiovascular 
risk is well established and is now reflected in the most recent clinical practice guidelines 
from the ACC/AHA on lipid-lowering treatment for primary prevention of atherosclerotic CVD 
(ASCVD).6, 9 Specifically, these guidelines recommend that lifetime risk estimation can be used 
as a communication strategy for adults younger than 60 years free of ASCVD and not candidates 
for lipid-lowering therapy. Although a high lifetime ASCVD risk has not been recommended 
as a class I indication for lipid-lowering treatment, the acknowledgement of lifetime risk in 
the guidelines indicates a more comprehensive awareness of the importance of prevention 
of ASCVD over a lifespan. Yet, cut-points indicating a high lifetime risk of CVD have not been 
established.399
Risk estimation remains an imperfect science. However, by focusing on the key elements of risk 
prediction over a lifetime – the treatment thresholds, risk factors trajectories, and predicted 
outcome – advances can be made to more accurately identify individuals at an increased 
lifetime ASCVD risk to tailor optimal primary prevention strategies.
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Treating a ‘lifetime risk equivalent’
For decades, guidelines have recommended lipid-lowering therapy for individuals with an 
low-density lipoprotein (LDL) cholesterol level ≥ 190 mg/dL (4.9 mmol/L), irrespective of 
short-term risk, because these individuals have a “high lifetime risk for ASCVD”.9 Treatment is 
recommended for these individuals because of the cumulative effects of a lifetime exposure 
to high LDL cholesterol. This recommendation is not based on clinical trial data, as no primary 
prevention trial testing the effect of statin therapy on cardiovascular endpoints has included only 
individuals with an LDL cholesterol level ≥ 190 mg/dL.9 In addition, this recommendation is also 
not based on a strategy to identify patients with heterozygous familial hypercholesterolemia.400
Although a high lifetime risk represents the primary rationale for treatment of an LDL cholesterol 
level ≥ 190 mg/dL, an elevated LDL cholesterol is not the only cause for a high lifetime risk. 
Hypertension, diabetes, and smoking are also associated with substantial differences in risk of 
ASCVD across the lifespan.2 This well-established fact creates a dilemma. For example, a 45-
year old non-smoking white man with a systolic blood pressure of 120 mmHg, no diabetes, and 
normal high-density lipoprotein (HDL) cholesterol level (40 mg/dL, 1.0 mmol/L) but with an LDL 
cholesterol level of 190 mg/dL (corresponding to a total cholesterol of 260 mg/dL, 6.7 mmol/L) 
would have a 10-year risk of hard ASCVD events (coronary death, myocardial infarction, stroke) 
of just 3.7% (Online calculator: http://tools.acc.org/ascvd-risk-estimator/).6 However, current 
guidelines would indicate a class I recommendation for statin therapy because of this patient’s 
LDL cholesterol level.9 In contrast, another 45-year old non-smoking white man with a systolic 
blood pressure of 138 mmHg, no diabetes, normal HDL cholesterol, and an LDL cholesterol 
level of 150 mg/dL (3.9 mmol/L; corresponding to a total cholesterol level of 220 mg/dL, 5.7 
mmol/L), would have a similar 10-year risk of ASCVD events of 3.6%, but current guidelines 
would not recommend lipid-lowering therapy for this patient.9
However, using the Framingham Heart Study 30-year risk calculator (Online calculator: https://
www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/30-year-risk.php#), 
these individuals have identical 30-year risks for hard ASCVD events, approximately 24%.218 
Given the clinical trial evidence of a similar relative benefit of lipid-lowering therapy across a 
broad range of LDL cholesterol in the short-term, it would be reasonable that lipid-lowering 
therapy should be considered in both cases, and the second patient should be treated because 
of the presence of a ‘lifetime risk equivalent’.
Lifetime risk factor trajectories
Understanding the lifetime risk for ASCVD requires not only a measure of current risk factor 
levels, but should also account for the accumulated long-term exposure to risk factors. 
However, current CVD risk prediction algorithms are limited to single, cross-sectional measures 
of risk factor levels. Most often these risk prediction algorithms are applied for patients later in 
life, at the time of increasing absolute ASCVD risk. However, the adverse effects of risk factors 
accumulate over the lifetime and, thus, long-term patterns in risk factor levels provide greater 
ability to identify individuals at high risk of experiencing an cardiovascular event. Given the rapid 
expansion of electronic health records, the increasing use of data within the electronic health 
record, and clinical decision support systems to calculate an individual’s ASCVD risk, addition of 
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these long-term risk factor patterns into risk prediction algorithms has now become feasible.
Prospective epidemiologic studies have consistently found that risk factor levels measured early 
in life are more strongly associated with cardiovascular outcomes compared to contemporary 
levels later in life. Recently, a growing body of evidence demonstrates that the long-term 
patterns of risk factor levels, including blood pressure and cholesterol levels, provide additional 
information above and beyond single measurements to identify individuals at increased 
risk of future CVD.401, 402 This cumulative exposure over a lifetime is not captured in current 
risk prediction algorithms and, as a consequence, risk estimates may be overestimated or 
underestimated depending on whether risk factors were accrued recently or earlier in life. 
Incorporating long-term risk factor patterns into risk prediction algorithms may improve the 
performance of these equations and would provide patients with a more accurate estimate of 
their future risk.
Cardiovascular disease manifestations over a lifetime
Traditional cardiovascular prediction algorithms were limited to predicting the risk of CVD 
mortality or CHD. The most recent iteration of the ACC/AHA prevention guidelines adds stroke 
to hard CHD events to form a composite ASCVD outcome of the 10-year risk calculators.6 This 
is a major step forward, as this better reflects the overall burden of CVD in women and African 
Americans, among whom the stroke-to-CHD ratio is known to be greater.116 However, limiting 
predicted ASCVD risk to endpoints of hard CHD and stroke does not reflect the entire risk of 
developing ASCVD over a lifetime. Most first manifestations of ASCVD are not hard endpoints 
with fatal or incapacitating consequences and include angina, transient ischemic attacks, or 
intermittent claudication.116 These ‘soft’ endpoints should be incorporated in global ASCVD 
risk prediction algorithms as they represent a greater portion of the events in women and, 
particularly, younger individuals.116 The latter is also reflected by the substantially greater case 
fatality of a first CVD event with increasing age.116 Therefore, the effect of age on the overall 
burden of ASCVD in risk prediction algorithms is greater when solely predicting hard outcomes 
or CVD mortality compared with a broader outcome.
Incorporating soft atherosclerotic outcomes (and potentially also ischemic heart failure) into 
the outcome of risk calculators would generate higher lifetime risks than calculators restricted 
to hard outcomes.116, 218 Calculators with more inclusive outcomes would yield more realistic 
estimates for patients on their risk of ASCVD, as, on average, 2 out of 3 will develop some form 
of ASCVD during their lifespan, whereas less than 1 out of 3 will die of ASCVD.2, 116 Experiencing 
an ASCVD event and its consequences during life may be of greater importance to patients than 
their mode of death when balancing the risks and benefits of preventive measures.
Existing Resources
All of the suggested modifications to more accurately identify asymptomatic individuals at 
increased ASCVD risk over a lifetime can be made using existing resources. Most high-quality 
population-based studies have collected outcome data on a wide range of cardiovascular 
outcomes over decades with repeated measurement of traditional and novel risk factors. 
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Therefore, creativity, commitment, and persistence of researchers and clinicians will be 
instrumental in finding and implementing optimal strategies to quantify lifetime risk and 
subsequent potential benefit from preventive treatment to further lower the burden of ASCVD.
The role of age in treatment allocation for primary prevention of cardiovascular disease
Since CVD is highly age-related, age is universally the strongest predictor for CVD in risk 
calculators. In the most recent revisions of American and British prevention guidelines, risk 
thresholds for initiation of pharmacological treatment, to reduce LDL cholesterol, have 
been substantially lowered. This decision has been driven by the accumulating data on the 
Table 16.1 – Age (years) at which persons with recommended optimal risk factor profiles 
exceed recommended cardiovascular risk thresholds for lipid-lowering treatment
Prevention guidelines Men Women
ESC 2012
  Treatment considered LDL ≥ 2.5 mmol/L (≥ 97 mg/dL) a 55 62
LDL < 2.5 mmol/L (< 97 mg/dL) b 74 79
  Treatment recommended LDL ≥ 2.5 mmol/L (≥ 97 mg/dL) c 74 79
LDL < 2.5 mmol/L (< 97 mg/dL) d 85 88
ACC/AHA 2013
  Treatment considered e White 59 67
African-American 56 66
  Treatment recommended f White 63 71
African-American 66 70
NICE 2014
  Treatment recommended g White 64 69
The Appendix to this chapter provides detailed descriptions of recommended optimal risk factor profiles for each 
guideline and methods for age threshold calculations. ACC/AHA, American College of Cardiology/American Heart 
Association; CVD, cardiovascular disease; ESC, European Society of Cardiology; LDL-C, low-density lipoprotein 
cholesterol; NICE, National Institute for Health Care and Excellence.
a ≥ 1% to < 5% 10-year risk of CVD mortality.8
b ≥ 5% to < 10% 10-year risk of CVD mortality.8
c ≥ 5% 10-year risk of CVD mortality.8
d ≥ 10% 10-year risk of CVD mortality.8
e ≥ 5% to < 7.5% 10-year risk of atherosclerotic CVD.9
f ≥ 7.5% 10-year risk of atherosclerotic CVD.9
g ≥ 10% 10-year risk of CVD.10
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efficacy 320, 403 and safety profile 404, 405 of statins in primary prevention, as well as the low costs 
of generic statins. However, by lowering the thresholds, otherwise healthy older adults with 
minimal or no risk factors are now considered candidates for statin treatment solely by virtue 
of their age. Doctors are recommended to discuss statin initiation with men who have optimal 
risk factor levels at an age between 63 and 66 in the U.S. or U.K. (Table 16.1). For women this 
is the case around the age of 70. As a consequence, the vast majority of individuals aged 55-65 
and almost everyone aged ≥ 65 in the general population is currently considered a candidate for 
statin treatment in both the U.S. and Europe.119, 406, 407
This dominant role of age on the guideline recommendations changes the clinical question to 
when rather than whether an individual will qualify for lipid-lowering treatment. This raises a 
number of fundamental questions: Do we want to treat all healthy older persons in the absence 
of risk factors? Can we identify younger persons at low short-term risk but high long-term risk, 
and how long should we wait before we initiate treatment to mitigate their risk? And how can 
we effectively communicate to patients the contribution of cardiovascular risk factors to overall 
CVD risk?
Adaptations to risk-based strategies
Cardiovascular risk is overestimated in older populations, due to competition of non-
cardiovascular causes of death.104 This leads to inflated risk estimates and thereby potentially 
overtreatment. For instance, smoking substantially increases risk of CVD, but also the risk of a 
number of other conditions, including various types of cancer and pulmonary disease, which 
may result in death prior to the occurrence of CVD. Some of the advocated risk calculators try 
to accommodate this by including interaction terms of risk factors with age or (age)2.6, 7 Others 
have suggested to improve the accuracy of the calculators using competing risk regression.104, 408 
Such methods account for the overestimation and improve the agreement between predicted 
and observed risk. However, changes in treatment recommendations are generally minimal, 
since most of the overestimation due to competing risks occurs in those with very high predicted 
risks, rather than in healthy elderly without risk factors.104, 408 Therefore, competing risk models 
appear to have limited clinical application.
A more recently proposed approach to reduce overtreatment is imaging of subclinical 
atherosclerosis to ‘de-risk’ older individuals with minimal or no cardiovascular risk factors.409 
Absence of coronary artery calcifications for example, has consistently been accompanied with 
very low probabilities of developing CVD and mortality,410 especially in those with optimal risk 
factors according to current guidelines.411 Results from ongoing trials on the use of coronary 
calcium screening in primary prevention of CVD are therefore much awaited.412, 413 This strategy, 
however, also requires further careful evaluation with regards to points like cost-effectiveness, 
radiation exposure, and consequences of incidental findings in older individuals.
On the other end of the spectrum there are younger individuals with multiple cardiovascular 
risk factors who are at low absolute short-term (e.g. 10-year) risk of CVD. For instance, a 
young woman who smokes and has moderate hypercholesterolemia will have a 10-year risk 
that does not qualify her for lipid-lowering treatment, but at some point later in life she will 
qualify for treatment. Substantial amounts of atherosclerosis will likely have built up by that 
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time. Therefore, recent U.S. and British guidelines have incorporated the concept of ‘lifetime 
risk’ along with the traditional 10-year risk estimates in treatment recommendations, to guide 
treatment in younger individuals with substantial risk factor burden, who do not yet have a high 
10-year risk of CVD.9, 298 In conjunction with lowering the treatment thresholds, the inclusion 
of a high lifetime risk as a treatment indication ensures that a greater proportion of especially 
younger and middle-aged individuals with a high risk factor burden are recommended for early 
preventive treatment. This will result in small absolute risk reductions at younger ages, but the 
pay-off with early intervention may be substantially larger over the lifespan.
The role of age in alternative treatment allocation strategies
Since the early 1990s prevention strategies have revolved around risk-based strategies, yet 
multiple other approaches have been advocated. The role of age in each of these strategies 
varies greatly.
First of all, the strategy that solely relies on age. More than a decade ago Wald and Law suggested 
to initiate drug treatment for prevention of CVD in everyone above age 55, irrespective of risk 
factor burden.321 Despite inherent overtreatment of a substantial proportion of the population, 
this age-based strategy has been reported to be more cost-effective than screening for risk 
factors in current risk-based strategies.414 The age-based approach was considered “radical” by 
the authors upon its introduction, yet, with the recent lowering of the treatment thresholds, 
current guidelines also have inherent sex-specific upper age-thresholds at which basically 
everyone qualifies for drug treatment, irrespective of risk factor burden (Table 16.1).
A completely different approach would be to provide treatment recommendations solely based 
on available evidence from randomized clinical trials.415 This approach does not rely on age, 
but rather aims to answer the question “what works in whom?”.416 For allocation of statins 
in primary prevention this would imply treating all persons who would have been eligible for 
enrollment in trials that showed a favorable outcome with statin therapy (Table 16.2). A hybrid 
strategy of risk-based and trial-based approaches was recently proposed and may seem more 
feasible in the absence of evidence in a substantial part of the population.417 A key advantage 
of incorporating trial evidence into clinical recommendations is the transparency of these 
recommendations: for the majority of middle-aged persons for whom preventive treatment 
with statins is recommended, evidence from randomized clinical trials is available.417 Providing 
clear insight into this, should discourage practicing clinicians to withhold treatment in whom 
statins have been proven to be effective and moreover augment the informed discussions 
between patients and clinicians on initiation of treatment.
Absolute risk is considered a direct proxy for the absolute benefit from lipid-lowering treatment. 
However, ideally the field should evolve from allocating treatment based on estimated risk 
to allocation based on anticipated benefit. The recent British CVD prevention guidelines 
have made important steps towards implementing anticipated treatment benefit into an 
online decision aid for clinicians and patients in order to facilitate informed shared decision 
making.298 This third strategy would involve integrating CVD risk prediction, life-expectancy, 
and treatment efficacy (all based on age and risk factor levels). Preventing a CVD event does 
not translate into similar gains in (CVD free) life-expectancy in persons with identical predicted 
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Table 16.2 – Randomized clinical trials on primary prevention of cardiovascular disease using 
statins
Randomized 
clinical trial
Study drug Participants Events Mean
age
Age
range
Target population
n n years years
WOSCOPS, 
1995
Pravastatin 
40 mg
6595 a 422 a 55 45-64 Men with moderate 
hypercholesterolemia
AFCAPS/
TexCAPS, 1998
Lovastatin 
20-40 mg
6605 419 58 45-73 Persons with below 
average cholesterol levels
PROSPER, 2002 Pravastatin 
40 mg
3239 b 381 b 75 70-82 Older persons with risk 
factors
ALLHAT-LLT, 
2002
Pravastatin 
40 mg
10,355 a 801 a 66 51-81 Persons with 
hypertension, moderate 
hypercholesterolemia, 
and ≥ 1 other risk factor
ASCOT-LLA, 
2003
Atorvastatin 
10 mg
10,305 a 254 a 63 40-79 Persons with 
hypertension, below 
average cholesterol 
levels, and ≥ 3 other risk 
factors
MRC/BHF HPS, 
2003
Simvastatin 
40 mg
2912 b 329 b NR 40-80 Persons with diabetes 
mellitus
CARDS, 2004 Atorvastatin 
10 mg
2838 210 62 40-75 Persons with diabetes 
mellitus, low LDL 
cholesterol, and ≥ 1 other 
risk factor
ASPEN, 2006 Atorvastatin 
10 mg
1905 b 147 b 61 40-75 Persons with diabetes 
mellitus and low LDL 
cholesterol
MEGA, 2006 Pravastatin 
10-20 mg
7832 167 58 40-70 Persons with 
hypercholesterolemia
JUPITER, 2008 Rosuvastatin 
20 mg
17,802 393 66 50-97 Persons with elevated 
CRP and low LDL 
cholesterol
HOPE-3, 2016 Rosuvastatin 
10 mg
12,705 539 66 55-NR Persons with  ≥ 1 risk 
factor
Selection of trials was based on previously published meta-analyses on statins for primary prevention of cardiovascular 
disease,322, 403 supplemented with the recently published HOPE-3 trial.418 NR, not reported.
a Up to 15% of the participants had a history of cardiovascular disease at baseline; no data presented on subgroup of 
participants free of cardiovascular disease.
b Data from persons free of cardiovascular disease at baseline.
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risks, and differences in gains in life-expectancy with statin therapy are generally smaller than 
the differences in cardiovascular risk between individuals.304 Three important reasons for this 
can be identified. First, relative risk reduction of CVD with statins varies by levels of risk, with 
greater benefit at lower predicted risks.320 Secondly, important determinants of predicted 
cardiovascular risk, such as age and smoking, are also strongly related to non-cardiovascular 
mortality, which competes with the incidence of CVD.304 Third, absolute risk reduction of statin 
therapy is dependent on the achieved reduction in LDL cholesterol, which in turn is directly 
proportional to the pretreatment LDL cholesterol levels.419 So, for valid estimation of individual 
benefits of statin treatment, all these factors need to be taken into account and long-term 
efficacy data in persons with a wide spectrum risk factor combinations (preferably including 
those without risk factors) are needed to avoid having to rely on assumptions or extrapolations 
of existing data. In such calculations similar anticipated benefits of smoking cessation and blood 
pressure control could be incorporated. This allows for better insight in the risk reduction that 
can be achieved by multifactorial interventions, which may show that in persons with certain 
risk factor combinations, time and resources may be better allocated to motivating individuals 
to quit smoking and intensifying blood pressure treatment rather than prescribing lipid-lowering 
treatment.
Age in communicating cardiovascular risk
Clinician-patient discussion on CVD risk, prior to making a decision on initiating therapy, has 
an important role in the current clinical practice guidelines.9, 298 Whereas most clinicians who 
work in the field of CVD prevention are accustomed to probability estimates from CVD risk 
calculators, patients are generally not. As such, placing risk in context of everyday risks with 
which the patient is familiar can be challenging.420
A way to convey absolute cardiovascular risk estimates to patients, is by conversion of risk 
to vascular age. An individual’s vascular age is defined as the age at which someone of the 
same sex with recommended optimal risk factors would have had the same absolute risk of 
CVD.363 However, vascular age is still only a sex-specific transformation of absolute risk and its 
interpretation depends on an individual’s calendar age and sex. The age thresholds in Table 16.1 
are a direct transformation of the absolute risk thresholds from the guidelines. Let us examine 
vascular age using the example patients in Table 16.3. Patient 1 is a 65-year old man with 
optimal risk factors. His vascular age thus equals his calendar age. Note that solely because of 
his age he would be recommended for statin therapy under the current U.S. guidelines.9 Patient 
2 represents a 40-year old woman with a suboptimal risk factor burden, but without extreme 
levels of blood pressure or cholesterol that would qualify her for immediate pharmacological 
intervention. Her vascular age, however, is somewhat higher than that of a 50-year old man 
with less pronounced risk factor levels, who would qualify for statin treatment.
Can we get age out of the equation?
How can the effects of age be taken out of the equation when expressing cardiovascular risk? 
Let us consider two complementary measures of expressing cardiovascular risk, either relative 
to a man or woman of the same age with optimal risk factors (‘relative risk factor burden’), or 
217
16
General discussion
relative to a man or woman of the same risk with optimal risk factors (‘vascular ageing ratio’). 
Both can be readily calculated from existing risk prediction models and may be best explored 
using the example patients from Table 16.3.
The relative risk factor burden is the predicted risk of an individual divided by the risk for a 
person of the same age and sex with optimal risk factor levels (as defined by current guidelines). 
Example patient 1 has a relative risk factor burden of 1, consistent with his optimal risk factor 
levels. The man representing patient 3 has a 3.7-fold higher risk compared to the other 50-year 
old man with optimal risk factors, despite having only a borderline treatment recommendation, 
based on 10-year ASVCD risk. Patient 2, the 40-year old woman with a low 10-year risk of ASCVD, 
has a nearly 13-fold increased risk as compared to women of her age with optimal risk factors, 
which reflects her high propensity of long-term risk of CVD when her risk factor profile remains 
unmodified. Other measures with similar intent have been proposed previously, including age-
specific relative lifetime risks for younger individuals,421 comparisons of absolute risk estimates 
of the individual versus optimal risk,422 and relative risk estimates relative to the average risk 
factor burden in the population.298, 423 The advantage of the relative risk factor burden is that it 
can be derived from existing risk models and it is not depending on the risk factor burden in the 
general population.
Vascular ageing ratio can be computed by dividing an individual’s vascular age by his or her 
Table 16.3 – Examples of vascular age, vascular ageing ratio, and relative risk factor burden
Calendar age 10-year 
ASCVD risk a
Vascular
age
Vascular ageing ratio Relative risk factor 
burden
Predicted Optimal
Patient 1: 65-year old white man, non-smoker, non-diabetic, untreated SBP 110 mmHg, TC 
4.4 mmol/L (170 mg/dL), HDL-C 1.3 mmol/L (50 mg/dL)
65 year 8.8% 8.8% 65 year 65 year / 65 year = 1.0 8.8% / 8.8% = 1.0
Patient 2: 40-year old white women, smoker, non-diabetic, untreated SBP 135 mmHg, TC 5.7 
mmol/L (220 mg/dL), HDL-C 1.2 mmol/L (45 mg/dL)
40 year 4.7% 0.4% 67 year 67 year / 40 year = 1.7 4.7% / 0.4% = 12.8 b
Patient 3: 50-year old white man, smoker, non-diabetic, treated SBP 120 mmHg, TC 5.4 
mmol/L (210 mg/dL), HDL-C 1.4 mmol/L (55 mg/dL)
50 year 7.7% 2.1% 63 year 63 year / 50 year = 1.3 7.7% / 2.1% = 3.7
The Appendix to this chapter provides detailed descriptions of recommended optimal risk factor profile and vascular 
age calculations. ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; SBP, 
systolic blood pressure; TC, total cholesterol.
a Based on 2013 ACC/AHA guideline on the assessment of cardiovascular risk.6
b Due to rounding in 10-year predicted and recommended optimal 10-year ASCVD risk.
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calendar age. All three example patients have a similar vascular age, yet the vascular ageing 
ratio is very different due to differences in calendar age and sex. The vascular age of a person 
with optimal risk factor levels (as defined by current guidelines) is identical to his or her calendar 
age (patient 1). Consequently the vascular ageing ratio is 1.Patient 2, the 40-year old woman, 
has a vascular age of 67: this corresponds to a vascular ageing ratio of 1.7. Whereas the 50-year 
old man with a vascular age of 63 has a much lower vascular ageing ratio of 1.3.
None of these measures require new modelling efforts and can be directly incorporated into 
existing online calculators and applications on hand-held electronic devices. Another advantage 
is that these measures are less prone to the effects of systematic over- or underestimation of 
risk (i.e. miscalibration), for instance due to differences in underlying event rates in populations 
where models were derived as compared to where they will be applied.119, 264 However, the 
proposed measures do not mend all shortcomings of current strategies that greatly rely on age, 
but at least the contribution of age can be better distinguished from the contribution of other 
risk factors. Both relative risk factor burden and vascular ageing ratio require further evaluation 
in population studies, as well as more rigorous exploration of their mathematical properties. 
Before these measures can be implemented in prevention strategies, correlation with absolute 
risk at different ages, and selection of thresholds are issues that need to be addressed in future 
research. Also, the definition of optimal risk factor levels warrants further evaluation in the light 
of recent results demonstrating even lower CVD event rates when LDL cholesterol is reduced 
beyond levels that are currently considered to be optimal in the guidelines.424 Therefore, 
measures expressing cardiovascular risk relative to optimal risk factor levels are subject to 
change when optimal cholesterol levels are redefined by guideline committees. Nonetheless, 
vascular ageing ratio and relative risk factor burden can be informative in adjunct to absolute 
risk estimates in clinician-patient discussion on cardiovascular risk.
Reconsidering the role of age
Back in the 17th century, British physician Thomas Sydenham wrote “a man is as old as his 
arteries”.425 More than 3 centuries later, cumulative length of exposure to known and unknown 
cardiovascular risk factors is only reflected by calendar age. Yet, the effects of age can be 
decomposed into time-related effects that affect everyone and cumulative exposure to the 
risk factors that affect some more than others.426 Therefore, primordial prevention of accruing 
CVD risk factors and subsequent atherosclerosis is the key to reduce the impact of age on 
cardiovascular risk. However, adopting and maintaining a healthy lifestyle is challenging in our 
contemporary society and some individuals will accrue cardiovascular risk factors, irrespective 
of their lifestyle. Given that the accumulation of risk factors and atherosclerosis starts early in 
life 427 and benefits of lipid-lowering treatment extend for decades after actual treatment,428 we 
may need to reconsider the current role of age in allocating lipid-lowering medication.
Concluding remarks
Risk-based strategies have become the cornerstone of personalized CVD prevention. Yet, despite 
great progress made, there is plenty of opportunity for further improvement and as discussed 
above risk-based approaches to allocation of preventive treatment should not necessarily 
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be considered a dictum for the future. Each approach to primary prevention of CVD has its 
different pros and cons to consider, which highlights the challenges in constructing guidance for 
optimal use of resources to reduce the global burden of CVD.
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Appendix
Optimal risk factor profiles, age threshold calculations, and vascular age
The European Society of Cardiology defines optimal risk factors as a total cholesterol of 4.0 
mmol/L (155 mg/dL), systolic blood pressure of 120 mmHg, no current smoking, and absence 
of diabetes mellitus.8 Age thresholds were calculated for low-risk countries (Andorra, Austria, 
Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, 
Luxembourg, Malta, Monaco, the Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, 
Sweden, Switzerland, U.K.), using the published Systematic Coronary Risk Evaluation (SCORE) 
equations.5
The ACC/AHA define optimal risk factors as a total cholesterol of 170 mg/dL (4.4 mmol/L), 
HDL cholesterol of 50 mg/dL (1.3 mmol/L), untreated systolic blood pressure of 110 mmHg, 
no current smoking, and absence of diabetes mellitus.6 Age thresholds were calculated using 
the Pooled Cohort equations calculator (Online calculator: http://tools.acc.org/ascvd-risk-
estimator/).9 Vascular age was calculated using the according to the sex-specific Pooled Cohorts 
equations as described previously: the predicted risk of an individual is transformed to the 
calendar age of a man or woman with the same absolute 10-year risk, but with all risk factors 
set to optimal levels.363 For an individual with optimal risk factors according to the guidelines, 
the vascular age equals the calendar age.
The 3rd Joint British Societies recommendations define optimal risk factors as a total cholesterol/
HDL cholesterol ratio of 3.5, untreated systolic blood pressure of 120 mmHg, body mass index 
of 25.8 kg/m2 for women and 26.3 kg/m2 for men, no current smoking, absence of diabetes 
mellitus, atrial fibrillation, chronic kidney disease, rheumatoid arthritis, and family history 
of premature coronary heart disease.298 Age thresholds were calculated using the QRISK2 
calculator (Online calculator: http://www.qrisk.org/index.php).7
Note that vascular age for men and women are not to be interpreted on the same scale 
because they derive from sex-specific formulas. This reflects the lower incidence of CVD 
in women as compared to men, hence identical absolute 10-year risks in men and women 
translate into a higher heart age in women.
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Summary
Despite great improvements in treatment, cardiovascular diseases (CVD) remain among the 
leading causes of death and disability in almost all societies. Since atherosclerosis – subclinical 
vascular alterations leading to CVD – accumulates over decades and the mechanisms though 
which atherosclerosis develops are reasonably well understood, there is great opportunity 
for prevention of atherosclerotic CVD (ASCVD). Current individualized primary prevention 
strategies focus on pharmacological treatment of modifiable ASCVD risk factors in individuals 
at high risk for ASCVD in the following 10 years, mostly with lipid-lowering medication (i.e. 
statins). Since decisions on initiating lipid-lowering medication are in part based on ASCVD 
risk estimates, adequate risk stratification is of great importance. Improving risk stratification 
for the development of ASCVD has the potential to translate into more effective and efficient 
prevention of ASCVD.
Chapter 1 summarizes the contemporary prevention strategies recommended by leading clinical 
societies in Europe and the U.S. as well as the outline and aims of the research described in this 
thesis. A brief description of the main study population, the Rotterdam Study, is provided. The 
Rotterdam Study is a prospective population-based cohort study of the community-dwelling 
population of a suburb of Rotterdam, the Netherlands.
In Part I of this thesis several methodological aspects of working with population-based data 
are discussed. Specific issues that are addressed include the methods and definitions on the 
follow-up of cardiac outcomes in the Rotterdam Study (Chapter 2), the healthy volunteer 
effect (Chapter 3), and comparisons to data obtained from population registries (Chapter 4). 
In Chapter 3, we confirm the existence of the healthy volunteer effect in the Rotterdam Study. 
This indicates that those invitees who agree to participate in a population-based study, have a 
lower cardiovascular risk factor burden and subsequent lower risk of dying compared to those 
who decline the invitation to participate. These differences diminished with increasing follow-
up time.
Part II of this thesis is focused on a relatively novel statistical measure, net reclassification 
improvement (NRI), used to quantify differences in risk stratification when comparing 2 
strategies. In Chapter 5 of this thesis, we provide an overview of the history and definitions 
of NRI, and practical applications in 67 research papers published in top-medical journals. 
The results from this analysis highlight several challenges and limitations of NRI. Therefore, 
we constructed an educational part on NRI specifically for clinicians with examples from the 
literature and clear clinical applications. Some of the pitfalls identified in Chapter 5 are worked 
out further in the subsequent chapters using examples from the medical literature. In Chapter 6, 
we delineate how NRI incorporates an implicit weighing factor for the frequency of occurrence of 
the studied outcome. The clinical and statistical importance of the placement of risk thresholds 
in NRI analyses are discussed in Chapter 7. The results from Chapter 8 demonstrate that subtle 
differences in the selection of the studied outcome, in this particular instance coronary heart 
disease (CHD) versus CVD, can influence the estimates and subsequent interpretation of NRI 
for a newer risk marker. Last, Chapter 9 of this thesis highlights the important role of model 
calibration on the interpretation of NRI.
The next part of this thesis, Part III, contains data on the contemporary burden of CVD in the 
general population. In Chapter 10 we summarize the most recent Dutch nation-wide statistics. 
Over the past 50 years cardiovascular mortality has plummeted, yet the burden of heart disease 
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remains high. More recently, we have observed dramatic increases in the overall number of 
cardiac interventions, including percutaneous coronary interventions and implantations of 
pacemakers and ICDs. In Chapter 11 of this thesis, we present the lifetime risk of CVD and 
the distribution of its first manifestations for men and women from the Rotterdam Study. This 
provided insight into the relative contribution of various types of CVD (i.e. CHD, cerebrovascular 
disease, and heart failure) among men and women. Two-thirds of all men and women will 
develop some form of CVD during their life. However, women generally developed CVD at a 
later age and were more likely to have it present as a cerebrovascular disease event or heart 
failure compared to men. This may have bearing on prioritizing specific preventive efforts in 
men and women.
Part IV of this thesis is entirely focused on cardiovascular risk estimation within the framework 
of the Rotterdam Study. In Chapter 12, we compare the implications of the contemporary 
European and U.S. clinical practice guidelines for primary prevention of CVD in the Rotterdam 
Study population. Following the U.S. guidelines would result in almost all men aged 55 and 
over to be recommended for statin treatment, as well as the majority of women. Also, the 
underlying models used to identify individuals at increased CVD risk performed suboptimal in the 
Rotterdam Study population. Chapters 13 through 15 focus on ways to improve cardiovascular 
risk estimation. In Chapter 13, we compare the added predictive ability of 12 putative CVD 
risk markers, including blood biomarkers and measures to quantify subclinical atherosclerosis. 
Coronary artery calcification (CAC), measured by non-contrast computed tomography, yielded 
the strongest improvements in discrimination and subsequent risk classification to identify 
individuals at increased risk of future CHD. The results from Chapter 14 indicate that CAC score 
does not only predict CHD, but also heart failure, even in the absence of clinical manifest CHD. 
As such, it would be worthwhile to consider heart failure as an additional outcome in ongoing 
screening trials using CAC for allocation of preventive treatment. In Chapter 15, we present 
the coronary risk in the elderly (CORE) model, a CHD prediction tool developed and validated 
for older populations. The CORE model is based on data from participants aged 65 years and 
older from the Rotterdam Study and the Cardiovascular Health Study (CHS) and uses competing 
risks regression in order to account for censoring due to death from non-coronary causes. The 
CORE model showed good generalizability in European and U.S. populations, but only moderate 
discrimination and no consistent improvements in risk classification compared with an existing 
CHD prediction model. Moreover, adding promising newer cardiovascular markers to the model 
did not substantially improve CHD risk prediction. These results emphasize the need for further 
work to improve cardiovascular risk prediction in an elderly population.
The general discussion in Chapter 16 is focused on the limitations of the work described in this 
thesis, and how the same work can contribute to future strategies for primary prevention of 
ASCVD and preventive cardiology at large. This discussion can be broken down into two main 
focal points. First, a transition should be made in cardiovascular risk assessment from 10-year 
risk of hard ASCVD based on a single measurement of risk factor levels, to remaining lifetime 
risk of a broad spectrum of ASCVD based on trajectories of risk factor levels. This can be done 
using existing data resources. The second part of the discussion focusses on a critical point of 
current risk-based strategies, namely the dominant role of age in CVD prediction models. We 
discuss a number of potential adaptations, as well as entirely alternative strategies that do not 
depend on cardiovascular risk calculations. As such, many challenges remain in constructing 
guidance for optimal use of resources to reduce the global burden of CVD.
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Ondanks de verbeterde behandeling van hart- en vaatziekten blijft dit de belangrijkste oorzaak 
voor overlijden en lichamelijke beperkingen in vrijwel alle samenlevingen. Atherosclerose, 
de subklinische vasculaire veranderingen die leiden tot hart- en vaatziekten, ontwikkelt zich 
over tientallen jaren. De onderliggende mechanismen waardoor atherosclerose ontstaat, zijn 
redelijk goed in kaart gebracht. Hierdoor bestaat er de mogelijkheid om atherosclerotische hart- 
en vaatziekten te voorkomen. De huidige geïndividualiseerde preventiestrategieën richten zich 
op de medicamenteuze behandeling van modificeerbare risicofactoren voor het ontwikkelen 
van atherosclerose. Geldende richtlijnen adviseren personen met een hoog 10-jaars risico op 
atherosclerotische hart- en vaatziekten te behandelen, meestal met cholesterolverlagende 
medicatie (statines). Aangezien de keuze om iemand te gaan behandelen mede bepaald wordt 
door een risicoschatting, is adequate risicostratificatie van groot belang. Het verbeteren van 
deze risicostratificatie heeft de potentie om zich uiteindelijk te vertalen in effectievere en 
efficiëntere preventie van hart- en vaatziekten.
Hoofdstuk 1 is een inleiding op dit proefschrift en begint met een korte introductie in de huidige 
preventiestrategieën die aangeraden worden door de gezaghebbende beroepsverenigingen in 
Europa en de V.S. Daarnaast staan in dit hoofdstuk de opzet en doelen van het onderzoek dat in 
dit proefschrift beschreven wordt. Als laatste volgt een korte beschrijving van de belangrijkste 
onderzoekspopulatie waarop de meeste resultaten, beschreven in dit proefschrift, zijn 
gebaseerd: het Erasmus Rotterdam Gezondheid Onderzoek (ERGO, ‘The Rotterdam Study’). 
ERGO is een langlopend prospectief cohort onderzoek in de algemene bevolking van Ommoord, 
een buitenwijk van Rotterdam.
In Deel I van dit proefschrift worden verschillende aspecten uitgelicht van het werken met 
gegevens verkregen uit bevolkingsonderzoeken. In het bijzonder beschrijven we de methoden 
en definities van hartaandoeningen welke gebruikt worden in ERGO (Hoofdstuk 2), het ‘gezonde 
vrijwilligers effect’ (Hoofdstuk 3) en vergelijkingen met gegevens verzameld uit digitale 
huisartsendossiers (Hoofdstuk 4). In Hoofdstuk 3 bevestigen we het bestaan van het gezonde 
vrijwilligers effect in ERGO. Dit betekent dat de mensen die uitgenodigd zijn en vervolgens ook 
daadwerkelijk deelnemen aan een bevolkingsonderzoek een beter cardiovasculair risicoprofiel 
en lagere sterftecijfers hebben vergeleken met degenen die de uitnodiging afsloegen. De 
verschillen in sterftecijfers namen af naarmate deelnemers langer gevolgd werden.
Deel II van dit proefschrift is volledig gewijd aan een nieuwere statistische maat genaamd ‘net 
reclassification improvement’ (NRI). Deze maat wordt gebruikt om het verschil te kwantificeren 
tussen twee strategieën van risicoclassificatie. In Hoofdstuk 5 van dit proefschrift geven we een 
overzicht van de totstandkoming en de definities van NRI. Daarnaast beschrijven we de toepassing 
van NRI in 67 wetenschappelijke publicaties, gepubliceerd in medische toptijdschriften. Deze 
resultaten leggen meerdere uitdagingen en beperkingen bloot ten aanzien van het gebruik van 
NRI. Daarom hebben we een educatief stuk geschreven, specifiek voor clinici met voorbeelden 
uit de medische literatuur. Een aantal van de valkuilen in het gebruik van NRI die we in 
Hoofdstuk 5 hebben geïdentificeerd zijn verder uitgewerkt in de daaropvolgende hoofdstukken 
naar aanleiding van voorbeelden uit de literatuur. In Hoofdstuk 6 zetten we uiteen hoe NRI 
een impliciete weging bevat voor de frequentie van optreden van de uitkomst die bestudeerd 
wordt. De klinische en statistische relevantie van het bepalen van NRI afkapwaarden wordt 
beschreven in Hoofdstuk 7. De resultaten uit Hoofdstuk 8 tonen aan dat puntschattingen, en 
daaruit volgende interpretaties, van NRI voor een nieuwere risicomarker beïnvloed kunnen 
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worden door subtiele verschillen in de keuze van de bestudeerde uitkomst. In dit hoofdstuk 
hebben we dat uitgewerkt aan de hand van het voorbeeld van coronaire hartziekte versus 
atherosclerotische hart- en vaatziekten. Als laatste, in Hoofdstuk 9, benadrukken we het belang 
van kalibratie van risicomodellen in de context van de interpretatie van NRI.
Het volgende deel van dit proefschrift, Deel III, bevat gegevens over de hedendaagse ziektelast 
van hart- en vaatziekten in de algemene bevolking. In Hoofdstuk 10 vatten we de meest recente 
Nederlandse landelijke statistieken samen. De afgelopen 50 jaar is de sterfte aan hart- en 
vaatziekten zeer sterk gedaald, echter de ziektelast van hartaandoeningen blijft nog altijd hoog. 
De afgelopen decennia hebben we een dramatische stijging van het aantal ingrepen aan het 
hart waargenomen, onder andere percutane coronaire interventies (dotterbehandelingen) 
en implantaties van pacemakers en ICDs. In Hoofdstuk 11 van dit proefschrift presenteren we 
het risico op het ontwikkelen van hart- en vaatziekten over de gehele levensspan. Daarnaast 
beschrijven we hoe hart- en vaatziekten zich als eerste manifesteren in mannen en vrouwen 
binnen ERGO. Dit geeft inzage in de relatieve bijdrage van verschillende typen hart- en 
vaatziekten (d.w.z. coronaire hartziekte, cerebrovasculaire aandoeningen en hartfalen) in 
mannen en vrouwen. Twee derde van alle mannen en vrouwen ontwikkelt op enig moment 
tijdens het leven een vorm van hart- en vaatziekten. Echter bij vrouwen manifesteren hart- en 
vaatziekten zich op hogere leeftijd en vaker in de vorm van cerebrovasculaire aandoeningen of 
hartfalen. Dit kan consequenties hebben voor het prioriteren van specifieke preventieve zorg in 
mannen en vrouwen.
Deel IV van dit proefschrift is volledig gericht op cardiovasculaire risicoschattingen binnen 
het raamwerk van ERGO. In Hoofdstuk 12 vergelijken we de implicaties van de hedendaagse 
Europese en Amerikaanse klinische richtlijnen voor primaire preventie van hart- en vaatziekten 
in de ERGO populatie. Het navolgen van de Amerikaanse richtlijnen zou betekenen dat vrijwel 
alle mannen van 55 jaar en ouder een statine wordt aanbevolen, evenals de meerderheid van 
de vrouwen. Daarnaast functioneren de onderliggende modellen suboptimaal met het oog op 
het identificeren van personen met een verhoogd risico op hart- en vaatziekten binnen de ERGO 
populatie. Hoofdstukken 13 tot en met 15 zijn gericht op het verbeteren van cardiovasculaire 
risicomodellen. In Hoofdstuk 13 vergelijken we 12 vermeende risicomarkers voor hart- en 
vaatziekten ten aanzien van de toegevoegde waarde op de precisie van risicoschattingen. 
Hierbij vergeleken we onder andere verschillende bloedwaarden en methoden om subklinische 
atherosclerose te kwantificeren. De coronaire calcium (CAC) score, gemeten met CT zonder 
contrastmedia, toonde de sterkste verbetering in discriminerend vermogen om personen met 
toekomstige coronaire hartziekte te identificeren en deze correct te classificeren. De resultaten 
uit Hoofdstuk 14 tonen aan dat de CAC score niet alleen coronaire hartziekte voorspelt, maar 
ook hartfalen, zelfs in de afwezigheid van klinisch manifeste coronaire hartziekte. Daarom zou 
het interessant zijn om hartfalen mee te nemen als een additioneel eindpunt in reeds lopende 
screeningsstudies die gebruik maken van CAC om preventieve behandeling toe te wijzen. In 
Hoofdstuk 15 presenteren we het coronaire risico bij ouderen (CORE, ‘coronary risk in the 
elderly’) model. Dit is een predictiemodel voor coronaire hartziekte ontwikkeld en gevalideerd 
bij ouderen. Het CORE model is gebaseerd op gegevens verzameld bij deelnemers van 65 jaar 
en ouder uit ERGO en ‘the Cardiovascular Health Study’ (CHS). Het model is ontwikkeld met 
behulp van regressietechnieken die rekening houden met concurrerende risico’s op dood 
door niet-coronaire aandoeningen. Het CORE model toonde goede generaliseerbaarheid in 
zowel Europese als Amerikaanse populaties. Echter het discriminerend vermogen was matig 
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en het model toonde geen consistente verbeteringen in risicoclassificatie vergeleken met 
een bestaand predictiemodel voor coronaire hartziekte. Het toevoegen van veelbelovende 
nieuwere risicomarkers aan het CORE model resulteerde niet in een substantiële verbetering in 
risicoschattingen. Deze bevindingen benadrukken dat meer gericht onderzoek noodzakelijk is 
om cardiovasculaire risicoschattingen bij ouderen te kunnen verbeteren.
De algemene beschouwing in Hoofdstuk 16 is gericht op de beperkingen van de verschillende 
onderzoeken beschreven in dit proefschrift, alsmede hoe deze onderzoeken bij kunnen dragen 
aan de toekomst van primaire preventie van hart- en vaatziekten en preventieve cardiologie 
in brede zin. De algemene beschouwing kan onderverdeeld worden in twee grote punten. 
Ten eerste lijkt een transitie nodig van 10-jaars risico op harde atherosclerotische eindpunten, 
gebaseerd op een enkele meting van risicofactoren, naar een risicoschatting voor het gehele 
leven op een breed spectrum van atherosclerotische hart- en vaatziekten, gebaseerd op trends 
in herhaalde metingen van risicofactoren. Dit is allemaal te realiseren met reeds verzamelde 
onderzoeksgegevens. Het tweede deel van de beschouwing richt zich op een zorgwekkend 
fenomeen binnen hedendaagse risico-gedreven preventiestrategieën, namelijk de dominante 
rol van leeftijd in predictiemodellen voor hart- en vaatziekten. Hiertoe beschrijven we een aantal 
potentiële aanpassingen aan predictiemodellen en alternatieve strategieën die niet gebaseerd 
zijn op dergelijke risicoschattingen. Hieruit valt te concluderen dat er nog vele uitdagingen zijn 
in het opstellen van het richtlijnen voor het optimale gebruik van mankracht en middelen om 
de wereldwijde ziektelast van hart- en vaatziekten te reduceren.
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